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Prior research has indicated that healthcare personnel (HCP) who work in areas where 
Mycobacterium tuberculosis poses an occupational hazard are at high risk of tuberculin 
skin test (TST) positivity and subsequent conversion to active tuberculosis (TB).  U.S. 
medical laboratory microbiologists confront similar hazards but have not been studied 
outside of the HCP aggregate.  The purpose of this study was to fill this gap by 
examining the relationships between the predictor variables of self-reported history of 
bacille Calmette-Guérin (BCG) immunization, place of birth, and years of laboratory 
experience and the outcomes of self-reported lifetime TST positivity, preventive 
treatment noninitiation, and barriers to treatment adherence for this subgroup.  This 
quantitative, cross-sectional study was guided by the epidemiologic triad model.  A 
researcher-designed self-administered questionnaire including Part A of the Brief 
Medication Questionnaire was mailed to 4,335 U.S. microbiologist members of the 
American Society for Clinical Pathology.  From the 1,628 eligible respondents, results 
showed that prevalence of positive TSTs (17.0%) and treatment noninitiation (9.8%) was 
low.  Multivariate analysis identified BCG and foreign birth, as well as age, 
nonoccupational exposure, history of TB, work in mycobacteriology, and work outside of 
microbiology as predictors of a positive TST; foreign birth was a predictor of treatment 
noninitiation.  Additional research is needed to identify other laboratorian groups at 
increased risk for developing TB.  These results enhance positive social change by 
helping to inform recommendations in the global fight to stop the spread of TB, as well 
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Chapter 1: Introduction to the Study  
Background of the Study 
Active tuberculosis (TB) disease is a significant public health problem at the 
global level.  Statistics regarding the transition from inactive or latent tuberculosis 
infection (LTBI) to active TB disease remain relatively unknown because the priority of 
the World Health Organization (WHO) has been to detect and prevent active forms of TB 
disease (WHO, 2011b).  Worldwide in 2010, 1.1 million people died from TB and 8.8 
million new TB cases were reported (WHO, 2011b).  In addition to serious morbidity and 
mortality, control of TB is expensive, predicted to reach almost 5 billion U.S. dollars in 
2011 (WHO, 2010b), and 1-4 million U.S. dollars with each national prevalence survey 
worldwide (WHO, 2011a; WHO, 2011b).  Expenses incurred in WHO-guided prevalence 
surveys are derived from chest x-rays, interviews, and laboratory testing of sample sizes 
in populations, usually numbering > 50,000 people each (WHO, 2011a, 2011b).   In the 
United States, cases of active TB reported in 2009 numbered 10,893 (Centers for Disease 
Control and Prevention [CDC], 2010b).  While not every individual infected with 
inactive or latent tuberculosis infection becomes sick, about 5% to 10% of persons with 
normal immune systems will develop active TB disease at some point in their lives; this 
risk is the highest in the first 2 years after infection (CDC, 2005a, 2011a, 2011b).  
TB is spread among individuals via the forceful exhalation (coughing or sneezing) 
of aerosolized droplet nuclei containing viable tubercle bacilli (TB bacteria) in cases of 
active disease.  Risk of infectivity depends upon exposure and host factors (Heymann, 





(latent) disease.  While active TB disease is diagnosed using culture and direct 
microscopy techniques, inactive disease has been diagnosed historically using the 
tuberculin skin test (TST).  The TST has been used to evaluate close contacts of 
individuals with active TB disease, to screen high-risk groups (immigrants, the 
immunosuppressed), and to screen healthcare personnel (CDC, 2005b).  The TST screen 
examines an individual’s antibody response to TB antigens present in purified protein 
derivative (PPD) tuberculin solution (National Tuberculosis Curriculum Consortium 
[NTCC], 2010).  Although the TST continues to be utilized as a test of choice in the 
targeted tuberculin testing of inactive (latent) TB infection, the risk of false-positive or 
false-negative reactions is possible, as is a risk of misreading the test.  In the United 
States, a low-incidence country, TST sensitivity is 0.59 to 1.0 and specificity is 0.95 to 
1.0 (Rose, Schechter, & Adler, 1995).  TST positivity is considered a hypersensitivity 
response, indicative of exposure to the TB bacterium and the presence of some form of 
inactive (latent) or active infection, warranting further investigation by a healthcare 
provider. 
The percentage of active TB cases among healthcare personnel (HCP) in the 
United States reached 3.8%, second among occupations only to unemployed and retired 
individuals (CDC, 2010b). Because the latent period from initial infection to active TB 
disease can be long, infection rates and fatalities from TB disease as reported to the 
Occupational Safety and Health Administration (OSHA) may be underrepresented 
(Sepkowitz & Eisenberg, 2005).  In the United States, occupational deaths due to active 





However, during the late 1980s and early 1990s, the TB-related deaths of at least 10 HCP 
contracting the infection occupationally were reported (Sepkowitz & Eisenberg, 2005).   
A resurgence of TB during this time coincided with the HIV/AIDS epidemic, 
contributing to health care facility outbreaks (Field, 2001).  Many U.S. HCP remain at 
risk today for activation of inactive TB to active TB disease due to these past exposures 
(Sepkowitz & Eisenberg, 2005).  While the risk of activation appears no greater for HCP 
than for the general public, the risk of latent and active infection globally due to 
occupational contact does appear higher (Baussano et al., 2011).  The risk of progression 
from latent to active TB disease and the subsequent spread of TB among coworkers, 
patients, and families can create a public health problem (CDC, 2000, 2005b; 
Drobniewski et al., 2007).  Several high-profile cases among HCP have prompted major 
contact investigations (Fitzpatrick et al., 2005; Hickstein et al., 2004; Nania et al., 2007), 
making the targeting of certain HCP groups for latent TB infection a priority (CDC, 
2005b). 
Researchers such as Baussano et al. (2011) have reported that globally, rates of 
new active TB cases (incidence) for HCP are higher than for the general population, 
representing TB as an occupational disease.  While occupation alone cannot predict TST 
results, certain occupational factors involving contact with TB-contaminated patients or 
specimens remain well-known risk factors (CDC, 2005b, 2009).  Among HCP, medical 
laboratorians are at high risk for TST positivity, indicating inactive TB infection, as well 
as for developing active TB. Since the 1940s and 1950s, laboratory workers repeatedly 





greater risk for incidence of TB infection (inactive and active) when compared to the 
general public (CDC, 2005b; Reid, 1957).  Exposures typically occur in the microbiology 
laboratory; very high (11.4%) incidence of new TST positivity (conversion within 2 
years) among high-risk work settings including the microbiology laboratory was recorded 
in one study (Kraut, Coodin, Plessis, & McLean, 2004).  CDC has targeted laboratory 
workers in guidelines for TB screening programs at the level of the health-care setting, 
and anyone participating in aerosol-generating procedures or in specimen-processing 
procedures (including processing for Mycobacterium tuberculosis) should take part in 
regular TST screening protocols (CDC, 2005b).  In addition, specific factors further 
increasing risk include (a) place of birth (immigration from endemic countries); (b) 
location of work (working in hospitals or other congregate health-care facilities); (c) type 
of work, such as microbiology staff in a mycobacteriology laboratory (CDC, 2000, 
2005b); and (d) years of work experience in the lab setting (Menzies, Fanning, Yuan, 
Fitzgerald, & the Canadian Collaborative Group, 2003; Rafiza, Rampal, & Tahir, 2011).  
LTBI prevalence, a potential precursor to active TB (CDC, 2005a, 2011a, 2011b), 
has been associated with working in laboratories, especially in low-income countries 
(Joshi, Reingold, Menzies, & Pai, 2006).  In Russia, LTBI prevalence has been 
documented at 40.8% in HCP staff but 61.1% in laboratory workers (Drobniewski et al., 
2007).  A Malaysian study was the exception; no laboratorians were positive (Rafiza et 
al., 2011).  In U.S. HCP, LTBI prevalence (reported as TST positivity) rates have been 
reported to range from 11.3% (Bailey, Fraser, Spitznagel, & Dunagan, 1995) to 32% 





linked to an increase in foreign-born HCP (Cook et al., 2003).  Among microbiology 
laboratory healthcare workers in New York City, a baseline TST positivity rate of 57% 
was reported (Garber, San Gabriel, Lambert, & Saiman, 2003), compared to a baseline 
TST positivity rate of 36.2% among health department HCP in the same locale (Cook et 
al., 2003).  Risk factors of history of BCG immunization (a vaccine used to reduce risk of 
TB in highly endemic countries), foreign birth, and employment in the mycobacteriology 
laboratory have been found to be significantly associated with TST positivity in the U.S. 
microbiology laboratory workers (Garber et al., 2003).  
Preventive treatment for latent tuberculosis infection (LTBI) is of great interest 
for slowing or stopping the spread of TB from inactive TB infection to active TB 
infection.  Prescribed treatment is important because it is thought to prevent latent TB 
infection from becoming active TB disease (Heymann, 2008), thus breaking the chain of 
disease transmission.  HCP diagnosed with LTBI are at risk of not initiating and not 
adhering to prescribed treatment for reasons of inaccessibility of easy treatment regimens 
(treatment site hours, ease of obtaining medications), long treatment duration, stigma 
associated with treatment, and barriers associated with adverse drug effects (Bieberly & 
Ali, 2008; Gershon, McGeer, Bayoumi, Raboud, & Yang, 2004).  Preventive treatment 
completion rates among HCP have been reported as inconsistent, ranging anywhere from 
48% in one retrospective analysis to 93% in a separate post intervention analysis (Hirsch-
Moverman, Daftary, Franks, & Colson, 2008).  The general public’s completion rate 
approximates 60% (CDC, 2000).  Preventive treatment among microbiology 





having an initiation rate of 58% overall, which compares to 20% reported among 
microbiology lab workers (Garber et al., 2003).  As many as 11.4% of HCP who did not 
complete treatment in the Camins, Bock, Watkins, and Blumberg (1996) study reportedly 
stopped because of real or perceived drug effects.  Preventive treatment noninitiation and 
treatment nonadherence (due to the presence of barriers such as medication side effects) 
in medical laboratory microbiologists as a subgroup of HCP are yet to be described at the 
national level.  This subgroup has been largely ignored in literature referencing HCP 
(Bailey, Fraser, Spitznagel, & Dunagan, 1995) or misclassified as part of a larger group 
(Louther, 1998).   
For this study, a U.S. medical laboratory microbiologist subgroup was accessed 
through the national registry known as the American Society for Clinical Pathology 
(ASCP, 2009).  Results from this study will make an important contribution and enhance 
social change by helping inform recommendations in the global fight to stop the spread of 
TB, decrease TB deaths and disabilities, and improve allocation of resources among this 
specific group.         
Chapter 1 will present (a) a statement of the problem, (b) the purpose of this 
study, (c) the nature of this study, and (d) the research questions.  In addition, a 
discussion of the study’s theoretical base, important terms, assumptions, limitations, 
delimitations, and significance will be presented.  A detailed discussion of the literature 






Globally, millions of individuals continue to become infected with and die from 
TB or complications of TB every year (WHO, 2011).  The elimination of TB infection in 
the United States is an overarching goal of the Institutes of Medicine (IOM, 2000) and 
the CDC (2002).  The U.S. Healthy People 2020 document (U.S. Department of Health & 
Human Services, n.d.) has deemed at-risk groups important in the targeted treatment of 
latent and active TB infection (CDC, 2003a, 2005a).  Additionally, guidelines for 
preventing the transmission of Mycobacteria tuberculosis in health-care settings, 
specifically targeting persons at risk (including employees having contact with infected 
patients, foreign-born HCP, and mycobacteriology laboratory workers) have been 
provided by the CDC (2005b).  Healthcare personnel (HCP) diagnosed with LTBI are at 
risk of conversion to active tuberculosis (TB) disease status (CDC, 2000; Drobniewski et 
al., 2007) and may create conditions for the spread of TB among coworkers, patients, and 
families (CDC, 2005b).  In the United States, several high-profile cases of active TB in 
HCP have been documented, and at least two were the result of LTBI treatment 
noninitiation (Fitzpatrick et al., 2005; Hickstein et al., 2004; Nania et al., 2007).  In 
addition, HCP with LTBI may be at higher risk of treatment nonadherence (Bieberly & 
Ali, 2008; Gershon et al., 2004).  This may complicate the spread of TB by introducing 
drug-resistant strains (CDC, 2011e).  Among HCP, those working in mycobacteriology 
and emigrating from TB-endemic countries may be at high risk of LTBI as identified 





An initial review of the literature revealed that (a) tuberculin skin test (TST) 
positivity is used as a surrogate in the literature to represent prevalence of LTBI or 
unsuspected active TB infection and (b) HCP as a group have already been studied for 
TB-related epidemiologic purposes.  Therefore, the problem is that while researchers 
have reported conglomerate data on the prevalence and risk factors associated with TST 
positivity among HCP, a gap in the current literature remains regarding prevalence and 
risk factors of (a) self-reported lifetime TST positivity, (b) treatment noninitiation, and 
(c) treatment nonadherence (presence of barriers) among any U.S. subgroup of HCP in its 
entirety, specifically among U.S. medical laboratory microbiologists.  In addition, new 
and shortened preventive treatment guidelines have been published (Jereb, Goldberg, 
Powell, Villarino, & Lobue, 2011), further promoting a need to determine baseline data 
in target populations.  Baseline data such as those collected in this study will assist in 
determining effectiveness of these new LTBI treatment guidelines in future research.  
Results are expected to add to the existing literature on HCP by reporting an analysis of 
the self-reported data assembled through surveying an entire national registry of medical 
microbiologists in the Unites States.   
Purpose of the Study 
The purpose of this cross-sectional quantitative study is to fill in the gap detailed 
above and describe the population of U.S. medical laboratory microbiologists in terms of  
prevalence and 
 Independent variables, including risk factors of history of BCG immunization, 





dependent dichotomous variable of self-reported lifetime TST positivity 
status, 
 Independent variables, including risk factors of history of BCG immunization, 
place of birth (U.S. or foreign), and years of laboratory experience, and the 
dependent  variable of preventive TB treatment noninitiation (past or present) 
among those acknowledging ever having had a positive tuberculin skin test, 
and 
 Independent variables, including risk factors of history of BCG immunization, 
place of birth (U.S. or foreign), and years of laboratory experience, and the 
dependent  variable of barriers to treatment adherence (presence of medication 
side-effect barriers as measured by the Brief Medication Questionnaire) 
among those acknowledging ever having had a positive tuberculin skin test 
and initiating preventive TB treatment. 
In addition, gender, age, type of laboratory work, nonoccupational exposure, and 
history of TB disease have been assessed as covariates or confounders.  An evaluation of 
how each outcome varied across demographic and work-related factors took place.  It 
was reasonable and anticipated that risk factors such as a history of BCG immunization 
and place of birth (nonoccupational), as well as years of work experience (occupational), 
might be associated with self-reported lifetime TST positivity.  However, not much was 
known with regard to preventive treatment noninitiation and barriers to treatment 





Nature of the Study 
The rationale for this study was based on research by Garber et al. (2003) (n = 
342), which has appeared as the largest and most recent study of medical laboratory 
microbiologists in the United States.  This and other studies identified through this 
literature review used survey questionnaires of HCP or of the laboratorian subpopulation 
for the gathering of data on the prevalence or incidence of active TB (Harrington & 
Shannon, 1976) or prevalence of LTBI (Alonso-Echanove et al., 2001; Drobniewski, 
Balabanova, Zakamova, Nikolayevskyy, & Fedorin, 2007; Garber et al., 2003; Menzies 
et al, 2003; Rafiza et al., 2011).  The cross-sectional design was chosen for this study 
because the baseline TST prevalence of U.S. medical laboratory microbiologists as a 
whole is relatively unknown.  Findings indicated that the prevalence of a positive TST in 
the Garber et al. (2003) group was 57%, while only 20% received Isoniazid preventive 
treatment; multivariate analysis in this study revealed age, foreign birth, BCG 
immunization, and employment in the mycobacteriology laboratory as risk factors for 
positive TST (Garber et al, 2003).  This study builds on (a) previous TST positivity 
prevalence and associated risk factor research by Garber et al. (2003) and (b) related 
nonadherence and medication side-effect barriers as researched by Garber et al. (2003), 
Shukla, Warren, Woeltje, Gruber, and Fraser (2002), and others by surveying U.S. 
medical laboratory microbiologists certified with a nationally recognized registry. 
In this cross-sectional quantitative study, a dichotomous dependent variable of 
self-reported lifetime TST positivity status was evaluated against a set of independent 





years of laboratory experience.  These items were chosen because they have appeared as 
proposed risk factors in prior TST research involving laboratory personnel (Garber et al., 
2003) and elsewhere in the literature.  Any history of self-reported preventive treatment 
initiation as reported on the questionnaire provided an opportunity to examine additional 
dichotomous dependent variables of (a) treatment noninitiation, and (b) barriers to 
treatment adherence as the presence of medication side-effect barriers (measured using a 
screening section of the Brief Medication Questionnaire [BMQ], devised by Svarstad, 
Chewning, Sleath, and Claesson in 1999) against the same independent variables above.  
The research tested the above-reported independent variables in subsequent hypotheses 
about whether specific factors were associated with the constructs of interest as 
represented by the epidemiologic triad model theory.  A questionnaire survey was used in 
this process.  
The nature of this study was a quantitative cross-sectional survey design using a 
one-time written self-administered questionnaire (Appendix A).  The single-stage 
questionnaire using closed-ended questions targeted eligible U.S. medical laboratory 
microbiologists, a cohort of approximately 5,138 registrants at the time of the research 
proposal, registered as members of the national professional association known as the 
American Society for Clinical Pathology (ASCP).  ASCP is the principal registry for 
most U.S. medical laboratory personnel (ASCP, 2009).  For the purposes of this study, 
the U.S. medical laboratory scientist population registered with the ASCP and reportedly 
working in area of responsibility referred to as “Microbiology/Mycology/Parasitology/ 





was chosen for cross-sectional study because medical laboratory microbiologists include 
mycobacteriology workers, those most likely to perform high-complexity specimen 
processing and TB testing on patient specimens (CDC, 2005b).  U.S. mailing addresses 
were accessed through INFOCUS Marketing (2011).  The ASCP mailing list is updated 
monthly, and addresses are run through the National Change of Address database, 
resulting in an estimated loss of no more than 1% of addresses (S. Blake, INFOCUS 
Marketing Consultant, personal communication, September 17, 2012).  Calculation of 
sample size justified use of the entire cohort in order to statistically satisfy all research 
questions as posed (Appendix B).  An announcement postcard including a scholarship 
donation incentive (Appendix C) was mailed 1 week prior to the survey packet.  Two 
items from the Brief Medication Questionnaire (BMQ) Part A were included in the 
written survey (Appendix D).  Statistical methodologies, including univariate, bivariate, 
and multivariate statistics, were used in the data analysis.  The end product of the survey 
was that of lifetime prevalence involving any self-reported lifetime TST positivity 
outcome, risk factors of self-reported TST positivity, risk factors of preventive TB 
treatment noninitiation, and risk factors of barriers to treatment adherence from an 
individual’s past or present (lifetime) history.  More detail regarding research methods is 
presented in Chapter 3 of this dissertation. 
Research Questions and Hypotheses 
This study seeks to supply new data on a subset of HCP (the medical laboratory 
microbiologist) who may be at higher risk for developing LTBI but have been 





test positivity rate and how it varied across demographic and work-related characteristics.  
In addition, the proportion of (a) infected workers who self-reported as having been 
prescribed preventive treatment, (b) those initiating this treatment, and (c) those initiating 
treatment who encountered barriers to treatment adherence (medication side effects), as 
well as how these measures varied across demographic and work-related characteristics, 
have been reported in this dissertation study. 
Specific research questions addressed in this quantitative study are as follows: 
 Research Question 1:  What is the relationship of history of BCG 
immunization, place of birth (U.S. or foreign), and years of laboratory 
experience with self-reported lifetime tuberculin skin test (TST) positivity? 
o Null Hypothesis:  There is no statistical association between self-reported 
individual independent variables of history of BCG immunization, place 
of birth (U.S. or foreign), and years of laboratory experience and the 
dependent variable of self-reported lifetime TST positivity. 
o Alternate Hypothesis:  There is a statistical association between self-
reported individual independent variables of history of BCG 
immunization, place of birth (U.S. or foreign), and years of laboratory 
experience and the dependent variable of self-reported lifetime TST 
positivity. 
The three independent variables were analyzed using bivariate analysis to 





significant associations in a multiple regression analysis predicting the most 
parsimonious model for self-reported lifetime TST positivity.  
 Research Question 2:  What is the relationship of history of BCG 
immunization, place of birth (U.S. or foreign), and years of laboratory 
experience with preventive treatment noninitiation among those individuals 
prescribed treatment for a positive tuberculin skin test? 
o Null Hypothesis:  There is no statistical association between self-reported 
individual independent variables of history of BCG immunization, place 
of birth (U.S. or foreign), and years of laboratory experience and the 
dependent variable of preventive treatment noninitiation. 
o Alternate Hypothesis:  There is a statistical association between self-
reported individual independent variables of history of BCG 
immunization, place of birth (U.S. or foreign), and years of laboratory 
experience and the dependent variable of preventive treatment 
noninitiation. 
The three independent variables were analyzed using bivariate analysis to 
determine odds ratios and were evaluated as a group using the individual statistically 
significant associations in a multiple regression analysis predicting the most 
parsimonious model for treatment noninitiation. 
 Research Question 3:  What is the relationship of history of BCG 





experience with barriers to treatment adherence (medication side effects) 
among those initiating preventive treatment for a positive tuberculin skin test? 
o Null Hypothesis:  There is no statistical association between self-reported 
individual independent variables of history of BCG immunization, place 
of birth (U.S. or foreign), and years of laboratory experience, and the 
dependent variable of barriers to treatment adherence (medication side 
effects) as identified using the Brief Medication Questionnaire (BMQ) in 
those respondents ever having initiated preventive treatment for a positive 
tuberculin skin test.   
o Alternate Hypothesis:  There is a statistical association between self-
reported individual independent variables of history of BCG 
immunization, place of birth (U.S. or foreign), and years of laboratory 
experience, and the dependent variable of barriers to treatment adherence 
(medication side effects) as identified using the Brief Medication 
Questionnaire (BMQ) in those respondents ever having initiated 
preventive treatment for a positive tuberculin skin test.   
The three independent variables were analyzed using bivariate analysis to 
determine odds ratios and were also evaluated as a group using the individual statistically 
significant associations in a multiple regression analysis predicting the most 
parsimonious model representing barriers to treatment adherence (presence of medication 





Table 1 represents a summary of the research questions, variables, scale of 
measure, and analysis used in this study.  For more detail, please refer to Chapter 3 and 
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The research was conducted as a quantitative study based on the epidemiologic 
triad theoretical model.  The epidemiologic triad is used to describe the occurrence of 
disease as linked to host and environment.  Texts have articulated use of this triangle in 
several ways involving spread of infectious diseases from an epidemiologic perspective 
(Rockett, 1999; Smith, 2002; Williams & Nelson, 2007).  Constructs of the triad model 
originated in the mid-1800s (Smith, 2002).  One of the first pieces of literature supporting 
the development and formal use of the epidemiologic triad involved studies of infectious 
diseases of fish (Snieszko, 1974).  (More detail regarding theory and this literature review 
may be found in Chapter 2.)  In the epidemiological triad model, emphasis is on the 
relationship between agent, host, and environment (Rockett, 1999; Smith, 2002).  
Constructs as related to the survey questionnaire are as follows: 
1. Agent: Tuberculosis bacterium is considered the agent. Presence of the agent 
was measured by asking these written survey questions of the survey 
respondent: 
o Lifetime history of positive TST? (Research Question 1) 
o Ever received an interferon gamma-releasing assay (IGRA) blood test and 
was the result “positive”?  
o Lifetime history of active TB? 
o Nonoccupational contact with anyone diagnosed with active TB? 
2. Host: The host is the human reservoir who becomes infected and sheds the 





contact, thereby shedding and spreading the infection to new hosts (Rockett, 
1999).  Host characteristics may include factors of resistance (strengthened 
resistance may occur through BCG immunization or preventive treatment 
initiation to stop infection once an individual has been diagnosed).  
Information regarding the construct of host was collected through the 
following questions: 
o Ever received a BCG immunization? (Independent Variable 1) 
o Ever initiated preventive treatment for a positive TST? (Research 
Question 2) 
3. Environment:  Environmental conditions contribute to the spread of agent and 
include overcrowding, poor ventilation, and bad sanitation (usually present in 
developing countries, according to Heymann [2008]).  Environmental 
conditions might also include exposure to agent through lack of, or improper 
use of, engineering controls or personal protective equipment in the 
microbiology lab setting (CDC, 2009).  Barriers to preventive treatment 
initiation may also be considered environmental (medication side effects) and 
act as barriers to treatment adherence (Svarstad et al., 1999).  Information 
regarding the construct of environment was collected through the following 
questions: 
o Place of birth (U.S. or foreign)? (Independent Variable 2) 
o How many years worked in a laboratory setting? (Independent Variable 3) 





o If anti-TB medication was ever initiated, how well did it work?  Were the 
medications bothersome?  (Taken from the Brief Medication 
Questionnaire, Svarstad et al., 1999; Research Question 3) 
These interconnected factors can lead to disease.  In this research, TB infection 
(latent or active) is the disease outcome of interest (Figure 1): 
 
Figure 1. TB infection (LTBI or active TB) as an outcome of the constructs associated 
with the epidemiologic triad model. 
 
With regard to the dependent and independent variables of this study, the research 
tested hypotheses as they related to the theory of the epidemiologic triad model by first 
identifying presence of agent by measuring lifetime prevalence of self-reported tuberculin 
skin test (TST) positivity and TST positivity risk factors in the selected U.S. medical 
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identification of the latent (and sometimes, active) TB infection agent in humans.  
Second, in those respondents self-reporting a lifetime history of TST positivity, the 
remaining host and environmental variables were measured (see Table 2). 
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The epidemiologic triad model is relevant to this research for three reasons.  First, 
given the increase in foreign-born immigrants entering the HCP pool (Clearfield & 
Batalova, 2007) and the increased exposure (contact) with TB in specific workplaces 
(CDC, 2005b), it was reasonable to surmise that medical laboratory microbiologists in the 
United States might be at greater risk of reporting TST positivity than other HCP groups 
(Garber et al., 2003).  Second, given the inconsistencies in numbers of U.S. HCP who do 
not initiate preventive treatment (Garber et al., 2003; Hirsch-Moverman et al, 2008), it 
was reasonable to surmise that this subpopulation could also be at risk of treatment 
noninitiation.  And finally, given the reports that barriers to treatment adherence such as 
medication side effects prevent treatment completion in HCP (Camins et al., 1996), it was 
reasonable to surmise that this subpopulation might also be at risk for experiencing these 
barriers.  In all three scenarios, the risk of acquiring TB infection (disease outcome 
reflected as TST positivity) was conjectured to be associated with (a) the exposure to 
tubercle bacilli (agent); (b) a lack of preventive treatment (host); and (c) place of birth, 
years of exposure, and barriers to treatment (environment). 
The final analysis leading to summarization of descriptive data on the chosen 
study population and parsimonious models pertaining to the research questions have been 
discussed as they relate to the triad model.  The resulting conclusion comments more 
broadly on the relevance of this study’s findings to the epidemiologic triad model as it 
pertains to the overarching problem of identifying and halting the spread of tuberculosis 





Definition of Terms 
The following terms are definitions of technical terms, jargon, or special word 
uses found in this study.  Some terms are operational in nature and will be so designated.  
Detail of coding terms will be described in Chapter 3. 
Acid-fast bacilli (AFB): Bacteria belonging to the genus Mycobacteria, 
distinguished by their ability to retain specific stains after an acid solution rinse.  AFB 
may include Mycobacterium tuberculosis complex, as well as nontuberculosis 
mycobacteria.  Additional testing is needed in order to differentiate Mycobacterium 
tuberculosis (MTB) from other mycobacteria (NTCC, 2010). 
Active tuberculosis: Illness in which TB bacteria actively multiply. These bacteria 
usually attack the lungs of the body.  The case patient is infectious and symptomatic and 
may cough up blood and present with chest pain.  The infected individual may spread TB 
to others while in this active disease state (NTCC, 2010). 
American Society for Clinical Pathology (ASCP); ASCP Board of Registry 
(BOR): A U.S. certification registry established in 1928 for medical laboratory 
professionals, composed of members from different specialties or areas of responsibility 
within the medical laboratory scenario (ASCP, 2009). 
Bacille Calmette-Guérin immunization (BCG): A vaccine for tuberculosis named 
after French scientists Calmette and Guérin.  This vaccine has been used to reduce risk of 
TB disease in infants and children. Commonly used in highly TB-endemic countries, 
BCG use in adults is controversial (NTCC, 2010).  For the purposes of this study, BCG 





Biological safety cabinet (BSC): A BSC is a laminar flow hood used in biosafety 
levels greater than Level 2, where aerosol-generating manipulations are contained. 
Brief Medication Questionnaire (BMQ): The BMQ is a validated survey 
questionnaire tool used for screening patient adherence to treatment, as well as barriers to 
adherence (Svarstad et al., 1999). 
Contact: Refers to individual who has been exposed to M. tuberculosis infection, 
and possibly contaminated, by the sharing of air space with an individual sick with active 
TB (NTCC, 2010). 
Culture: Laboratory test in which patient specimens (sputum, body fluids, or 
tissues) are processed and plated to special media in order to grow TB bacteria.  Growth 
of MTB on culture media typically takes 2-4 weeks (NTCC, 2010). 
Directly observed therapy (DOT): Strategy designed to help with adherence to 
LTBI treatment.  A healthcare worker witnesses the patient swallow each dose of 
prescribed medication (CDC, 1999; NTCC, 2010). 
Droplet nuclei: Small droplets (1 to 5 microns in diameter) that may be expelled 
into the air as an individual with active TB coughs or sneezes.  Droplet nuclei can remain 
airborne for several hours, depending on environmental conditions (NTCC, 2010). 
Drug-resistant TB: TB disease caused by MTB bacteria that are resistant (cannot 
be killed) to at least one of the first-line antituberculosis drugs (NTCC, 2010). 
Epidemiological triad: A model used to describe the occurrence of disease as 
linked to host and environment.  By breaking one of the three triad links, the occurrence 





Exposure: Condition of being subjected to or in contact with an infectious agent, 
such as the TB organism; exposure does not guarantee infection (NTCC, 2010). 
Extensively drug-resistant tuberculosis (XDR TB): TB disease caused by infection 
with a TB strain that is resistant to INH and RIF, plus additional resistance to any 
fluoroquinolone antibiotic and at least one of the following: amikacin, kanamycin, or 
capreomycin (NTCC, 2010). 
First line TB drugs: Initial drug therapy for treatment of TB. Includes isoniazid, 
rifampin, pyrazinamide, and either ethambutol or streptomycin (CDC, 1999). 
Foreign-born persons: Individuals born outside the United States; foreign-born 
persons from TB-endemic countries are “more likely to become exposed to and infected 
with TB” (NTCC, 2010, p. 9).  For TB surveillance, a U.S.-born person is defined as 
someone born in the United States or its associated jurisdictions (U.S. territories include 
American Samoa, C.N.M.I. [Commonwealth of Northern Mariana Islands], Guam, Puerto 
Rico, U.S. Virgin Islands), or someone born in a foreign country but having at least one 
U.S.-citizen parent (CDC, 2012). For purposes of this study, foreign-born persons are not 
U.S.-born. 
Health belief model (HBM): A model used to explore why populations tend not to 
complete LTBI treatment (Glanz, Lewis, & Rimer, n.d.).  
Healthcare personnel (HCP); healthcare worker (HCW): Workers in healthcare 
organizations such as hospitals, clinics, nursing homes (NTCC, 2010).  The preferred 
terminology is HCP, where HCP refers to “all paid and unpaid persons working in 





infectious materials, including body substances, contaminated medical supplies and 
equipment, contaminated environmental surfaces, or contaminated air” (U.S. Department 
of Health and Human Services, 2008, para. 1). 
Induration: In the skin test reaction, the area of firmness produced by immune-
cell infiltration in response to intradermal introduction of tuberculin antigen.  The area is 
measured by palpation.  Results are recorded in millimeters in order to classify as a 
positive or negative skin test (NTCC, 2010). 
Interferon-gamma release assay (IGRA) or Interferon (IFN)-γ assay: Recently 
described in vitro whole blood test used to detect a component of cell-mediated immune 
reactivity to the M. tuberculosis bacteria.  Interferon-gamma is released from sensitized 
lymphocytes in specially processed whole blood (NTCC, 2010). 
Isoniazid (INH): A first-line treatment agent for latent and active TB (NTCC, 
2010). 
Laboratory work: For this study, years of laboratory work refers to clinical or 
medical laboratory experience and includes training as well as paid and unpaid work in 
areas where testing was performed on clinical specimens, controls, or isolates. 
Latent tuberculosis infection (LTBI): Known as TB infection; the infected carry 
the TB organism but do not have TB disease; the infected are asymptomatic and 
noninfectious.  These individuals usually demonstrate a positive tuberculin skin test 
reaction (CDC, 1999).  LTBI is inactive TB; however, latent infection may lead to active 





Lifetime prevalence (period prevalence): For the purposes of this study, lifetime 
prevalence refers to the proportion of the population with self-reported TST positivity (a 
given condition) over a specified time period (past and present lifetime of the individual 
study participant). 
Medical laboratory microbiologists: For the purposes of this study, this 
terminology refers to the group of members registered with and designated by ASCP as 
primarily working in the area of the laboratory known as Microbiology/Mycology/ 
Parasitology/Virology. 
Microbiology/Mycology/Parasitology/Virology: Primary area of work 
responsibility as designated by ASCP (INFOCUS Marketing, 2011).  For the purposes of 
this study, ASCP member registrants designated as working in the area of 
Microbiology/Mycology/Parasitology/Virology will be referred to as medical laboratory 
microbiologists. 
Multidrug-resistant tuberculosis (MDR TB); multi-drug resistant latent 
tuberculosis infection (LTBI): TB caused by a strain resistant to more than one anti-TB 
drug; usually resistant to isoniazid and rifampin.  May also refer to LTBI caused by 
contacts of confirmed resistant cases (NTCC, 2010). 
Mycobacteriology: Laboratory department responsible for processing and testing 
specimens for Mycobacteria (MTB and nontuberculosis). 
N-95 respirator: Personal protective equipment device; a particulate respirator 
used to remove 95% or more of TB infected particles from air inhaled by individual 





Rifampin (RIF): A first-line agent for treating TB (NTCC, 2010). 
Rifapentine (RPT): An antibiotic used for treating TB (Jereb et al., 2011). 
Treatment adherence: Following a recommended course of treatment by taking 
all prescribed medications for the entire length of time (CDC, 1999).   
Treatment barrier; treatment adherence barrier; barriers to treatment adherence: 
Anything that prevents a case patient from adhering to a treatment regimen (CDC, 1999).  
For the purposes of this study, screening for possible barriers to treatment adherence 
(leading to nonadherence) was measured as the reporting of medication side effects using 
the Belief Screen portion (Part A) of the Brief Medication Questionnaire (Svarstad et al., 
1999). 
Treatment initiation; preventive treatment initiation: Begin taking prescribed anti-
TB medications. For the purposes of this study, treatment initiation refers to starting or 
beginning treatment, even if treatment was not completed.  For this study, noninitiation 
refers to never commencing prescribed anti-TB treatment. 
Treatment of LTBI: Treatment with medication that prevents development of 
active TB disease (CDC, 1999; CDC, 2005). 
Treatment nonadherence: Inability or refusal to take TB drugs as prescribed 
(CDC, 1999).  For the purposes of this study, treatment nonadherence was measured in 
terms of self-reported completion of an entire prescribed course of treatment. 
Tuberculin skin test (TST); Mantoux skin test method: A skin test performed by 
intradermal injection of 0.1 mL of purified protein derivative (PPD) tuberculin solution to 





from a negative to a positive reading occurs in an individual undergoing repeated testing. 
An increase in reaction size by ≥ 10mm within 2 years is considered positive and 
indicates recent MTB infection.  A positive (reactive) result may also occur on the very 
first attempt at TST testing of an individual.  False-negative reactions may occur in a 
person having a recent infection or in a child under 6 months of age; false-positive 
reactions may occur because of infection with nontuberculosis mycobacteria or by history 
of BCG immunization (NTCC, 2010).   
Tuberculin skin test (TST) convertor: For this study, a TST convertor was 
identified as an individual who ever received a verbal or written report of a positive TST 
result from a healthcare or occupational services provider, and had received a negative 
TST result prior to that point in time. 
Tuberculin skin test (TST) positivity or TST status: For the purposes of this study, 
TST status refers to a self-reported lifetime history of positive TST by the survey 
participant.  The respondent was asked if he or she was ever told by a health department 
employee, occupational health department employee, or other provider (doctor) that his 
or her TST was positive.  The term status may refer to a history of either positive or 
negative TST. 
Tuberculosis: Symptomatic disease caused by Mycobacterium tuberculosis 
bacteria (tubercle bacilli). 
Tuberculosis Adherence Determination Questionnaire (TBADQ); Tuberculosis 
General Adherence Scale (TBGAS): Validated survey questionnaires in which self-





(McDonnell, Turner, & Weaver, 2001).  (These scales were discussed but not used in this 
research because of lengthy questionnaire presentations and applicability to patients with 
active TB disease and not latent disease.) 
Assumptions 
The following assumptions are facts assumed to be true but not actually verified: 
 The postal list addresses on file of ASCP registrants were assumed to be 
current and correct for use in mailing the marketing packet designated for this 
survey campaign.  Addresses on file were obtained from ASCP’s only 
approved source, INFOCUS Marketing, Inc.  This marketing source has 
reported an estimated loss of no more than 1% of addresses (S. Blake: 
INFOCUS Marketing Consultant, personal communication, September 17, 
2012).  I calculated the actual rate of returned mail. (Please refer to Chapter 
4.) 
 Correct and timely postal delivery service (with no mail lost) was assumed.  
All surveys placed in U.S. mail by respondents were assumed returned to the 
address as listed on the self-addressed return envelopes in a timely manner. 
 The Brief Medication Questionnaire (BMQ) survey tool section used in this 
survey was assumed to have been validated as reported by its authors. 
 This cohort had contact with case patient specimens in the work environment.  
These data were collected by asking respondents to designate the specific 
microbiology sections (or other areas of the laboratory) in which they worked 





These assumptions are necessary in the context of this study in order to address response 
rate as a function of the mailing process, to avoid revalidating the BMQ questions, and to 
justify use of the chosen cohort’s occupational specimen contact. 
Limitations 
The following limitations were potential weaknesses of the study: 
 The complete research survey tool is a questionnaire designed for the study 
population of ASCP professional health care personnel and is not necessarily 
generalizable to other groups.  U.S. medical laboratory microbiologists 
belonging to other registry groups were not included in this survey. 
 Questions on the questionnaire may be inherently flawed.  To avoid problems 
associated with the question structure, the questionnaire was pretested and 
pilot tested.  (Refer to Chapter 3 for detail.) 
 The questionnaire design involved self-report, which may have caused 
inherent confusion in comprehension and interpretation of survey questions.  
Possible confusion was decreased by use of the same survey question syntax 
as used in previous research by Garber et al. (2003) and in the Svarsted et al. 
(1999) validated BMQ survey research.  
 Use of a portion of the BMQ in the survey questionnaire, while useful in past 
research on general medication nonadherence, has not been implemented in 
anti-TB medication studies (Lavsa, Holzworth, & Ansani, 2011; Svarstad et 
al., 1999) until now.  The question syntax was slightly modified in the 





 Lack of willingness to respond to questions about self-reported TST may have 
led to attrition.  (Questionnaires of those who chose not to participate in the 
survey were not included in the analysis.)  Confidentiality was stressed on 
each survey cover letter.  Information on nonrespondents was not collected for 
several reasons: (a) this survey was anonymous; (b) ASCP management 
reported collecting individual demographic data as they pertained to the 
individual member profile but did not allow access to this data; and (c) ASCP 
does not assess demographic data as it pertains to the group demographic (J. 
Johnson: ASCP Customer Service Representative, personal communication, 
September 9, 2012).  
 Self-reported nature of the study:  Interpretation of what survey respondents 
were told in the past about TST status may have led to recall bias.  Although 
educated health care personnel, these respondents may have comprehended 
the questions but not remembered correctly (or at all) with regard to TST 
results, history of BCG immunization history, preventive treatment 
prescription or initiation, or treatment adherence barriers as having transpired 
in the past.  In addition, records detailing millimeters of TST induration were 
not collected, nor did any medical records undergo review. 
 Misclassification bias:  Some workers may have performed microbiology 
duties in past work although their work was not characterized as such.  An 
attempt to assess and document both past and present microbiology work in 





 Low response rate may have occurred due to the nature of the single-stage 
mail questionnaire process.  An announcement postcard preceded mailing of 
the actual survey packet by 1 week in an attempt to improve response rate.  In 
a different questionnaire mailing to an ASCP study population, response rate 
was only 22.5% (Clark, 2008).  Historically, low response rate may lead to 
selection bias and may limit precision among results as they apply to the full 
population.  An incentive, a contribution to the ASCP Scholarship Fund, was 
added in order to improve survey response.  With every 1,000 completed 
surveys returned on time, $250 (U.S.) was donated on behalf of the study 
group to the ASCP Scholarship Fund.  A charitable contribution was chosen 
as an incentive because incentives have been known to increase survey 
response rates by up to 78% (Mangione, 1995). 
 Study results were based only on those questionnaires returned within the 
allotted time frame.  Late responses postmarked more than 1 month past due 
date were not included, eliminating a portion of the survey sample results.  
Notation in large case letters was made on the front of each survey consent 
form and on the questionnaire itself to denote the time frame by which 
surveys were due. 
 Limitations of the use of tuberculin skin test (TST) as a tool include possible 
reporting of false results due to BCG immunization interference and 





results.  These problems are inherent in the use of the TST and have been 
reported as such in previous research.   
Delimitations 
The scope of this study includes addressing the following specific aspects of the 
research problem:  
 Choice of study population:  Medical laboratory scientists were chosen as a 
focus for this study because prior literature sporadically addressed regional 
subpopulations of health care personnel and laboratory personnel in the 
United States.  The ASCP membership provided an opportunity to access a 
national board of registry whose participant members actively work in the 
medical laboratory field.  The cohort with the area of responsibility of 
“Microbiology/Mycology/Parasitology/Virology” was chosen as the 
subpopulation of microbiologists for this study because a literature review 
revealed that this group is at high risk of infection with tuberculosis due to 
repeated exposure to actual case patient specimens. This group was accessed 
through the only marketing firm approved by ASCP to provide mailing lists, 
INFOCUS Marketing.  Postal mailings were used rather than email lists 
because the email list on file with INFOCUS Marketing did not represent the 
complete cohort.  At the time of this study, current email lists represented 
approximately one-third to one-half of the cohort only (INFOCUS Marketing, 
2011).  INFOCUS Marketing allowed access to the mailing list based on prior 





on a written agreement with INFOCUS Marketing (INFOCUS Marketing, 
2011).  INFOCUS Marketing reprinted all required survey packet materials 
and mailed them to the ASCP mailing list of members on my behalf. 
 Choice of method:  A quantitative, cross-sectional survey design using a 
structured written questionnaire composed of closed-ended questions was 
used because this method is inexpensive and provides an easy way to obtain 
data.  Self-reported data were expected to include some bias (see section on 
limitations).  However, the use of educated medical laboratory personnel (who 
have knowledge of tuberculosis and use of the TST) in this survey decreased 
some of the variability in reporting confusion as compared to use of other 
HCP populations. 
The scope of this study has been hereby bounded by both aspects of the study 
population and study design: 
 The population of interest was the ASCP cohort of registrants known as 
members of the “Microbiology/ Mycology/Parastiology/Virology” area of 
responsibility with U.S. mailing addresses that were most currently on file 
with ASCP during Spring 2013.  Other ASCP categories of members were not 
included in this study.  The reason for focusing on the full cohort of those 
members reported to work primarily in microbiology was that these medical 
laboratory scientists have a greater occupational exposure to tubercle bacilli 
by virtue of the type of work they perform (direct handling and processing of 





initial inquiry numbered at least 5,138 records (INFOCUS Marketing, 2011); 
the actual membership cohort numbered 4,335 at the time of mailing.  The 
focus on using ASCP certified registrants was due to the presence of the 
ASCP Board of Registry as the most prevalent registry for all medical 
laboratory scientists in the United States (ASCP, 2009).     
 The cross-sectional nature of this survey design, allowing for prevalence of 
self-reported lifetime TST-positive status reporting, is not a reflection of 
incidence.  This study was intended to serve as a single-stage sampling 
method, a snapshot in time of an individual’s status to date.  This survey 
design may be referred to as a lifetime prevalence of any past and present TST 
positivity, preventive treatment initiation (and subsequently calculated 
noninitiation), and barriers to treatment adherence (medication side effects). 
 The scope of self-reported demographics and history studied in this population 
(in order of questionnaire sections) included (a) gender, (b) age, (c) type and 
years of laboratory experience, (d) place of birth (U.S. or foreign), (e) history 
of prior BCG immunization, and (f) history of active TB and/or 
nonoccupational exposure.  These items have been the basis of previous 
research.  In addition, history of ever receiving an interferon gamma-releasing 
assay (IGRA) was explored, as it is a new blood test used now by many 
occupational health providers to replace the TST (Jereb et al., 2011). 
 Self-reported lifetime TST-positive individuals who indicated ever initiating 





allowing assessment of barriers to treatment adherence (which included drug 
side effects and bothersome features).  These two questions were derived from 
one validated section of the Brief Medication Questionnaire (BMQ).  The 
BMQ has been found to be brief and valid in screening for treatment 
nonadherence barriers (Lavsa et al., 2011).   
 This study was bounded by the epidemiologic triad model and the model’s 
associated characteristics of infectivity. 
 Time: Respondents were instructed to return study questionnaires within 4 
weeks of receipt of mail delivery, in line with acceptable time lines for data 
collection (Mangione, 1995).  Returns postmarked more than 1 month late (8 
weeks after [first class] mailing of study packet) were not analyzed.  Handling 
of incomplete questionnaires is discussed in Chapter 3. 
Because this study was limited to ASCP professional health care personnel 
reportedly working in the primary area of responsibility of Microbiology/Mycology/ 
Parasitology/Virology, results are not necessarily generalizable to other health care 
professionals or to other groups. 
Significance of the Study 
These results make an important contribution to the existing literature, enhancing 
social change initiatives through identifying prevalence and associated risk factors of 
self-reported lifetime tuberculin skin test positivity, preventive treatment noninitiation, 
and barriers to treatment adherence (presence of medication side effects) in the U.S. 





promote improved understanding of TB prevention treatment in this high-risk 
subpopulation may be achieved by using knowledge obtained from this research.  
Positive social change at this level results in the improvement of human and social 
conditions by contributing to decreases in TB disease mortality and morbidity and proper 
stewardship of ever-decreasing resources.  Targeted strategies intended to reduce 
prevalence of positive TSTs among healthcare personnel and improve treatment initiation 
rates, as well as reduce barriers to treatment adherence, are important in preventing TB 
reactivation to active TB disease (CDC 2005a, 2005b; Charles P. Felton National 
Tuberculosis Center, 2005; Fitzpatrick et al., 2005).  For example, one connection 
between actual results that this study has generated and how specific use of these results 
in making changes may occur is within the ASCP professional registry itself.  This 
research has demonstrated that this group of HCP is indeed at great risk for increased 
TST positivity and that foreign birth is one associated risk factor.  Educational strategies 
designed to target specific personnel when first certifying with ASCP or upon 
membership renewal may assist in promoting treatment initiation.  Any barriers to 
treatment adherence (such as medication side effects) in this same group may be 
addressed by educational interventions designed to alleviate these barriers.  Additional 
research among other certification groups of ASCP might follow, adding to the initiative 
among all laboratorians to halt the spread of TB. 
This research is significant in order to assist in identification of subpopulations at 
risk of developing active TB.  The literature has addressed prevalence and predictors of 





However, a literature review has revealed that a single study has neither addressed U.S. 
medical laboratory microbiologists nor been conducted from the perspective of a national 
registry cohort.  This study differs from previous studies by addressing the U.S. medical 
laboratory scientist population identified by ASCP as working in the area of 
responsibility known as “Microbiology/Mycology/Parasitology/Virology.”  By 
identifying the prevalence of (a) self-reported lifetime tuberculin skin test (TST) 
positivity, (b) preventive treatment noninitiation, and (c) barriers to treatment adherence 
(the presence of medication side-effect barriers as measured by the Brief Medication 
Questionnaire) and predicting models of associated risk factors for each in this 
subpopulation,  the overall health of medical laboratory HCP, families, patients, and 
coworkers will improve due to focused preventive treatment with recommended regimens 
(Lambreghts, 2008).  In addition, this study assesses gender, age, type of laboratory 
work, and nonoccupational contact as confounders or modifiers.  An evaluation of how 
each outcome varies across demographic and work-related factors has taken place and is 
represented in Chapters 4 and 5.  The collection of these data and subsequent analysis 
support an epidemiologic model for describing this ASCP subpopulation. 
The sharing of research findings with the ASCP and its membership, other 
healthcare professionals, and the public health community at the close of this study will 
assist in bringing the issue of TST positivity from an historic lifetime prevalence 
perspective and aspects of preventive treatment noninitiation and adherence barriers to 
light.  In addition, published findings will be shared with the owners of the BMQ survey 





promise more accurate identification of LTBI status, at present, the TST remains a 
recommended, inexpensive method for detecting LTBI among healthcare personnel 
(CDC, 2005a).  Gauging TST positivity among a national HCP group such as this ASCP 
subpopulation aids public health professionals in further understanding LTBI among U.S. 
medical laboratorians. 
The first step in controlling the burden of active TB disease is to identify LTBI 
and active TB disease in at-risk populations and initiate appropriate treatment (CDC, 
2000).  As a result of this study, positive social change is expected to occur through the 
description of an at-risk population in order to assist in reducing TB mortality and 
morbidity and improving stewardship of TB control resources.  An overall decrease in 
monetary costs of TB may follow.  The Centers for Disease Control and Prevention 
(CDC, 2002) have estimated that TB-related costs approach $1 billion in the United 
States each year. 
This study promotes greater understanding of LTBI (prevalence as measured with 
TST history) among the cohort of medical laboratory microbiologists, a subpopulation of 
healthcare personnel in the United States.  The CDC (2002) has reported that to maintain 
the current decline in TB incidence in the United States, timely treatment management of 
TB by “prevention of transmission through infection control” (CDC, 2002, p. 6) is of 
great importance. 
Summary and Transition 
In summary, this research study is intended to provide a snapshot of TST 





barriers to treatment adherence (medication side effects) among a subpopulation of U.S. 
HCP known as medical laboratory microbiologists.  Access to the scientists registered 
with ASCP has provided an opportunity to compile and analyze new data on 
laboratorians while comparing results to other well-documented studies, such as those 
reported by Garber et al. (2003).  The key points of this research were to 
1. Survey this HCP subpopulation for prevalence of self-assessed TST results 
throughout the lifetime and determine risk factors of self-reported lifetime 
history of TST positivity; 
2. Determine treatment initiation rates among self-reported TST ever-positive 
individuals who were prescribed preventive treatment and predict a model for 
risk factors of preventive treatment noninitiation; 
3. Determine barriers to treatment adherence (medication side effects) among 
those ever initiating preventive treatment using the belief screen portion (Part 
A) of the BMQ and predict a model for barriers to treatment adherence (due to 
medication side effects) using BQM scores; and 
4. Evaluate how each outcome varied across demographic and work-related 
factors. 
The remainder of this study is described in Chapters 2 and 3, following prescribed 
guidelines of the Walden University School of Health and Human Services.  Chapters 4 
and 5 of the dissertation cover study results and final discussion, describing data 





Chapter 2, the literature review, addresses pertinent TB and LTBI literature as it 
pertains to descriptive epidemiology of (a) global, (b) U.S., and (c) HCP populations, and 
drill-down to the level of (d) the medical laboratory microbiologist.  History of the 
tuberculin skin test and specifics on treatment initiation and nonadherence among HCP 
and the subpopulation of laboratorians are reviewed.  Literature referring to the 
independent and dependent variables is scrutinized.  Survey instruments used to 
determine adherence to treatment regimens and related barriers to treatment are explored 
and compared.  A review of the literature as it pertains to public health prevention and 
control, as well as LTBI and TB theory and methods is presented.   
Chapter 3, Research Method, discusses the intended use of the self-administered 
mail questionnaire for this quantitative survey method research.  A thorough review and 
discussion of the operationalized definitions, questionnaire tool, as well as the validated 
survey tool, the BMQ (Svarstad et al., 1999) follow.  Sample size requirement 
calculations are demonstrated.  Intended methods for univariate, bivariate, and 
multivariate analysis are described in detail. 
Chapter 4, Results, covers the actual research results as obtained during the mail 
survey of medical laboratory workers.  Results are presented in table format, and analyses 
using Epi Info™ software (CDC, 2011c) are provided. 
Chapter 5, Discussion, Conclusions, and Recommendations, discusses the 
interpretation of the research results in detail.  Conclusions from this study and 





Chapter 2: Literature Review 
Introduction 
Halting the global spread of tuberculosis (TB) is one of the significant public 
health challenges of this century (IOM, 2000; StopTB Partnership, n.d.; World Health 
Organization [WHO], 2010b).  Identification and treatment of individuals at risk for 
developing LTBI and active TB are of the utmost importance in stopping TB’s spread 
(CDC, 2002, 2003a), as well as in controlling costs.  “In New York City alone, for 
example, the monetary costs for losing control of TB proved to be in excess of $1 billion” 
(IOM, 2000, p. 1).  Losing control of the spread of TB has led to emergence of drug-
resistant strains (Bradford et al., 1996; WHO, 2001a, 2001b).  These costs and resistance 
have been described as threats to “global stability and national security” (WHO, 2001b, 
p. 1). 
For years, the tuberculin skin test (TST) has been the screening test of choice for 
identifying individuals infected with the latent (inactive) form of TB. Once identified, 
these individuals are targeted for preventive treatment.  Although treatment is usually 
indicated in these cases, many individuals resist initiation of treatment or adherence to a 
prescribed course of treatment; identification of barriers to completion of treatment is 
needed to maintain control of TB (CDC, 2003a).  Healthcare professionals (HCP), 
especially medical laboratory microbiologists, comprise a group of individuals thought to 
be at higher risk of acquiring TB infection than the general population, either through 





This chapter presents an overview of the following: (a) the historical background 
of Mycobacterium tuberculosis (TB) infection (including descriptive epidemiology and 
TB infection prevalence and risk factors drilled down from global to U.S. levels), (b) 
aspects of TB infection in healthcare personnel (HCP) and the laboratorian 
subpopulation, (c) the public health impact of TB infection, (d) the study’s research 
variables, (e) relevant theories in TB research, and (f) design, research, and analysis 
methods.  Addressing these topics is necessary in demonstrating the gap found while 
researching the literature: the lack of current information regarding TST positivity, 
treatment noninitiation, and treatment nonadherence (medication side-effect) barriers in 
specific groups of U.S. healthcare personnel, such as U.S. medical laboratory 
microbiologists.  The content of this literature review will address TST-positivity 
prevalence among HCP, specifically what is known regarding the HCP subgroup of 
medical laboratory microbiologists.  In addition, this review will focus on research 
methods used in obtaining TST positivity (prevalence) and risk factors compared with 
TST conversion (incidence) statistical data, preventive treatment initiation, and treatment 
nonadherence (barrier) data from several populations, but mainly focused on different 
HCP populations.  Finally, the medical laboratory microbiologist population will be 
addressed.   
Review of the Literature 
Organization of the Review 
The review of the literature begins with a brief description and background of the 





(MTB) bacteria, clinical characteristics of TB infection, diagnosis, testing for TB 
infection, treatment, and descriptive epidemiology of TB as an infectious agent. 
Understanding prevalence and incidence, and risk factors as they pertain to the general 
population will be covered.  More detail on the healthcare personnel (HCP) and then the 
laboratorian subpopulation follows, including literature pertaining to occupational risk, 
prevalence (TST-positivity) and incidence (TST-conversion), preventive treatment 
initiation, treatment nonadherence, and treatment barriers.  Current recommendations for 
TB prevention and control are also discussed in detail. 
A thorough description of the research variables as risk factors is presented, as 
well as a description of this study’s specific research variables.  Past research and history 
of theory as it applies to the current literature are reviewed, and current research 
regarding risk factors for infection with active and inactive TB infections is discussed in 
the context of the hypotheses under study.  Finally, comparisons of relevant research and 
analysis methods are discussed in detail, and the gap is explained. 
Search Strategy 
Pertinent scholarly, peer-reviewed literature was identified through a search of 
databases using the search terms TB or tuberculosis and tuberculin skin test or TST, 
and/or healthcare worker or HCW, and/or healthcare personnel and/or HCP.  A separate 
search was performed using the term tuberculin skin test positivity.  Additional search 
terms included mycobacteriology or laboratory, as well as self-reported.  LTBI treatment 
plus initiation or adherence or nonadherence and healthcare worker were also used in 





TST, the search terms self-reported tuberculin skin test plus validity were used.  Initial 
searches were limited to publications between January 1, 1980, and January 1, 2012. 
Individual publications were first searched, including Emerging Infectious Diseases 
(EID) and Clinical Infectious Diseases (CID).  PubMed, Academic Search Premier 
within the EBSCO database, CINHAL within the EBSCO database, Google Scholar 
database, and the dissertation database for ProQuest were searched using the search terms 
listed above.  If at any time an article was not located using traditional databases, the 
Walden Library Document Delivery Service (Illiad) was used.  Of great use was the 
special search query using the phrase “What's new for 'tuberculosis'” in PubMed.  I 
received periodic emails from the My NCBI “What's new” search for results from the 
National Center for Biotechnology Information (NCBI) at the U.S. National Library of 
Medicine (NLM).   
In addition to journal and database searches, reference lists of selected peer-
reviewed journal articles were reviewed to identify additional studies pertinent to this 
review.  This process was used most frequently.  (Some historic and sentinel theory 
articles dating from the 1940s, 1950s, 1960s, and 1970s were located using this latter 
method.) 
Inclusion criteria were as follows: articles with abstracts that focused on LTBI or 
active TB among healthcare personnel (HCP), as well as among subgroups of clinical or 
medical laboratorians.  Article abstracts describing occupational risk factors were also 
perused prior to retrieving the entire article from the source. TST positivity or TST 





criteria.  Studies related to TST conversion were added later, in an attempt to compare 
research methods and gain additional information on risk factors.  Inclusion criteria 
included articles with a focus on LTBI or active TB treatment initiation (noninitiation) or 
treatment adherence (nonadherence).  Later attempts at expanding the search criteria to 
include treatment adherence barriers among different populations and different disease 
outcomes were also added.  Articles focusing on cross-sectional research methodologies 
(surveys and questionnaires) and epidemiologic triad models were highly desirable, as 
were articles using other research and analysis methods for purposes of comparison. 
Relevance of the Literature to the Research Questions 
This literature review is intended to evaluate the historical and current literature 
with regard to an overview of the different aspects of tuberculosis infection (latent and 
active), as well as with regard to the research questions as described in Chapter 1 of this 
study.  In addition, a focus on the HCP subpopulation of medical laboratorians, 
specifically that of medical laboratory microbiologists as a subgroup, will take place.  
Much of the literature regarding etiology, epidemiology, and treatment was extracted 
from CDC and WHO resources.  Those resources and the primary journal articles will be 
used to explain what is known about tuberculosis infection.  This review will also attempt 
to answer the following questions: What is the relationship between history of BCG 
immunization, place of birth (U.S. or foreign), and years of laboratory experience, and 
 Self-reported lifetime history of tuberculin skin test (TST) positivity?   
 Preventive treatment noninitiation among those individuals prescribed 





 Treatment adherence barriers (medication side-effects measured with the 
BMQ) among those initiating treatment for latent or active TB? 
Overview of Clinical Tuberculosis 
Discovery of Tuberculosis Bacteria 
Tuberculosis, also known as TB, is considered an ancient disease.  Egyptian 
mummies dating back 4,000 years have produced evidence of tubercular decay 
(Nobelprize.org, 2012).  For centuries, TB has been described in the literature (CDC, 
2011e).  Hippocrates once noted that consumption was the most widespread and fatal 
disease of his time (Nobelprize.org, 2012).  Considered a death sentence to anyone 
diagnosed with the disease (CDC, 2011e), TB became treatable after the 1940s and 1950s 
with the development of antibiotics (Nobelprize.org, 2012). 
Mycobacterium tuberculosis (MTB) bacteria were first described by Robert Koch, 
a German physician and scientist.  Koch’s discovery and presentation of TB involved a 
new staining method, which he demonstrated to an audience in 1882 during a medical 
lecture (Nobelprize.org, 2012).  Koch’s staining method remains in use by laboratory 
microbiologists to this day.   
Following the establishment of tuberculosis as an infectious disease, antibacterial 
drugs were developed, a significant landmark in the fight to control TB infection.  Three 
Nobel Laureates, Paul Ehrlich, Gerhard Domagk, and Selman Waksman, have been 
largely credited for this early work.  From 1944 to 1954, three drugs—streptomycin, 
para-aminosalicylic acid (PAS), and isoniazid—became available for use in treating TB 





active TB infection was significant among individuals who could take a combination of 
drugs for an extended period of time.  Today’s anti-TB medications continue to require 
this combination of drugs taken over several weeks or months.    
Etiology of Tuberculosis  
Tuberculosis bacteria belong to the genus Mycobacterium, where over 150 
different species have been identified to date (Behr, 2010).  The majority of the 
Mycobacteria are nonpathogenic.  Tuberculosis (TB) infections are caused by the species 
Mycobacterium tuberculosis (MTB) complex.  The complex includes subspecies M. 
tuberculosis, M. bovis (cow), M. africanum, M. canettii, and occasionally M. microti, M. 
caprae, and M. pinnipedii (Heymann, 2008).  Although the vast majority of human 
clinical cases are caused by M. tuberculosis, all of these organisms may produce 
clinically similar symptoms (Heymann, 2008).  Many different strains of MTB exist 
worldwide, complicating all aspects of TB disease (Behr, 2010). 
The Mycobacterium tuberculosis genome has been sequenced, revealing over 
4,000 genes (Heymann, 2008).  The complete genome sequence of Mycobacterium 
tuberculosis was published in 1998, accelerating the study of MTB pathogenesis (Cole et 
al., 1998; Mathema, Kurepina, Bifani, & Kreiswirth, 2006).  The belief at the time was 
that human TB originated with the domestication of cattle, as linked to M. bovis (to be 
mentioned later in the discussion on immunization).  However, Mostowy and Behr 
(2005) determined this to be improbable; rather, MTB belonged to the Mycobacterium 
tuberculosis complex.   In 2009, researchers derived a phylogeny, a lineage for the 





many other species within the genus are nonpathogenic (Veyrier, Pletzer, Turenne, & 
Behr, 2009).  
Clinical Characteristics of Tuberculosis Infection 
Manifestations.  Clinical manifestations of tuberculosis infection may take one of 
two forms: latent or active TB disease.  Initial infection may go unnoticed.  Although 
individuals with either form are considered infected with bacterium belonging to the 
Mycobacterium tuberculosis complex, clinical characteristics differ.  For the purposes of 
the remainder of this literature review, and because most public health research involving 
tuberculin skin testing is in agreement on this point (CDC, 2005a, 2010a), discussion will 
relate only to the Mycobacterium tuberculosis organism within the MTB complex. 
Latent infection.  Latent TB infection (LTBI) is a condition in which persons 
infected with the tuberculosis bacteria may harbor the bacteria without displaying 
symptoms.  The bacteria are inactive in this state, or dormant, and kept in check by the 
body’s immune system (Nobelprize.org, 2012).  Although the individual does not feel 
sick, the dormant bacteria may become active in the future for many different reasons.  
Reports have indicated that “as many as one-third of all living beings are latently 
infected” (Nobelprize.org, 2012, p. 2).  While not every infected individual becomes sick, 
about 5% to 10% of persons with normal immune systems will develop TB disease at 
some point in their lives; this risk is the highest in the first 2 years after infection (CDC, 
2011a, 2011b).  Latent TB infection may persist throughout the entire lifetime of an 





Active infection.  Active TB infection is a disease condition in which persons 
infected with the tuberculosis bacteria harbor the bacteria and do indeed display one or 
more symptoms.  The TB bacteria have created a state of active disease after a short 
period of incubation, or after reactivation of latency.  The activation of latent TB may 
occur in individuals with a weakened immune system, as in HIV-infected individuals.  
“About one-third of the more than 40 million HIV/AIDS patients are co-infected with TB 
bacteria” (Nobelprize.org, 2012, p. 2).  During this time frame, these individuals begin to 
exhibit symptoms of active disease and may be able to spread TB bacteria to others 
(CDC, 2011e). 
Although different parts of the human body can be affected in TB infection 
(active disease), the lungs remain the primary cause for concern.  General symptoms of 
active TB disease may include (a) fever, (b) chills, (c) night sweats, (d) weight loss, (e) 
loss of appetite, (f) fatigue, and (g) malaise (CDC, 2011b).  According to CDC (2011b), 
the primary symptoms of pulmonary TB disease include (a) cough lasting for 3 or more 
weeks, (b) chest pain, and (c) coughing up blood or sputum.  In extrapulmonary TB 
disease, spinal TB disease may cause back pain, while TB disease of the kidneys may 
present with blood in urine, and TB in lymph nodes may present as neck swelling (CDC, 
2011a, 2011e). 
Diagnosis: Medical Evaluation and Testing 
A thorough medical history to detect risk factors for developing TB (active 
disease) should include an individual’s social, family, medical, and occupational 





infectious TB should be documented.  In addition, history of latent TB infection 
(previous positive tuberculin skin test or blood test result) and information on any 
treatment initiation and completion should be documented.  If any of these risk factors 
are present, a medical professional should suspect TB disease (CDC, 2011a, 2011e).  
Once active TB disease is suspected, a physical exam should follow and include a chest 
x-ray and bacteriological examination (tests for smear and culture). 
The bacteriological examination is performed by a microbiology laboratory that 
performs identification and/or susceptibility testing of Mycobacteria tuberculosis (MTB) 
and other Mycobacteria species.  Specimens are collected at a health center, clinic, or 
hospital setting and sent to the laboratory for testing.  (Of note, this examination and 
subsequent handling of specimens poses a point of possible exposure to the laboratorian.)  
CDC (2011b) guidelines for testing of the specimen (usually sputum) include the 
following: 
1. Proper collection of a specimen representative of the sputum, body fluid, or 
tissue under study, 
2. Processing the specimen for microscopic examination of acid-fast bacilli 
(AFB) on smears, 
3. Direct identification of specimen (using nucleic acid amplification test 
methods), 
4. Culture (growth) and identification (of AFB bacteria), and 





Testing is intended to rule in or rule out MTB as soon as possible in order to 
implement infection control guidelines and initiate proper treatment of patient.  
Characteristics associated with active tuberculosis include cough persisting 3 weeks or 
more, insufficient treatment for a latent TB infection, cavitations on chest X-ray, positive 
AFB smear result, or positive AFB culture where MTB has been definitively identified 
(CDC, 2011a).  While active TB disease is diagnosed using culture and direct microscopy 
techniques, inactive disease has been diagnosed historically using the tuberculin skin test 
(TST). 
To test for TB infection (infection with M. tuberculosis), specific diagnostic tests 
may include the following: 
 Mantoux tuberculin skin test (TST), 
 Interferon-gamma release assays (IGRAs)—blood tests, and/or 
 Smears and cultures, as mentioned in the previous section on Medical 
Evaluation. 
CDC (2011e) has reported that a positive TST or IGRA indicates infection, but 
cannot serve to identify an active state of disease.  Further medical evaluation is 
recommended at this stage. 
Tuberculin skin test (TST).  The tuberculin skin test (TST) has been used as an 
initial screening test for detecting LTBI and active TB in the United States.  LTBI has 
been diagnosed historically using the tuberculin skin test (TST).  The TST has been used 
to evaluate close contacts of individuals with active TB disease, to screen high-risk 





2005b).  The TST has been used to examine an individual’s antibody response to 
Mycobacterium tuberculosis antigens present in purified protein derivative (PPD) 
tuberculin solution (NTCC, 2010).  The test, performed using the Mantoux technique, has 
required injecting 0.1ml of 5 TU purified protein derivative (PPD) solution under the 
forearm skin intradermally.  A delayed hypersensitivity reaction is detectable and read 
within a 48-72 hour time frame by a trained professional.  The hypersensitivity reaction is 
detectable within 2-8 weeks after initial infection (CDC, 2010a).  In the United States, a 
positive TST is determined by measuring zone size and combining these results with risk 
of exposure to TB and risk of progression to active TB disease (Heymann, 2008).  
According to CDC (2010a), the TST should be 
 Interpreted the same as for individuals having received the BCG vaccine.  
 Read in millimeters of skin induration and based on risk of exposure.   
 Performed on HCP (and especially on mycobacteriology laboratory 
employees) considered to be at high risk of exposure. 
Proper interpretation of the TST zone of induration size determines the need to begin 
preventive treatment (Heymann, 2008).   
Positivity.  TST positivity is the consequence of an initially positive TST result or 
conversion from a negative to a positive TST result over the long-term.  An individual 
may present with a positive TST result on the first attempt at skin testing or may have 
converted from negative to positive status.  (Conversion is discussed further in the next 





form of latent or active infection with the TB organism and warrants further investigation 
by a healthcare provider (CDC, 2010a). 
At present, prevalence of LTBI is estimated using the TST or the IGRA blood test 
and is useful as a baseline indicator.  The resulting TST- or IGRA-positive result 
(indicating positivity) is a gauge of prevalence in a population provided the individual 
does not display characteristics of active TB disease.  Examples of TST positivity and 
prevalence data will be discussed later in this chapter. 
Conversion.  Incidence of LTBI is currently estimated through a documented 
conversion, using the TST or the IGRA blood test.   Use of the TST to determine 
conversion includes performing a two-step test with a negative baseline (CDC, 2010a).   
A subsequent positive TST indicates that conversion has occurred.  This conversion 
means that the individual has experienced an exposure leading to infection, and this 
infection is usually latent (but may become active TB disease in some at-risk 
individuals).  The conversion period must be documented, as it is a test reaction change 
occurring over a set time frame. 
Examples of TST conversion have been well-documented in the literature.  
Among HCP at low risk of TST conversion are administrative personnel, demonstrated to 
have a TST conversion rate of 0.3% when compared with the clinical staff conversion 
rates of 1.1% to 1.5%  reported in an Atlanta hospital from 1994-1998 (Larsen et al., 
2002).   In the same study, TST conversions among the BCG-vaccinated reached 20.0% 
(an increase suspected to be due to boosting), while nonBCG-vaccinated conversions 





(second only to nurses) in one retrospective cohort study (Miller, Tepper, & Sieber, 
2002).  Years of employment within the same occupation were also a factor in the Miller 
et al. research.  In the microbiology laboratory, considered a high-risk setting, a very high 
11.4% TST conversion rate was reported in one study (Kraut et al., 2004). 
Tuberculin skin test imitations and usefulness.  Although the TST continues to 
be utilized as a test of choice in detecting inactive (latent) TB infection, the test is subject 
to several limitations.  First, difficulty in proper placement of the purified protein 
derivative (PPD) or reading the results properly may lead to false positive or false 
negative results (CDC, 2011a).   Second, false positive results can result from cross-
reactivity caused by host exposure to other mycobacteria such as those included in the 
BCG vaccine (CDC, 2011a).  No studies involving laboratorians and cross-reactivity 
exposures were located while performing this literature review.  However, one study 
reported an absolute false positive prevalence rate of 0.1% (Canada) to 2.3% (India), 
depending on a country’s prevalence of sensitization to nontuberculosis mycobacteria 
(Farhat, Greenaway, Pai, & Menzies, 2006).  Third, immunosuppression of the host (such 
as in cases of HIV infection) may cause a falsely decreased response to the PPD (CDC, 
2011a, 2011e).   
One such example was a study in which a falsely elevated TST conversion rate 
was reported to be as high as 9.8% among a group of medical students.  Only half of 
those were true TST convertors, determined by repeat testing with a different PPD 
material and read by a trained individual upon retesting (Wurtz, Fernandez, & Jovanovic, 





Interferon-gamma assays (IGRA blood tests).  In recent years, new IGRA 
blood tests have entered the market with the intended role of improving sensitivity and 
specificity over the TST for diagnosis of tuberculosis infection.  These blood tests 
measure immune reactivity to M. tuberculosis.  An infected individual’s blood should 
release interferon-gamma (IFN-γ) from white blood cells when mixed with proteins 
derived from M. tuberculosis antigens.  One visit to the laboratory for testing (as opposed 
to two for TST) and less cross-reactivity with BCG immunization and nontuberculosis 
mycobacteria (Mazurek et al., 2001) are definite advantages.  High expense and special 
specimen processing requirements are limitations to using this test over the TST.  In 
addition, these blood tests are like the TST in that impaired immune function in an 
individual may decrease test sensitivity, leading to indeterminate or false negative 
screening test results (Heymann, 2008).  The IGRA tests are available in limited use at 
present, and several researchers have stated that these assays are now widely recognized 
as “the 100-yr up-grade on tuberculin skin test for diagnosis of latent tuberculosis 
infection” (Lalvani & Millington, 2008, p. 1429).  The IGRA tests deserve mentioning, 
but at the time of this literature review, remain an evolving test protocol.   
Research to date has determined that the IGRA tests have a place in diagnosing 
LTBI in high-risk groups and in countries where BCG vaccination is routinely performed 
(Ozekinci, Ozbek, & Celik, 2007), as well as in the hospital setting (Ferrara et al. 2005).  
In low-risk populations, these tests may be useful in helping to diagnose both LTBI and 
active TB (Tahereh, Alireza, Massoud, & Amina, 2010).  However, IGRA blood tests 





results (Ferrara et al., 2005).  In one study, the difference between diagnostic confidence 
of one IGRA blood test (QuantiFERON™-TB Gold) and the TST were determined as a 
(a) Positive Predictive Value (PPV) of 52% for the blood test and 54% for the TST, and a 
(b) Negative Predictive Value (NPV) of 86% for the blood test and 67% for the TST 
(Tahereh et al., 2010).  The importance of gauging a useful NPV is justified in the 
knowledge of high costs involved in treating a case of LTBI over many months. 
Among healthcare personnel, one particular study demonstrated differences that 
have been observed between one blood test method and the TST.  In Denmark, a low-
incidence tuberculosis country, TST positivity among a group of 192 infectious disease 
department workers was reported at 34%, while the same group demonstrated a positivity 
rate of 1% by IGRA blood test method (Soborg et al., 2006).  The differences were linked 
to prior BCG immunization as the only significant risk factor in the study.  Soborg et al. 
(2006) reported that in contrast, these differences are much less in countries with 
medium- or high-risk.   An example of this scenario was found in research where 
participants living along a Turkish region of the Mediterranean demonstrated a BCG 
vaccination rate of 94.2%, but TST-positivity rate of 7.4% (Kazanci et al., 2010).  In 
Turkey, where TB disease remains prevalent, BCG vaccination is compulsory for all 
infants (Kazanci et al., 2010; WHO, 2011b). 
Although promising, the IGRA blood test is not logistically practical in many 
settings.  At present, the TST remains the most widely used and cost-effective screening 






Treatment of Inactive (Latent) and Active Infections 
In addition to knowledge of TST positivity and related predictive factors, it must 
be stressed that preventive treatment for latent tuberculosis infection (LTBI) is of great 
interest in slowing or stopping the spread of TB.  Prescribed treatment is important 
because it is thought to prevent latent TB infection from becoming active TB disease 
(Heymann, 2008).  Candidates for treatment of LTBI include certain high-risk groups 
identified through targeted public health programs, such as immigrants (especially those 
from TB-endemic regions), injection drug users, residents and employees of high-risk 
congregate settings (such as correctional facilities, homeless shelters, hospitals), and 
persons with decreased immune system functionality (CDC, 2011e).  Of importance to 
this study, CDC has recommended treating personnel from mycobacteriology laboratories 
who have demonstrated a positive TST (or IGRA blood test) or conversion (CDC, 2005b, 
2011e).   
Treatment of LTBI is presently restricted to three generally accepted options, 
depending on age and presence of comorbidity (CDC, 2011e): 
 Isoniazid (INH) taken daily for a total of 9 months. 
 Isoniazid (INH) and rifapentine (RPT) given in 12 doses (once-weekly).  
 Rifampin (RIF) daily for a total of 4 months (or use of Rifabutin [RBT]).  
As noted, proper preventive treatment takes many months and many doses in 
order to sustain TB control and prevent development of resistance (Larson, 2007; WHO, 
2001a).  This long treatment duration may be why treatment noninitiation and 





by Jereb et al. (2011) has provided a more efficient regimen, intended to improve 
treatment adherence.  The recommended LTBI treatment consists of a 12-dose regimen, 
whereby 12 once-weekly doses are given over 3 months.  Two drugs, Isoniazid and 
Rifapentine, given as directly observed treatment, have been found just as effective as the 
standard 270-dose 9-month treatment (Jareb et al., 2011). 
No matter which course of preventive treatment is prescribed, all patients should 
be educated to recognize adverse reactions to the medications (CDC, 2011a, 2011e).  In 
addition, completion of treatment should be documented and retained with the individual 
(CDC, 2011e). 
Treatment for active TB disease will last from 6 to 9 months in drug-susceptible 
individuals, and longer (up to 24 months) if multidrug-resistant TB has been identified 
(CDC, 2011e).  CDC (2011e) reported that the preferred treatment regimen for treating 
drug-susceptible active TB disease in persons not infected with HIV includes a 
combination of several anti-TB medications taken over many weeks.  However, current 
global community prevalence of resistance to isoniazid and rifampin is about 0.7% for 
both drugs combined (Larson, 2007).  It is important to note that drug susceptibility 
results may not be available for many weeks due to the slow-growing nature of MTB 
bacteria and the individual laboratory’s processing-to-result turnaround time.   
Costs involved with treating MDR TB and XDR TB are several times higher per 
patient than costs involved with treating drug-susceptible strains of MTB (WHO, 2011b).  
In the United States for year 2010, cost per TB patient treated with first-line drugs was 





total health expenditures by the entire public sector (WHO, 2011b).  In other regions 
around the world, costs ranged from $100 to $500 per patient for treatment, while TB 
control cost was typically > 7% of total health expenditures by the public sector (WHO, 
2011b).  
The Infectious Diseases Society of America (IDSA, 2004) reported that some 
serious diseases have no treatment except for supportive care.  For diseases (like active 
tuberculosis) that do have effective treatments, complacency may delay new research 
causing existing treatments to be ineffective when resistant strains arise.  TB is an 
example of a disease where over 30 years have passed since a new class of antibiotic was 
approved for treatment (Larson, 2007).  In addition, TB treatment for inactive and active 
infections is complex and sometimes toxic, adding to the difficulty in ridding the world 
of this disease. 
Descriptive Epidemiology 
 Geography.  Every country is affected with over 95% of infections occurring in 
developing countries (Heymann, 2008, p. 643).  Worldwide in 2010, incident cases 
reached 6.2 million people diagnosed with active TB; 5.4 million had TB for the first 
time and 0.3 million had recurrence of TB after receiving prior treatment (WHO, 2011b).  
Forty percent of the world’s incident cases of active TB in 2010 were located in India and 
China, while Africa accounted for 24% (WHO, 2011b).  Of note, twenty-two high 
incidence countries accounted for 82% of the total incident cases (WHO, 2011b).  Cases 
are defined by WHO as confirmed Mycobacterium tuberculosis (MTB) isolated from 





TB strains has been identified in countries of Eastern Europe, Latin America, Africa, and 
Asia (WHO, 2001a, 2011b). 
In the United States, active TB has been reported in almost every state and while 
increasing in some geographical areas (CDC, 2011b, 2011d), the total number of active 
TB cases has decreased (CDC, 2011d).  According to CDC (2011b), other issues related 
to antimicrobial resistance have become problematic.  
Age.  U.S. cases of active TB by age demonstrated a downward trend in all age 
groups from 1993 to 2009 (CDC, 2010b).  In 1993, the highest incidence rate of active 
TB cases (per 100,000) reported was 17.7 in the > 65 year age group (this group had 
highest exposure occurring before the advent of treatment), while the four age groups 
denoting ages 0-14, 15-24, 2-44, and 45-64 years averaged rates of 2.9, 5.0, 11.5, and 
12.4, respectively (CDC, 2010b).  In 2009, incidence rates of active TB dropped to  5.8 
for the > 65 year age group, and 1.0, 3.0, 4.7, and 4.3 for divisions representing age  
groups 0-14, 15-24, 2-44, and 45-64 years, respectively (CDC, 2010b).  According to 
ASCP, the average age of the U.S. medical laboratory workforce was nearing 50 years in 
2008 (ASCP, 2008) making this subgroup of HCP at greater risk based on age alone. 
Gender.  In high-incidence countries, morbidity is highest among adult males 
(Heymann, 2008).  In the industrialized countries, mortality and morbidity have been 
trending downwards but have recently stagnated due to HIV infection, poverty, and the 
dismantling of TB control services (Heymann, 2008).  Males remain at a higher rate of 
11.8 per 100,000 and females at a rate of 5.1 per 100,000 for cases of active TB in the 





unemployment and the associated higher chances of contact with TB (McKenna, Hutton, 
Cauthen & Onorato, 1996).  ASCP (2008) reported that nearly three-fourths of the U.S. 
medical laboratory scientist workforce in 2005 was female, and therefore not as high-risk 
a group based on gender alone. 
Reservoir.  The reservoir of M. TB complex is primarily that of humans, and 
rarely found in other primates (Heymann, 2008).  The reservoir of M. bovis is cattle and 
other mammals (Heymann, 2008). 
Transmission.  TB is spread among individuals via forceful exhalation of 
aerosolized droplet nuclei (microscopic droplets) containing viable tubercle bacilli (TB 
bacteria) from individuals with active cavitary pulmonary or laryngeal disease (Mathema 
et al., 2006).  The risk of infectivity depends upon exposure and host factors (Heymann, 
2008).   
In laboratory workers, skin, eyes, alimentary tract, and respiratory tract have long 
been known as portals of entry for the airborne tuberculosis bacilli (Long, 1951).  Since 
the 1950s, many healthcare engineering controls have been implemented that have 
decreased this risk.  In addition to transmission between individuals via respiratory route, 
examples of portals of entry in laboratorians were first described by Long (1951) as skin 
(incision or glass puncture wounds, abrasives, prolonged contact with pus, finger in eye), 
alimentary tract (inhaled, then swallowed), respiratory tract (droplets), and intravenous 
(needle prick).  Although rare in number, and preventable through measures employed in 
the laboratory, these portals bear mentioning.  Long (1951) described work with infected 





although still infrequent.  Extrapulmonary specimens (urine, pus, fluids) may also be 
high-risk specimens, but again rarely causing active infection, according to Allen and 
Darrell (1981).   
Incubation period.  An incubation period of approximately 2 to 10 weeks post 
initial infection results as active disease lesions or inactive (latent) disease (Heymann, 
2008). 
Pathogenesis and host response.  Infection occurs when individuals inhale 
droplet nuclei containing the tubercle bacilli and the bacilli bacteria begin to multiply in 
the small air sacs of the lung (CDC, 2011a, 2011e).  After inhalation of particle sizes only 
1 to 5 microns in diameter, the particles are phagocytized by aveolar macrophages in the 
lung, leading to a vigorous immune response (Mathema et al., 2006).  According to CDC 
(2011b), the bacilli then enter the bloodstream and spread, and in individuals where the 
immune system is functioning correctly, continued spread is halted within 2 to 8 weeks 
post infection.   The individual is considered at this point to have LTBI.  If the host’s 
immune system cannot keep the tubercle bacilli under control, the bacteria multiplies, 
destroying tissue (usually in the lungs).  Individuals that have reached this point in the 
infective process are considered to have active TB disease and may now spread the 
bacteria to others. 
A more dynamic hypothesis by Cardona (2009) described that in LTBI, constant 
reinfection is occurring rather than tubercle bacilli residing in a state of dormancy.  The 
traditional version of the static LTBI state versus Cardona’s dynamic hypothesis is of 





Evidence of Mycobacterium tuberculosis reactivation occurring decades after 
initial infection has been demonstrated by Lillebaek et al. (2003).  Results indicated that 
1990 strains were not new, but reactivated dormant strains from those isolated in the 
1960s.  The rate of change of the DNA in latent infection (activated to active infection) 
was much longer than the rate seen during active disease. 
Communicability.  Heymann (2008) reported that as long as live TB organisms 
are discharged in sputum through coughing, singing, and like airborne routes, 
transmission between individuals will occur.  Effective treatment usually eliminates 
communicability within 2-4 weeks; however, TB may still be cultured from sputum 
during this time (Heymann, 2008).  Of note, some individuals (identified as Acid Fast 
Bacilli [AFB] smear-positive) may be intermittently positive and contagious for years 
until diagnosed and treated (Heymann, 2008).   According to Heymann, the degree of 
communicability depends on several factors: (a) degree of intimacy, (b) duration of 
exposure, (c) number of AFB bacilli actively discharged, (d) infectivity of the bacilli, (e) 
adequacy of ventilation, (f) exposure of bacilli to sun or ultraviolet light, and (g) 
opportunities for aerosolization (as in coughing, singing, and talking).  In addition, the 
degree of communicability among healthcare personnel may depend on the frequency or 
type of procedures performed where aerosolization or invasive contact may occur, 
especially when performing certain procedures in the medical laboratory (Heymann, 
2008).  Other characteristics associated with infectiousness (presenting a portal of exit for 
the bacterium) include a failure to cover mouth/nose when coughing or sneezing, and 





Regarding communicability, the American Thoracic Society (2005) recommends 
all inpatient facilities that manage persons at risk for TB have infection control policies 
and procedures in place to minimize the risk for nosocomial spread of infection.  In 
addition, facilities should report persons with suspected or confirmed TB to the local 
health department (American Thoracic Society, 2005).  Local and state statues that exist 
in many regions detail specifics regarding notification and treatment of diseased 
individuals because the communicability of these individuals poses a risk to society. 
Susceptibility to infection.  The risk of TB infection may depend on host’s 
ability to fight disease (Caminero, 2010; Heymann, 2008).  The HIV-infected and 
immunosuppressed have higher risk of infection leading to clinical disease following 
exposure, with the first 12-24 months post-exposure noted as a period of highest risk.  
Among those co-infected with HIV and latent TB, the lifetime risk of developing active 
TB disease is 10% to 50% (Heymann, 2008); management becomes complex and 
difficult when the patient has gone on to develop active TB infection (CDC, 2011e).  
While susceptibility to TB infection remains high in these patients, encouraging data has 
shown that HIV co-infection rates in persons with active TB in the U.S. fell from 15% in 
1993 to 6% in 2009 (CDC, 2011a) presumably due to better disease management.   
Dose and severity of infection (virulence).  A low infective dose for humans has 
been reported to be a 50% infective dose of < 10 bacilli (CDC, 2009).  Severity of 
infection is dependent on co-morbidity (host factors), as well as environmental factors 
mentioned previously.  And sometimes, individuals may be infected with more than one 





of latent infection and possible subsequent infection with an active resistant strain are 
severe.  Infective dose may have great bearing in the laboratory where concentrated 
numbers of bacilli may be present, becoming a reason for increased risk in this setting 
(CDC, 2009).   
Prevalence and incidence of latent infection.  In 2002, A Federal Tuberculosis 
Task Force Plan estimated prevalence of individuals in the United States with latent TB 
(LTBI) at 10 to 15 million (CDC, 2003a).  More recent estimates have reported 
prevalence of LTBI in the U.S. at 9 to 14 million (CDC, 2011e); lower, but still an 
alarming number.  The prevalence of LTBI increases with age; it is estimated that one 
third of world’s population is infected (Heymann, 2008).  There is no surveillance system 
in the United States for determining prevalence of LTBI; the United States depends on 
international calculations of prevalence by WHO in order to estimate risk (Khan, 
Muennig, Behta, & Zivin, 2002). 
In the United States, the annual risk of new TB infection is estimated to be 
approximately 10 in 100,000 people overall, with some segments of the population at 
higher risk (Heymann, 2008).  Approximately 10% of individuals diagnosed with 
inactive or latent tuberculosis infection (LTBI) progress to develop active TB disease, 
according to the CDC (2005a).   
Prevalence and incidence of active disease.  As mentioned earlier, many cases 
of active TB are the result of reactivation of inactive TB infection (LTBI).  This is why it 
is so important to follow active TB disease cases from the standpoints that (a) these cases 





promoting the cycle or chain of infection.  Global cases of active TB peaked around years 
2004-2005, and have since stabilized or are now decreasing (Heymann, 2008).  
According to Heymann (2008), the 22 highest-burden countries account for 80% of new 
cases each year, having reported a rate of 174 cases per 100,000 in 2005.  In 2009, 9.4 
million new TB cases were reported (WHO, 2010b).    
Emergence of resistant TB, categorized as multidrug-resistant tuberculosis (MDR 
TB) or multidrug-resistant latent tuberculosis infection (MDR LTBI) and extensively 
drug-resistant tuberculosis (XDR TB), has come to the forefront in recent years. 
Estimates of MDR TB are 4.8% of active TB cases worldwide, up to 20% of new cases in 
Eastern Europe and Central Asia, and up to 60% of previously treated cases (Heymann, 
2008).  The countries of China, India, and Russia accounted for 57% of the overall 
(estimated) incidence of MDR TB (Heymann, 2008).  In China alone, 120,000 new cases 
of MDR TB are identified each year and some are actually more resistant than first 
thought (Tang et al., 2011).  In 2009, 3.3% of all new TB cases were MDR TB, while in 
some regions, MDR TB  rates reached up to 28% of new TB cases in 2010 (WHO, 2010).  
XDR TB incidence is about 6% of all MDR TB isolated worldwide in 2007 (Heymann, 
2008), and reported to have high rates of mortality such as the 98% mortality rate 
reported in one South African outbreak (Calver et al., 2010; Heymann, 2008).  XDR TB, 
a major public health threat, has been confirmed in 58 countries according to WHO 
(2010).   
Cases of active TB in the United States have been trending downward (Figure 2); 





the United States result from reactivation of LTBI from a prior initial infection; however, 
in urban areas about one third of new cases of TB disease may result from recent 
infection or from exposure to areas where overcrowding occurs (Heymann, 2008).   
 
Figure 2.  Reported TB cases, United States, 1982–2010. From “Key Graphics From 
2010 U.S. TB Surveillance Data” (Public domain images), by Centers for Disease 
Control and Prevention, 2011, retrieved February 20, 2012, from 
http://www.cdc.gov/nchhstp/newsroom/TBSurveillanceGraphics.html 
 
CDC has reported “no apparent trend in the number of XDR TB cases over time 
in the United States” (CDC, 2011a, p. 12).  Ten cases were reported in 1993 in the United 
States, but very few since then.  No cases in 2009, according to CDC (2011a).  However, 
as more immigrants arrive in the United States, the numbers of MDR and XDR cases 
may increase over time.  It is important to remember that medical laboratory 
microbiologists may be at risk of exposure to these resistant strains as they are discovered 





Morbidity.  In the United States, the rate of morbidity has fallen from 2003 
through 2009 (rate of 5.1 per 100,000 to 3.9 per 100,000); morbidity in 2009 was 11,545 
individuals (CDC, 2011a). 
Mortality.  Estimates have been made placing global deaths due to tuberculosis 
from years 1700 to 1900 at 1 billion individuals, and annual death rate during the time of 
Koch’s discovery of the tubercle bacilli at about 7 million people (Nobelprize.org, 2012). 
In 2009, 1.7 million people died from TB (WHO, 2010b).  
Risk Factors 
Foreign birth.   “As of 2001, TB cases in foreign-born persons now account for 
at least 50% of all cases reported in the United States annually” (CDC, 2002, pp. 9-10).  
In 2001, this was news in the United States; but by 2010, up to 65% of all active TB 
cases were reported in the foreign-born (CDC, 2011d).  (Refer to Figure 3.)  By 
individual U.S. states and territories, New York, Washington D.C., New Jersey, Georgia, 
Florida, Mississippi, Louisiana, Texas, California, Nevada, and Hawaii averaged the 
highest case rates in the nation (CDC, 2011a).  Seven countries (Mexico, Philippines, 
India, Vietnam, China, Guatemala, and Haiti) accounted for 62% of foreign-born cases in 
United States (CDC, 2011a).  Among all reported cases of MDR TB in the United States, 
those reported from 1993-2009 among the foreign-born rose from 25% in 1993 to 88% in 







Figure 3. Proportion of U.S. TB cases by place of birth. From “Key Graphics From 2010 
U.S. TB Surveillance Data” (Public domain images), by Centers for Disease Control and 
Prevention, 2011, retrieved February 20, 2012, from http://www.cdc.gov/nchhstp 
/newsroom/TBSurveillanceGraphics.html 
 
By number of U.S. states, the percentage of TB cases among the foreign-born rose 
from 13 states in 1999 to 31 states in 2009 for ≥ 50% of cases, and 2 states in 1999 to 14 
states in 2009 for ≥ 70% of cases (CDC, 2011b, slide set).  In addition, among all 
reported cases of multidrug-resistant tuberculosis (MDR TB) in the United States, from 
1993 to 2009, cases among foreign-born rose from 25% in 1993 to 88% in 2009 (CDC, 





The active TB disease rate was calculated in 2004 to be 21.5 per 100,000 among 
foreign-born versus 2.7 per 100,000 among U.S.-born individuals… “almost one-quarter 
of all TB cases in the United States occur among foreign-born persons who have resided 
in the United States for longer than 5 yr” (Cain et al., 2007, p. 75).  Zuber, McKenna, 
Binkin, Onorato, and Castro (1997) have referred to this “imported” TB as preventable.  
In a study of 1986-1994 cases reported to the CDC, a majority of TB incident cases were 
in those younger than 35 years upon arrival to United States, and could have been 
prevented with initiation of preventive treatment (Zuber et al., 1997). 
Race and ethnicity.  By ethnicity in the United States, Asians and Pacific 
Islanders had the highest active TB case rates, while Black or African-American, and 
Hispanic followed in year 2010 (Figure 4).  This disproportionate burden depends on (a) 
infection acquired in country of origin, (b) unequal distribution of TB risk factors, (c) 
lower socioeconomic status, and (d) overcrowding (CDC, 2011a).  Medical laboratory 
scientists in the United States appeared representative of the diverse and ethnic makeup 







Figure 4. TB rates by race/ethnicity in the United States, 2010. From “Key Graphics 
From 2010 U.S. TB Surveillance Data” (Public domain images), by Centers for Disease 
Control and Prevention, 2011, retrieved February 20, 2012, from http://www.cdc.gov 
/nchhstp/newsroom/TBSurveillanceGraphics.html 
 
To summarize, active TB infection affects racial and ethnic minorities disproportionately 
in the United States (CDC, 2011e).   
Social determinants.  The distribution and course of TB is dependent on 
biological factors such as co-morbidity with HIV, resistant TB strains, and social forces 
such as poverty, economic inequality, political violence, racism—examined thru the lens 
of Farmer’s work in Haiti (Farmer, 1997), but also applicable to other countries where 
TB is moderate- or high-incidence.  More and more, TB is becoming known as a social 
disease (Lonnroth et al., 2010; WHO, 2010a).  Specific factors leading to high risk of TB 
transmission at the global level include overcrowding, poorly ventilated housing, poor 
living conditions, malnutrition, smoking, and stress (Figueroa-Munoz & Ramon-Pardo, 
2008; Lonnroth, Jaramillo, Williams, Dye, & Raviglione, 2009), as well as social 





2008).  Traditionally, vulnerable groups include the homeless, mobile communities, 
injecting drug users, and those co-infected with HIV.  Development of resistant TB 
strains among non-adherent household contacts living in poor conditions (Velasquez et 
al., 2011) and among certain groups of drug abusers (Perri et al., 2011) have added 
concern.  The impact of globalization on refugee migration patterns has been described as 
a risk factor where TB among migrants should be viewed and screened according to 
country of origin (Figueroa-Munoz & Ramon-Pardo, 2008).  It has been said that the real 
cause of the spread of TB is not so much the microbe as socioeconomic and political 
factors (WHO, 2010a). 
Occupation.  “Certain occupations may be associated with an elevated risk” 
(McKenna et al., 1996, p. 587).  Among 29 U.S. states during years 1984-1985, one 
occupational study presented data based on information gathered on all active TB cases.  
Census data was used to estimate number of individuals in each occupation.  This study, 
performed by McKenna et al. (1996), reported an overall case rate of 8.4 per 100,000 
individuals, where healthcare workers carried an overall  rate of 6.7 per 100,000, 
inhalation therapists rate of 15.6, and clinical laboratory technologists and technicians 
rate was reported at 6.7.  The study further identified a rate of 10.5 for nursing aides, 
orderlies, and attendants, 22.2 for those working with animals, 8.2 for those employed in 
food service, 10.7 for those employees exposed to dust, licensed nurses as 6.1, registered 
nurses (RNs) at 5.8, and physicians at a rate of 6.6 per 100,000 individuals.  McKenna et 
al. (1996) concluded that in low-incidence communities, healthcare workers do not 





to low SES were associated with elevated rates.  (For example, the laboratory worker 
category SES scores were listed as technical, faring better than farm workers, laborers, 
and service personnel.)  
Researchers such as Baussano et al. (2011) have reported that globally, rates of 
newly described active TB cases (incidence) for HCP are higher than the general 
population, representing TB as an occupational disease.  Rates of active TB infection in 
HCP have been DNA fingerprinted in order to determine an association with occupation 
(de Vries, Sebek, & Lambregts-van Weezenbeek, 2006). In the de Vries et al. (2006) 
research, 42% of TB cases in the Netherlands during 1995-1999 (those working in 
healthcare) were found to have been infected during work.  While occupation alone 
cannot predict TST results, certain occupational factors involving contact with TB-
contaminated patients or specimens remain well-known risk factors.   
The Healthcare Personnel (HCP) Population 
Definition of Healthcare Personnel (HCP) 
Throughout the literature search and review, a number of studies involved use of 
the terminology HCP versus HCW.  It became important to note the difference while 
reviewing the research results.  Further investigation revealed that in 2008, the general 
terminology health-care worker (HCW) was changed to healthcare personnel (HCP) by 
the U.S. Department of Health and Human Services (2008).  This terminology was 
changed in order to broaden the definition to clarify that HCP refers to both paid and 
unpaid workers.  This recommendation was made by the Advisory Committee on 





Committee (HICPAC).  In this recommendation, “HCP are defined as all paid and unpaid 
persons working in health-care settings who have the potential for exposure to case 
patients and/or to infectious materials, including body substances, contaminated medical 
supplies and equipment, contaminated environmental surfaces, or contaminated air.” 
(U.S. Department of Health and Human Services, 2008, para. 1).  While all HCP are 
included in this definition, the following reviewed HCP literature rarely included or 
operationally segregated medical laboratory microbiologists from the aggregate data. 
Healthcare Personnel: By Occupation 
By occupation, the percentage of active TB cases among healthcare personnel 
(HCP) in the United States reached 3.8%, second only to cases among unemployed and 
retired individuals in 2009 (CDC, 2010b).  Other high-risk occupational groups such as 
migrant workers and correctional employees were reported at 1.2% and 0.2%, 
respectively (CDC, 2010b).   
Tuberculin Skin Test Prevalence (Positivity) and Incidence (Conversion) Rates 
Among Healthcare Personnel 
Globally, much work has been done to seek out prevalence and incidence rates of 
LTBI among HCP (Joshi et al., 2006; Menzies, Joshi, & Pai, 2007).  LTBI prevalence 
rates ranged from 33% to 79% in low- and middle-income countries, to 5% to 55% in 
high-income countries (Joshi et al., 2006).  Incidence of active TB infection attributable 
to work in health care has been cited at ranging from 1.1% in high-income countries to 
5.8% in low- and middle-income countries, with rates of active TB infection consistently 





TB rates in low- and middle-income countries were associated with occupational 
exposure, while rates in high-income countries were associated with other factors 
(Menzies et al., 2007).  One study gauged LTBI incidence based on countries with 
historic rates of TB incidence (not based on income), reporting that LTBI incidence in 
low-TB incidence countries was found to be 3.8%, intermediate-TB incidence at 6.9%, 
and high-TB incidence at 8.4% (Baussano et al., 2011).  This latter research also reported 
that introduction of TB control measures (use of negative pressure rooms and N-95 
masks) appears to have decreased TB annual incidence among HCP by as much as 81% 
in high-income countries (Baussano et al., 2011).  In this literature search, several other 
international studies corroborated these findings (Baussano et al., 2007; Christopher et 
al., 2010; Drobniewski, Balabanova, Zakamova, Nikolayevskyy, & Fedorin, 2007; Roth 
et al., 2005).  The one exception was found in a recent Malaysian study where overall 
prevalence of LTBI among HCP was 10.6% using a combination of the TST and the 
IGRA blood test (Rafiza et al., 2011).  This exception may have occurred because of the 
better sensitivity and specificity associated with the blood test method. 
This search and review of the literature also found several U.S. studies of HCP 
describing LTBI prevalence (TST positivity) rates ranging from 11.3% (Bailey, Fraser, 
Spitznagel, & Dunagan, 1995) to 32% (Cook et al., 2003).  LTBI incidence (TST 
conversion) rates were reported at 1.2% (Larsen et al., 2002) and 1.5% (Panlilio et al., 
2002), to 5.7% in high-risk settings (Cook et al., 2003).  Miller et al. (2002) reported TST 
conversion rates of 5.8% among potentially exposed HCP, while a rate of 2.0% was 





presented by Joshi et al. (2006) and Menzies et al. (2007).  U.S. reports of higher LTBI 
prevalence rates have been linked to an increase in foreign-born HCP  (Cook et al., 
2003), while higher LTBI incidence rates have been reported among certain HCP 
occupations (Louther, 1998). 
Preventive Treatment Initiation Rates Among Healthcare Personnel 
In this search, findings were limited regarding rates of preventive treatment 
initiation among groups of HCP (other than laboratorians; see below).  A retrospective 
cohort study by Gershon et al. (2004) in Toronto described n = 308 HCP diagnosed with 
LTBI reported to have sustained a preventive treatment initiation rate of 58% overall.  
The authors surmised that the odds of HCP initiating treatment remain about one-half of 
those of a non-health care worker and depended on factors of age, BCG immunization, 
foreign birth, and contact with persons having TB. 
Treatment Nonadherence and Barriers Among Healthcare Personnel 
Preventive treatment completion rates among HCP and other high-risk groups 
have been reported to range anywhere from 27% to 82% (Hirsch-Moverman et al., 2008) 
when compared with the general public’s completion rates approximating 60% (CDC, 
2000). Overall completion rates may reach only 55% (Camins et al., 1996).  In the 
Camins et al. study, as many as 11.4% of those who did not complete treatment stopped 
because of real or perceived drug effects.  Other research has indicated that HCP 
nonadherence to preventive treatment may have been due to a perception that treatment 
was harmful with potential adverse drug effects (Joseph et al., 2004).  While treatment 





disease, provider, and patient-provider characteristics (Kennedy, 2000), barriers 
consistently reported among HCP were those of adverse drug effects. 
The Laboratorian Subpopulation 
Definitions and Background 
The U.S. Department of Labor Bureau of Labor Statistics (2011) has reported that 
May 2010 estimates of medical and clinical laboratory technologists in the United States 
numbered 164,430 individuals, while medical and clinical laboratory technicians 
numbered 156,480.  Not every technologist or technician has worked in the field of 
medical laboratory microbiology, and not every laboratorian in the U.S. who is working 
with Mycobacterium is working as a medical or clinical laboratorian.  At present, the 
Centers for Medicare & Medicaid Services (CMS, 2012) regulate all laboratory testing 
(except research) performed on humans in the United States through the 1988 Clinical 
Laboratory Improvement Amendments (CLIA).  This overarching authority to regulate 
these entities began with the CLIA Subpart M, an amendment containing the personnel 
sections of the CLIA regulations.  The Final Rule on these personnel requirements 
became effective on January 24, 2003.  One approved U.S. registry that fits the 
requirements of CLIA is the American Society for Clinical Pathology, established in 
1928 (ASCP, 2009).   
A search of the ProQuest Dissertations & Theses and EBSCO databases revealed 
one study only involving American Society for Clinical Pathology (ASCP) registrants.  In 
this study, a self-administered mail survey was performed using the ASCP mailing list.  





related to questions about job satisfaction, intent to quit, and job retention (Clark, 2008).  
A 10% returned-to-sender rate was realized in this research, as was a rejection rate of 
13.5%; the overall response rate was 22.5% (Clark, 2008). 
Tuberculin Skin Test Prevalence (Positivity) and Incidence (Conversion) Rates 
Among Laboratorians 
Among HCP, medical laboratorians have been at high risk for TST positivity as 
well as for developing active TB disease from a latent (inactive) form of TB.  Since the 
1940s and 1950s, laboratory workers exposed to sputum or post mortem samples from 
tuberculosis patients have been at greater risk for incidence of active TB when compared 
to the general public (Baussano et al., 2007; Harrington & Shannon, 1976; Reid, 1957).  
The CDC (2005) has included laboratory workers in guidelines for TB screening 
programs at the level of the health-care setting.  Anyone participating in aerosol-
generating procedures or in specimen-processing procedures (including processing for 
Mycobacterium tuberculosis) should take part in regular TST screening protocol 
according to CDC (2005).  In addition, other specific factors increasing risk in the United 
States include (a) recent immigration from endemic countries, (b) working in hospitals or 
other congregate healthcare facilities, and (c) microbiology staff working in the 
mycobacteriology laboratory (CDC, 2000, 2005b).   
Globally, high rates of LTBI prevalence have been associated with working in 
laboratories, especially in low-income countries (Joshi et al., 2006).  In Russia, LTBI 
prevalence rates determined by a combination of TST positivity and IGRA blood test 





workers (Drobniewski et al., 2007).  Roth et al. (2005) also reported high TST-positivity 
prevalence among Brazilian laboratorians—a rate of 61.2%.  The exception to these 
studies was a Malaysian study using a combination of TST and blood test to determine 
LTBI prevalence; n = 29 microbiology laboratory workers, where none tested positive 
(Rafiza et al., 2011). 
Literature was located in this search which also demonstrated high prevalence of 
TST positivity: a baseline of 57% among New York City laboratory workers (n = 345) 
with an accompanying incidence of LTBI determined to be 1% over a 2-year time period 
(Garber et al., 2003).  This figure is much lower than the Canadian LTBI TST-conversion 
rate of 13% among laboratory workers reported by a Menzies, Fanning, Yuan, Fitzgerald, 
and the Canadian Collaborative Group in Nosocomial Transmission of Tuberculosis 
(2003) study (n = 517).  In another U.S. study, incidence of TST-conversion was highest 
among laboratory technicians, as well as nurses and other subgroups of HCP (Miller et 
al., 2002). 
Because of choice of study design used in assessing TST rates, the laboratory 
worker has been notably omitted from HCP subgroupings (Bailey, Fraser, Spitznagel, & 
Dunagan, 1995), or has been grouped into a larger conglomerate of other non-related 
technical services (Louther, 1998).  Some studies surveyed entire laboratory entities 
rather than individuals (Jacobson, Orlob, & Clayton, 1985; Kao, Ashford, McNeil, 
Warren, & Good, 1997; Vaquero, Gomez, Romero, Casal, & Spanish Group of 
Mycobacteriology, 2003).  All studies included in this segment of the literature review 





Preventive Treatment Initiation, Treatment Nonadherence, and Barriers Among 
Laboratorians 
A literature review revealed that although microbiology laboratory HCP may be 
offered preventive isoniazid treatment therapy for suspected LTBI, initiation rates may be 
as low as 20% (Garber et al., 2003); access, eligibility, and barriers were not assessed.  In 
this review of the literature, no studies were located that described research involving 
LTBI treatment nonadherence or adherence barriers for the laboratorian or medical 
laboratory microbiologist population separate from HCP aggregate research. 
Brief History of Tuberculosis Risk Among Laboratorians 
The CDC has stated, “Microbiology laboratories are special, often unique work 
environments that may pose identifiable infectious disease risks to persons in or near 
them” (CDC, 2009, p. 1).  Throughout the history of microbiology, published reports 
have described laboratory-acquired infections with TB near the top of the list.  The first 
notable paper located in this literature search was that of Sulkin and Pike (1951), 
detailing the high number of suspected occupational cases of TB reported in 5,000 
laboratories surveyed by the authors.  At the time, laboratories kept few records of 
instances of laboratory infection.  In 1957, Reid reported incidence of TST positivity in 
studies of clinical laboratory recruits to be as high as 49.2% to 88.9%, but also pointed 
out that cases of TB in the general public were also rampant (Reid, 1957).   
Hazards of acquiring TB infection in the laboratory setting were becoming more 
frequent due to greater use of new culture methods, creation of aerosols in preparation of 





infected patients through necropsy (Collins, & Grange, 1999; Sewell, 1995; Sulkin, 
1961).  A review of the literature from 1950 to 1963 demonstrated that a new focus was 
placed on use of protective devices and analysis of occupational hazards (Pike, Sulkin, & 
Schulze, 1965).  Thus, after decades of debate regarding the increased incidence of active 
TB disease in physicians, nurses, and technical staff (laboratorians included), several 
states began offering workmen’s compensation for tuberculosis as an occupational 
disease (Sepkowitz, 1994).  Identification of TB risk in pathology and laboratory workers 
has since become important for reasons of (a) prevention, and (b) compensation practice 
(Seidler, Nienhaus, & Diel, 2005). 
Engineering controls in laboratories.  Laboratory-acquired infections like TB 
prompted the use of engineering controls, such as the laminar-flow biological safety 
cabinet (BSC) and special fit-tested respirators (such as N-95) in laboratories (Singh, 
2009).  In addition, the first edition of the Biosafety in Microbiological and Biomedical 
Laboratories (BMBL) was published in 1984 (CDC, 2009).  The BMBL outlined specific 
recommendations and guidelines for working with microorganisms like those belonging 
to the Mycobacterium tuberculosis complex.  The current version of the BMBL reported 
that the incidence of tuberculosis in laboratory personnel working with suspect agents has 
at times been three times higher than in those not working with the agent (CDC, 2009). 
Rates of active TB have been found to be significantly higher among laboratorians, and 
suspected as related to underperforming BSCs (Alonso-Echanove et al., 2001).  
Recommended use of another engineering control, the negative pressure room with 





Fitzgerald, and the Canadian Collaborative Group in Nosocomial Transmission of TB 
(2000).  Although laboratorians were not a part of this particular research, it is important 
to note that TST conversion among HCP groups was strongly associated with work in 
non-isolation rooms with less than 2 air exchanges per hour.  Engineering controls that 
are not working properly, are not used properly, or are not in use at all place the medical 
laboratory microbiologist at risk for exposure to TB. 
 Occupational injury and illness classification.  The current Occupational Injury 
and Illness Classification Manual (Version 2.0), used to code and recognize suspected 
occupational exposures for all U.S. workers, currently classifies tuberculosis by species 
of mycobacterium and characterization of clinical features, by TST positivity, by anxiety 
associated with exposure, and by exposure with no other manifestations (U.S. 
Department of Labor Bureau of Labor Statistics, 2010).  Because the latent period from 
initial infection to TB disease is long and subject to inaccuracies in reporting of rates, 
TST positivity occurring among all HCP (including laboratorians) and even a census of 
fatalities due to TB disease as reported to Occupational Safety and Health Administration 
(OSHA) may be underrepresented (Sepkowitz & Eisenberg, 2005).  Sepkowitz and 
Eisenberg reported that many HCP remain at risk today for activation of TB active 
disease due to TST conversions occurring in HCP during the late 1980s and 1990s, a time 
when nosocomial outbreaks in the United States were frequent due to resurgence of TB. 
Prevention and Control in Laboratorians 
Because TB is transmissible via airborne routes of infection, appropriate infection 





While the use of these measures has not been addressed in this survey, the importance of 
control measures cannot be understated.  Control measures have helped decrease 
occupational cases of TB infection over the past several decades (CDC, 2009).  In 
healthcare facilities and congregate settings, CDC (2011e) has recommended 
 prompt methods for detecting TB; 
 use of airborne precautions to prevent spread of tubercle bacilli; and 
 prompt and proper treatment of individuals who have suspected or confirmed 
disease.  
Occupational concerns must also be addressed, and include the implementation 
and use of environmental engineering controls.  Use of personal protective equipment, 
such as personal respirators to prevent inhalation of infectious droplet nuclei should be 
worn by healthcare workers (CDC, 2009, 2011e).  In addition, surgical masks should be 
worn by the infected patients to prevent spread of droplet nuclei into the air.  In the 
environment of the medical microbiology laboratory, use of the BSC equipped with 
special filters and negative pressure rooms help to prevent airborne tubercle bacilli from 
escaping into the work area room air (CDC, 2005b).  These examples demonstrate the 
importance of preventing spread of TB in the occupational setting. 
Importance of identifying and treating latent infection among healthcare 
personnel.  The importance of identifying and treating LTBI among HCP is evident in an 
example of transmission which took place during 2003, as reported by Fitzpatrick et al. 
(2005).  A foreign-born nurse with undiagnosed active tuberculosis exposed 32 





nursery and maternity ward.  An extensive contact investigation followed; transmission 
was documented in four infants that had positive TST.  This nurse had been diagnosed 
with LTBI 11 years prior, but did not initiate treatment to prevent latent TB bacteria from 
becoming active TB.  A similar scenario was reported in 2003 when a hemodialysis 
technician in Nevada became ill with pulmonary TB, exposing more than 400 patients 
and other employees (Hickstein et al., 2004).  The HCW also had a previous positive TST 
result but never initiated treatment.  The results of a contact investigation found that the 
HCW had transmitted M. tuberculosis to 29 patients and 13 employees.  In yet another 
case, a neonatal intensive care unit respiratory therapist with pulmonary TB exposed 180 
infant patients and 248 HCP (Nania et al., 2007).  These examples demonstrate the 
importance of identification of LTBI in health care personnel, as well as timely LTBI 
preventive treatment initiation and treatment adherence.   
Surveillance and Healthy People 2020.  Surveillance of active TB cases (as well 
as contacts of active cases suspect for LTBI) and associated preventive treatment is 
important in stopping the spread of TB in the United States.  The U.S. Department of 
Health & Human Services (n.d.) has set specific targets related to reducing active and 
inactive tuberculosis (TB) rates and increasing treatment completion rates in its Healthy 
People 2020 (HP2020) document.  What follows is a synopsis of these targets.  However, 
please note that only one of the four objectives (IID-31) is related to LTBI.   Foreign-
born persons are targeted in objective GH-2, treatment completion (adherence) rate is 





First, the global HP2020 objective GH-2 decribed decreasing the TB case rate for 
foreign-born persons living in the United States.  (A target of 14.0 cases per 100,000 
population was set in relation to a baseline of 20.2 cases of active TB per 100,000 
population, reported for foreign-born persons living in the United States in 2008.)  
Second, the Immunization and Infectious Disease objective IID-29 described reducing 
TB.  (A target of 1.0 new case per 100,000 population was set in relation to a baseline of 
4.9 confirmed new cases of TB per 100,000 population, reported to CDC by all 50 States 
and the District of Columbia in 2005.)  Third, objective IID-30 described increasing 
treatment completion rate of all TB patients who are eligible to complete therapy.  (The 
target has been set at 93% in relation to a baseline of 83.8% of persons with confirmed 
TB completed curative therapy in 2006.)  Fourth, objective IID-31 described increasing 
the treatment completion rate of contacts to sputum smear-positive cases diagnosed with 
latent tuberculosis infection and started on LTBI treatment.  (The target has been set at 
79.0% in relation to a baseline of 68.1% of contacts, diagnosed with LTBI, who 
completed a course of treatment in 2007.) 
Surveillance and molecular testing.  The advent of molecular testing has 
become important in prevention for several reasons.  To date, genotyping has assisted in 
public health outbreak investigations involving tuberculosis.  Current methods are used to 
study the molecular epidemiology of TB, such as tracing the chain of TB transmission in 
short-term and long-term outbreaks, determine global spread, detect mixed infections in 
TB patients, and help in identification of new strains and resistance, as well as understand 





important in detecting errors in handling and processing of TB isolates, such as cross-
contamination in laboratories which may lead to false-positive reports of TB (American 
Thoracic Society, 2005; Mathema et al., 2006).  The extensive topic of molecular 
surveillance is beyond the scope of this research. 
Screening and treating immigrants to the United States.  Globally, variation in 
TB resistance patterns makes treatment of latent or active tuberculosis difficult.  Given 
that the TB burden is disproportionately high among the foreign-born in the United 
States, the importance of screening and treating immigrants to the United States from 
developing regions of the world for LTBI has become an important strategy in stopping 
progression of TB and in halting development of resistant strains.  One model has 
predicted that if this strategy were implemented in the United States for one year, 9,000 
to 10,000 cases of active TB could be avoided at a savings of $60 million to $90 million 
(Khan et al., 2002).  Given that these benefits would accrue over the long-term, the same 
model predicted that half of the calculated benefit would be realized within 6 years.  
Vaccination (Bacille Calmette-Guérin immunization).  Bacille Calmette-
Guérin (BCG) immunization was first developed in 1908 by the French scientists, Calette 
and Guérin, and first administered in 1921 to ward off cases of TB (WHO, 2012).  BCG 
is no longer used in the United States because it is considered useless in preventing adult 
pulmonary tuberculosis (CDC, 2010b).  The vaccine contains a live attenuated 
(weakened) strain of Mycobacterium bovis (WHO, 2012).  BCG is an immunization used 
in many TB-endemic regions of the world.  The World Health Organization (WHO) has 





countries; however, BCG vaccination is not recommended in the United States (CDC, 
2010b).  As many as one-quarter of surveyed medical school graduates believe 
incorrectly that immunization with the BCG vaccine offers long-term protection (Salazar-
Schicchi et al., 2004). 
Direct observation.  Public health strategies that have been used to improve 
LTBI and TB treatment initiation and adherence have included forms of directly observed 
treatment (DOT).  DOT strategies have demonstrated significant improvement in 
treatment success when compared with control groups (Hsieh et al., 2008), although one 
study of cohorts followed throughout the 1990s may not be in agreement.  The Bayer et 
al. (1998) research demonstrated minimal improvement in TB treatment completion rates 
where completion rates reported from 80% to 87% overall were consistent, despite a 
DOT rate ranging from 16.8% to 49.4%.  A similar strategy was reported by Tavitian, 
Spakek, & Bailey (2003) and involved use of a hospital-based clinic to prescribe LTBI 
treatment to HCP.  Treatment completion rates ranged from 90% to 100% from 1997 to 
2001, demonstrating significant improvement in overall adherence and completion. 
Description of the Research Variables 
Risk factors associated with LTBI and active TB infection among the general 
population have been described previously in this chapter, as have risk factors among 
populations of HCP and subpopulations of laboratorians. 
Independent Variables (Risk Factors) 
The independent variables in this study are BCG immunization, place of birth 





questionnaires is justifiable in many studies of disease exposure.  These have been used 
to study occupational exposures in medical students (Koppaka, Harvey, Mertz, & 
Johnson, 2003).  The following section will attempt to explain why the variables have 
been chosen as risk factors, as well report on research associated with them. 
Bacille Calmette-Guérin (BCG) immunization.  BCG immunization was 
chosen as an independent variable because it has appeared in TB study literature as a 
significant predictor.  Two cross-sectional studies using self-administered surveys in this 
review of the literature found BCG as a significant predictor of TST positivity.  For 
example, among U.S. laboratory HCP self-reporting TST positivity, Garber et al. (2003) 
found BCG a significant predictor using both univariate and multivariate analyses.  Using 
multivariate analysis, an OR of 4.89 was realized when comparing TST positivity in 
individuals reporting ever having had a BCG immunization and those reporting never 
having received BCG.  In nearby Canadian populations, Hernandez-Garduno and Elwood 
(2008) reported BCG as a predictor of TST positivity prevalence (OR 19.6.), again, using 
multivariate analysis in the comparison of those reporting receipt of a BCG immunization 
versus those who had no recollection of BCG history.  BCG was not expected to be a 
significant predictor in research studies involving high-incidence TB countries, where 
BCG immunization is given routinely as a preventive course.  To demonstrate this, the 
U.S. study of medical school students by Koppaka et al. (2003) reported no such 
association between BCG and TST positivity based on birth in a high-risk country.  
Although the effect of BCG vaccine on TST reactions generally wanes over time, 





recommendations state that history of BCG vaccine is not a contraindication for 
performing or interpreting the TST.  Consequently, BCG may be a significant predictor 
of TB infection (latent or active) because (a) its result is a true positive result, or (b) BCG 
has caused a false-positive TST reaction to occur, leading to confounding due to cross-
reactivity (refer to Chapter 3 for more detail).  
Specific effects of BCG on the TST have been noted in the literature.  In a review 
of 24 studies where subjects were immunized as infants, 1% of subjects were TST-
positive when tested more than 10 years postvaccination (Farhat et al., 2006), a low 
percentage when compared with recent immunization.  The same review included 12 
studies involving subjects vaccinated after year one; 21.2% were positive after 10 years.  
Reviewing 18 studies where nontuberculosis mycobacteria (NTM) was a factor, cross-
reactivity was low with TST positivity ranging from 0.1% to 2.3% (Farhat et al., 2006).  
These researchers (Farhat et al., 2006) have concluded that BCG received in infancy is 
associated with minimal TST positivity, and NTM is not a big factor in TST positivity 
(unless the populations being tested have a high prevalence or exposure to NTM versus 
MTB).  In addition to cross-reactivity with BCG, the TST size of zone reactivity is also 
varied depending on age (older adults) and number of BCG vaccinations (Farhat et al., 
2006; Kazanci et al., 2010).   
Place of birth.  Place of birth (U.S. or foreign) was chosen as an independent 
variable for this study because foreign birth has been associated with increased TST 
positivity (LTBI) and active TB disease in the United States, reported previously in this 





Among HCP working in the United States, the following statistics have been 
quoted directly from a 2007 report: 
•In 2005, 15 percent of all US health-care workers were foreign born.  
•About 44 percent of the foreign born in health-care occupations arrived in the 
United States in 1990 or later.  
•One in four doctors (physicians and surgeons) was born abroad.  
•Foreign-born health-care workers, regardless of gender, were more likely to be 
physicians and surgeons as well as nursing and home-care aids than their native-
born colleagues.  
•Women accounted for more than 70 percent of the foreign born in health-care 
occupations. 
•Nearly 40 percent of all foreign born in health-care occupations were from Asia.  
•Foreign-born health-care workers were more likely to have a college education 
than their native-born counterparts. (Clearfield & Batalova, 2007, p. 1) 
While Clearfield and Batalova (2007) did not address HCP subgroups such as 
medical laboratorians, it is clear that large numbers of foreign-born healthcare workers 
are working in a variety of disciplines.   
According to Liu et al. (2012), in the United States from 2001 thru 2008 (a) 
41.6% of cases of TB occurred among immigrants and refugees, (b) 36.6% among 
students, exchange visitors, temporary workers, and (c) the remainder of cases occurred 
among tourists, business travelers, and Canadian & Mexican nonimmigrant workers.  Of 





to the United States received TB screening (Liu et al., 2012).  These figures demonstrate 
the importance of examining foreign birth as a predictor of TST positivity among 
immigrants, and especially among those destined for work in fields of health care. 
In cross-sectional studies using self-administered surveys, foreign birth as a 
predictor of TST positivity was found to be significant as a risk factor.  Garber et al. 
(2003) reported an OR of 3.80.  One U.S. study reported TST positivity at 48.5% among 
foreign-born (Cook et al., 2003).  Other cross-sectional studies citing place of birth as 
significant include Hernandez-Garduno and Elwood (2008), and Menzies et al. (2003).  
Li, Munsiff, and Agerton (2010) reported TST prevalence was four times higher among 
nonU.S.-born than U.S.-born in one large cohort study. 
Years of laboratory experience.  Years of laboratory experience was selected as 
an independent variable for this study.  While the Garber et al. (2003) cross-sectional 
survey used type of laboratory work in its assessment, other researchers added years of 
work experience to survey questions.  Years (or duration) of work experience have been 
found significant in predicting factors associated with TST positivity and/or conversion 
in several studies (Menzies et al., 2003; Rafiza et al., 2011) and depend on the risk group, 
job category, and/or workplace.  Garber et al. (2003) determined that mycobacteriology 
type of work experience was significantly associated with predicting TST positivity.  
However, calculation of years by date of hire was later considered a study limitation in 
the Garber et al. (2003) research, resulting in years as not significant in predicting TST 
positivity.  It is important to note that the operational definition of years of work 






The dependent variables in this study are self-reported lifetime TST positivity, 
preventive treatment initiation, and barriers to treatment adherence (medication side 
effects).  The following section will attempt to explain why each dependent variable was 
chosen for this study, and will describe some of the related research. 
Tuberculin skin test (TST) positivity.  TST positivity was chosen for this study 
because several studies have used TST positivity as a baseline in determining LTBI 
prevalence.  The most applicable study to this research was Garber et al. (2003); 
prevalence of latent TB infection was specifically defined as a positive TST result.  TST 
positivity prevalence has been used extensively as a dependent variable in the literature, 
as evidenced by studies mentioned previously in this chapter.   
Validity of the self-reported tuberculin skin test.  At this point of the literature 
review, it is important to discuss literature associated with self-reported TST results.  The 
search of the literature revealed several studies where self-reported TST data was 
validated using different methods now described. 
 Ascertainment of self-reported TST results with prior medical records of a 
subsample (n = 71) of injection drug users with HIV coinfection at a treatment program 
(Wolfe et al., 1995).  Results found a high degree of reliability; > 90% of results were 
classified correctly.  
 Ascertainment of self-reported TST results with prior Occupational Health 
Services medical records of a subsample (n = 42) of microbiology laboratory workers in a 





 Assessment of self-reported TST results among patients enrolled in a methadone 
treatment center compared with newly administered PPD booster tests.  Nearly a third of 
patient self-reports of positive tests did not match obtained booster PPD negative results, 
presumably due to reversion of the PPD due to immune dysfunction (Kunins et al., 2004).  
(The discordance rate among HIV-infected subjects was 43%, while the discordance rate 
among HIV sero-negative subjects was 27% in this study.)  While the phenomenon of 
TST reversion is currently under review (Tuberculosis Epidemiologic Studies 
Consortium, 2012), this study provided an example of assessment after initial survey, 
limited by inability to compare to prior medical records. 
 Research by Martin, Leff, Calonge, Garrett, and Nelson (2000) was more generic 
in nature, reflecting on validation of self-reported data as related to three chronic health 
conditions of hypertension, hypercholesterolemia, and diabetes (not specific to the TST 
result).  Results were obtained by comparing subject survey results to medical records.  
Results were considered generally valid, with a high degree of validity: > 80% 
sensitivity, 86% to 99% overall. 
Use of a self-reported TST was reported in several studies.  For example, in 
validating the reading of actual TST zones of induration by patients and trained 
healthcare professionals, patients detected presence/absence of induration 99.3% of the 
time (Ozuah, Burton, Lerro, Rosenstock, & Mulvihill, 1999).  Use of self-reported TST 
was also found in literature related to demographic characteristics and surveys in TB 
research to assist in diagnosing individuals (Bock, McGowan, Ahn, Tapia, & Blumberg, 





Preventive treatment noninitiation.  LTBI preventive treatment noninitiation 
rates were chosen as a dependent variable in this research because to date, very few 
studies have examined risk factors of TST positivity with treatment initiation.  The 
terminology of preventive treatment was chosen for this dissertation because of a 
recommended change from prior terminology of preventive therapy (Cohn, 2000).  
Garber et al. (2003) was the only article located in this search that reported on treatment 
initiation rates among medical laboratorians; however, no mention was made as to the 
association of risk factors to initiation (or noninitiation) of preventive treatment.  One 
U.S. study reported a high (84%) initiation rate among HCP (Camins et al., 1996).  This 
review has already noted that CDC recommends treating TST-positive personnel working 
in mycobacteriology laboratories (CDC, 2005b) as well as consideration of risk groups 
when prioritizing LTBI treatment (Horsburgh, 2004).   
LTBI treatment initiation rates of HCP are traditionally lower than those of non-
healthcare personnel, reported at rates of 58% (Gershon et al., 2004).  Treatment 
adherence and completion rates have been reported as suboptimal (Hirsch-Moverman et 
al., 2008), and as low as 19% (Bieberly & Ali, 2008) in some U.S. populations.  Studies 
have demonstrated stigma barriers as associated with treatment noncompliance (Macq, 
Solis, & Martinez, 2006), while other studies have found that harmful, adverse effects of 
treatment were problematic (Joseph et al., 2004).  Referring to health care workers 
(HCWs): “The most feasible means to improve LTBI treatment among HCWs is to 





Another concern is that physician attitudes toward treatment of latent tuberculosis 
infection may not match recommendations set forth by CDC and WHO.  International 
medical graduates have been surveyed and the majority was found to be less likely to 
treat themselves and family members, believing that BCG immunization protects long-
term, LTBI treatment is ineffective, and risks of treatment are greater than benefits 
(Salazar-Schicchi et al., 2004).  These attitudes, if present among healthcare providers, 
are yet another concern in initiating effective treatment.  Although causes of preventive 
treatment noninitiation appear multidimensional, this study planned only to document 
whether or not the respondent (host) ever initiated treatment for a positive TST. 
Treatment nonadherence (barriers).  The variable of treatment nonadherence 
(presence of medication side-effect barriers as measured by the Brief Medication 
Questionnaire) was chosen for this study because to date, this search and review of the 
literature has not located any study related specifically to medical laboratory 
microbiologists.  While treatment symptoms and BCG immunization have been found to 
be associated with nonadherence among HCP (Shukla et al., 2002) as well as in the 
general public (Hirsch-Moverman et al., 2008), no study has compared symptoms using a 
validated survey instrument among HCP.  Adherence to treatment is cost-effective 
(Sokol, McGuigan, Verbrugge, & Epstein, 2005) but difficult to sustain for many 
reasons.  In the case of active TB disease, treatment lasts many months and patients may 
stop taking medication(s) once they begin to feel better (CDC, 2011b).  Treatment for 
LTBI is even more difficult if the individuals remain asymptomatic (Charles P. Felton 





LTBI treatment predicts treatment completion (Menzies et al., 2005).  Nonadherence can 
lead to treatment failure and to development of drug-resistant strains of TB (CDC, 2011e) 
as discussed earlier in this chapter.   
It is important to note that CDC (2011e) defines treatment completion as 
determined by the number of doses taken over a defined period of time, and not the 
number of weeks or months of treatment.  (Number of doses is dependent on the type of 
treatment regimen.)  This research is not designed to gather detailed data on treatment 
completion; however, the question regarding completion was asked of survey 
respondents in order to help characterize the study cohort.  Blumberg (2004) reported that 
the greatest strategic need in the U.S. in the fight to control TB is to find ways to improve 
poor LTBI treatment completion rates. 
Treatment adherence is a multidimensional process including patient, treatment, 
environment, disease, provider, and patient-provider characteristics (Kennedy, 2000).  In 
one qualitative study, focus groups were utilized to gauge healthcare workers’ adherence 
to LTBI treatment in terms of barriers and perceptions (Joseph et al., 2004).  The Joseph 
et al. study identifed several items as important barriers to treatment adherence: 
 treatment is harmful with adverse effects; 
 no need for medication if asymptomatic; 
 misunderstanding of TB pathology; 
 failure of providers to recommend treatment; and 






Examples of behavioral barriers and stigma associated with poor treatment 
adherence have been reported (Macq et al., 2006; McEwen & Boyle, 2007), as well as 
barriers due to differences in cultural beliefs and values (Michaels, McEwen, & 
McArthur, 2008).  Adherence has been reported to be as low as 19% in some populations 
for reasons of insufficient infrastructure and social support (Bieberly & Ali, 2008).  Poor 
past adherence was found to be the best indicator of present adherence, and avoidance 
coping was a strong predictor of poor adherence (hoping the disease will go away on its 
own) as researched by Sherbourne, Hays, Ordway, DiMatteo, and Kravitz, (1992) in 
chronically ill patients. 
Harmful treatment with adverse effects was chosen as the type of barrier for this 
research, measured using the BMQ validated survey instrument.  In general, LTBI 
treatment was most affected by medication intolerance in one study (Machado et al., 
2009).  In a study of U.S. HCP, one-third of employees (12 of 36) initiating but not 
completing LTBI preventive treatment reported barriers of adverse drug effects (Camins 
et al, 1996).  Non-adherent HCP (26 of 51), a number approximating 51%, cited reasons 
of adverse drug effects, suspicions that medication was harmful or toxic, and feelings that 
the treatment was “overkill” (Joseph et al., 2004, p. 459) for not taking medication. 
A systematic review of U.S. and Canadian studies also pointed to concerns about 
LTBI and TB medication side effects and toxicity (Hirsch-Moverman et al., 2008), as did 
a study of male veterans (Fincke, Miller, & Spiro III, 1998).  The literature is in 
agreement: adherence decreases with an increase in duration of regimen and side effects 





The CDC (2005a) reported that adverse effects of drugs used to treat LTBI cause 
concerns related to length of treatment and potential side effects.   Possible medications 
and their adverse effects include the following (CDC, 2005a):  
Isoniazid (INH) 
 asymptomatic elevation of serum liver enzymes (occurs in 10 % to 20 % of 
those taking INH); 
 hepatitis in 0.1% to 0.15%, and is more common when INH is used in 
combination with other agents (alcohol consumption, underlying liver 
disease), sometimes fatal; and 
 peripheral neuropathy reported in 0.2%, more likely when INH combined with 
diabetes, HIV, renal failure, and alcoholism. 
Rifampin (RIF) 
 hepatotoxicity (hyperbilirubinemia) in 0.6%; 
 cutaneous reactions (pruritis with or without rash) in 6% of individuals; 
 gastrointestinal symptoms (nausea, abdominal pain); 
 orange discoloration of body fluids (orange staining of contact lenses); 
 drug-drug interactions; and 
 contraindicated in HIV patients being treated with certain anti-HIV 
medications. 
These side effects can be debilitating.  Predictors of nonadherence may include 
items affecting sick patients, but also things which may affect sick and well individuals 





Hepatotoxicity in INH treatment of LTBI has occurred at a rate of 5.6 per 1,000 patients 
and appears age-related, greatest in those age 50 years and older (Fountain, Tolley, 
Chrisman, & Self, 2005).  Healthcare personnel perceive that LTBI treatment is harmful 
and treatment carries a high probability of causing adverse effects (Joseph et al., 2004). 
Review of measurement tools for treatment nonadherence.  A review of the 
literature for survey tools used in assessing medication treatment adherence among 
individuals produced mixed results.  Much of the literature was geared toward a patient 
population, not the relatively healthy healthcare personnel population that is the intended 
population of interest in this study.  In addition, questionnaires specific to tuberculosis 
were few.  The Tuberculosis Adherence Determination Questionnaire (Holstad, 2001a) 
and the Tuberculosis General Adherence Scale (Holstad, 2001b) first appeared in 
“Antecedents of adherence to antituberculosis therapy” (McDonnell et al., 2001), and 
address medication adherence based on interpersonal aspects of care, perceived utility of 
treatment, subject norms, intentions, and support.  As mentioned, these surveys, as well 
as the Medication Adherence Questionnaire (Toll, McKee, Martin,  Jatlow, & O’Malley, 
2007) are used to assist in counseling patients regarding importance of medication 
adherence.  Self-efficacy and health belief model form the basis for these and many of the 
medication adherence questionnaires.  Variations of these questionnaires have appeared 
in literature associated with different infectious and chronic diseases such as HIV 
(Holstad, Foster, Dilorio, McCarty, & Teplinksy, 2010; Johnson et al., 2007). One basis 





which cancer control regimens were assessed using a 38-item self-reported adherence 
questionnaire.   
A review of five different adherence scales was performed by Lavsa et al. (2011) 
with the conclusion being that “no gold-standard medication adherence scale exists” (p. 
90).  One of the five under review was the Brief Medication Questionnaire (BMQ), a 
questionnaire developed by Svarstad et al., 1999) for use in detecting different types of 
nonadherence.  The scale includes a two-item belief screen to “assess beliefs about drug 
efficacy and bothersome effects” (Lavsa et al., 2011, p. 92).  The BMQ, initially 
validated in patients taking angiotensin-converting enzyme inhibitors, has also been used 
in patients with diabetes, depression, and other chronic diseases (Lavsa et al., 2011; 
Svarstad et al., 1999).   
The BMQ instrument was chosen over several other questionnaire tools for 
addition to this main survey instrument tool for several reasons.  The BMQ is short, 
already validated as a survey instrument tool, and relates directly to treatment 
medications.  Comparison of several other survey tools (Charles P. Felton National 
Tuberculosis Center, 2005; Holstad, 2001a, 2001b; New Jersey Medical School National 
Tuberculosis Center, n.d.) revealed that most tools were not useful for surveys such as 
this the one used in this study.  Other tools referred to active, current administration of 
treatment medications, or were geared toward patient populations (and not an educated 
HCP population).  These types of items are not applicable when asking HCP respondents 
to self-report past TST treatment history.  Specific questions pertaining to medication 





(Svarstad, Chewning, Sleath, & Claesson, 2003).  More information on the validation and 
use of the BMQ will be presented in Chapter 3. 
Description of the Research Variables 
The research variables for use in this study were based on those used in the 
Garber et al. (2003), Hernandez-Garduno and Elwood (2008), Menzies et al. (2003), and  
Rafiza et al. (2011) cross-sectional survey formats, as well as the BMQ as it applies to 
medication side effects (Svarstad et al., 2003).  I derived a master data set coded for the 
following variables of self-reported lifetime TST positivity, history of BCG 
immunization, place of birth, years of laboratory experience, self-reported initiation of 
treatment, and treatment nonadherence (medication side effect barriers) as addressed 
using two questions from the Brief Medication Questionnaire (Svarstad et al., 1999).  The 
nature of each variable is described as follows (as previously discussed in Table 1, 
Chapter 1): 
 Self –reported lifetime history of TST positivity: Dichotomous nominal 
variable, coded as either TST-negative or TST-positive. 
 History of BCG immunization: Nominal variable.  Two levels coded as no or 
yes. 
 Place of birth (U.S. or foreign): Nominal variable.  Two levels, coded as U.S. 
or foreign. 
 Years of laboratory experience: Nominal variable.  Six levels, coded as (a) 0-2 





over 21 years.  Nominal groupings of each (no or yes) may be collapsed if 
necessary. 
 Self-reported initiation of treatment (once prescribed): Nominal variable.  
Two levels coded as no or yes.  Risk factors to be assessed as related to 
noninitiation of treatment. 
 Barriers to treatment adherence (medication side effects):  Using the Brief 
Medication Questionnaire (BMQ) Belief Screen (Svarstad et al., 1999); 
questions 1(g), “How well did this medication work for you?” and 2(a), “Did 
any of your medications bother you in any way?”  Combined BMQ score 
coded for three levels, (a) 0 = score of 0, (b) 1 = score of 1, or (c) 2 = score of 
2.  Score will be translated to < 1 (no adherence barriers present = no); ≥ 1 
(adherence barriers present = yes).  This scoring is referenced as published in 
the original validation by Svarstad et al. (1999). 
These variables and the necessary inclusion criteria will be used in the study 
analyses to make descriptive comparisons between all subjects in the chosen, defined 
study population of medical laboratory microbiologists.  Please refer to Chapter 3 for 
study method detail. 
Theories in Latent and Active Tuberculosis Research 
Prior to discussing a comparison of the research designs, it is essential to discuss 
the literature as it pertains to grounded theory in past and current LTBI and TB research.  
Several different theories continued to appear throughout this review of the pertinent 





disease, and Koch’s Postulates on tuberculosis have led to the development of the present 
day epidemiologic triad model.  Use of these principles is the basic underpinning for 
much of the research pertaining to TST positivity and risk factors. 
Louis Pasteur’s development of the germ theory of disease in writings from 1857-
1858, helped form the basis for understanding of all microscopic organisms (Halsall, 
1998).  Koch subsequently published his discovery of tubercle bacilli in 1882 (Grimes, 
2006).  Koch’s Postulates describing ideas about tuberculosis were formalized between 
1884 and 1890 and were based on asking basic questions of (a) whether the organisms 
demonstrate consistency in characterization; (b) whether the organism is the cause of the 
illness; (c) whether the isolated organism is the cause of the disease when introduced into 
a health individual; and (d) if so, then the all the usual characteristics of the organism and 
disease are reproduced (Grimes, 2006).   
These theories have formed the basis for theories and models of infectious 
disease, including the epidemiological triad (or triangle) model.  The emphasis on the 
three sides of this conceptual triangle is the relationship of disease to the host, agent, and 
environment (Rockett, 1999; Smith, 2002).  Further description of this interaction has 
been defined earlier in this dissertation as a framework (Williams & Nelson, 2007) of: 
 agent (infecting organism or pathogen: bacteria, virus, parasite, fungi), 
 host (diseased individual), and 
 environment (setting where transmission occurs; factors involved). 
The first evidence supporting development and use of the epidemiologic triad 





fish.  In this research, infection occurred when susceptible fishes were “exposed to 
virulent pathogens under certain environmental stress conditions” (Snieszko, 1974, p. 
197).  More recent use of the model has involved a use of Haddon’s Mattrix for assessing 
injury with the epidemiologic triad to understand and design programs for injury control 
(Lett, Kobusingye, & Sethi, 2002).  In this research, injury was likened to the element of 
disease agent.  The triad model has also been useful in infection control research of 
susceptible hosts, using immune status, integrity of skin membranes, agents of normal 
flora, and the environment of the home setting to explain acquisition of infections in 
home healthcare (Friedman & Rhinehart, 2000).    
Research involving serious emerging infectious diseases having an animal source 
(such as severe acute respiratory syndrome [SARS], avian influenza, West Nile virus, 
monkeypox) and links between agent, host, and environment in the spread to humans 
have been of recent interest (Bender, Hueston, & Osterholm, 2006).  Along this line of 
thinking, Huerta and Leventhal (2002) have used the triad model to help explain a change 
in vectors of disease to new and dangerous intentional vectors, intended to spread agents 
through the environment to susceptible hosts.  An example of this concept has been in 
recent acts of bioterrorism using anthrax as the agent. 
While the epidemiologic triad model has been useful in explaining relationships 
between various aspects of LTBI (TST positivity, preventive treatment noninitiation, and 
select treatment adherence barriers, see Chapter 1 for detail), the Health Belief Model 
(HBM) has also been useful in exploring behaviors associated with treatment initiation 





The health belief model (HBM) was developed in the 1950s by the Public Health 
Service as a way to explain and predict preventive health behaviors, specifically, why 
individuals did not seek TB treatment (Abraham & Sheeran, 2007).  One aspect of HBM 
is known as perceived costs or barriers to taking action.  Preventive health behavior may 
not take place, even though an individual may believe benefits to taking action are 
worthwhile.  Barriers to treatment, for example, may include inconvenience, expense, 
unpleasantness, painfulness, or upsetting characteristics (Rosenstock, 1974). 
Characteristics referred to as barriers may prevent the individual from adhering to desired 
treatment action. While HBM has not been used as a basis for this study, its relevance to 
other material found during the search process is great.  Research by Bieberly and Ali 
(2008), Macq et al. (2006), McEwen and Boyle (2007), Michaels et al. (2008) and others 
have informed knowledge to date regarding treatment initiation and adherence, as well as 
adherence barriers. 
One last theory that will be mentioned is the social cognitive theory.  In research 
involving U.S. Hispanic migrant workers diagnosed with LTBI, social cognitive theory 
was used to ground a study that took place on several farms in the Midwestern U.S. 
(Wyss & Alderman, 2007).  Several environmental factors were identified as barriers to 
diagnosis and adherence with LTBI treatment. The most significant barriers may have 
been feelings of lack of control over the disease process and lack of treatment options 
available to migrants.  In addition, the researchers identified feelings of lack of control, 





TB have been reported to take place in the foreign-born, these types of barriers will be 
important in future LTBI research. 
Methods 
Design Methods Used in Latent and Active Tuberculosis Research  
In research on tuberculin skin test (TST) positivity, latent tuberculosis infection 
(LTBI) treatment initiation, and barriers to treatment adherence, methodologies and 
analysis methods presented in the literature review include observational (descriptive 
case series reports and cross-sectional surveys, as well as analytic studies including 
cohort and case-control designs), experimental, qualitative (ecologic and focus groups), 
and literature reviews. In most cases, studies were either in cross-sectional survey or 
cohort format, or a combination of both.    
While all methods revealed useful information as presented in other sections of 
this literature review, only the cross-sectional survey method emerged as appropriate for 
this study.  Examples of each method and the types of information gleaned from each are 
presented below. 
Case series reports.  Three different examples of case series were located in this 
search of relevant literature.  First is an important example of a nurse with undiagnosed 
active TB (point source and the resulting contact investigation demonstrating the 
importance of taking prescribed treatment for LTBI (Fitzpatrick et al., 2005).  Second, a 
case series which used Census data to estimate occupations associated with TB 
(McKenna et al., 1996).  The last case series report focused on HCP already diagnosed 





1996).  All three case reports were useful in identifying importance of initiating 
prescribed treatment, as well as in associating TB infection with certain occupations.   
Cross-sectional surveys.  Numerous studies located in this literature review were 
cross-sectional in nature.  Eighteen studies determined to be cross-sectional were 
examined more closely.  Two utilized a cross-sectional analysis of surveillance data 
(Cain et al., 2007; Zuber et al., 1997) to obtain data of the TB risk among the foreign-
born in the United States.  An anonymous survey of physicians’ attitudes gathered data 
on physician TST-positivity prevalence and perceptions of BCG protection (Salazar-
Schicchi et al., 2004), while another surveyed medical students for TST positivity, 
conversions, and risk factors (Wurtz et al., 1994).   
The vast majority of the cross-sectional studies utilized survey questionnaires of 
HCP or the subpopulation of laboratorians for gathering data on prevalence or incidence 
of active TB (Harrington, & Shannon, 1976) or prevalence of LTBI (Alonso-Echanove et 
al., 2001; Drobniewski, Balabanova, Zakamova, Nikolayevskyy, & Fedorin, 2007; 
Garber et al., 2003; Menzies et al, 2003; Rafiza et al., 2011).  One historical study (Reid, 
1957) utilized a cross-sectional approach in collecting data obtained from several sources 
in order to determine prevalence and incidence of TB in laboratorians compared with 
data obtained from the general public.  Two studies set out to evaluate occupational 
factors associated with LTBI (Menzies et al., 2000; Vaquero et al., 2003). In three 
studies, surveys were sent directly to U.S. laboratories to assess the prevalence of lab-
acquired infections (Jacobson et al., 1985; Kao et al., 1997; Sulkin & Pike, 1951).  The 





et al., 2001), and TST predictors and positivity prevalence among a large group of 
Canadians from the general population screened for reasons other than contact 
investigation (Hernandez-Garduno & Elwood, 2008). 
Cohort design.  In all, 30 articles undergoing this literature review were 
determined to have used a cohort design, either prospective or retrospective cohort.  In 
many cases a combination of the survey method and cohort design was used, most often 
to determine TST positivity and assess risk factors by survey, and then move on toward 
determination of TST-conversion over some predefined time period using cohort design.  
Strict use of the cohort appeared to be utilized more often when the desired study 
outcome was TST-conversion (LTBI incidence) or long-term treatment adherence 
outcome measures. 
Ten study articles referred to determining rates of TST conversion (in addition to 
risk factor assessment) among HCP.  Five took place in the United States (Bailey, Fraser, 
Spitznagel, & Dunagan, 1995; Cook, Maw, Munsiff, Fujiwara, & Frieden, 2003; Larsen 
et al., 2002; Miller et al., 2002; Panlilio et al., 2002), while another five took place 
outside the U.S. (Baussano et al., 2007; Christopher et al., 2010; de Vries et al., 2006; 
Kraut et al., 2004; Roth et al., 2005).  In addition, the Koppaka et al. (2003) and Li et al. 
(2010) research was included in this review as pertaining to TST conversion, although 
performed on university students and chest center patients, respectively. 
Only one retrospective cohort reported on preventive treatment initiation in HCP 
(Gershon et al., 2004), while one study developed a hypothetical cohort to detect and 





preventive treatment adherence, related to LTBI or other general disease states (Bayer et 
al., 1998; Bieberly & Ali, 2008; Sherbourne et al., 1992; Shukla et al., 2002; Sokol et al., 
2005; Tavitian et al., 2003), while another three reported on drug treatment adherence 
barriers and associated risk factors (Fincke et al., 1998; Fountain et al., 2005; Machado et 
al., 2009).  
Of related interest to the topic at hand, three cohort studies compared use of TST 
with IGRA blood tests (Ferrara et al., 2005; Mazurek et al., 2001; Soberg et al., 2007), 
while four detected strain resistance over time (Calver et al., 2010; Cohen et al., 2011; 
Tang et al., 2011; Velasquez et al., 2011).    
None of the cohort studies reflected in this review reporting on HCP and TST 
conversion specifically studied medical laboratorians or subgroups of the laboratorians in 
any detail.  One particular study (Bailey, Fraser, Spitznagel, & Dunagan, 1995) grouped 
different HCP by direct patient contact and appeared to misclassify the laboratorians 
completely, thus missing any laboratory occupational exposures. 
Case-control design.  In the literature review at hand, one case-control study only 
was located.  The study was not a true case-control, but a combination of methods.  In 
this study, a diagnosis of LTBI using different diagnostic methods prompted placement 
of subjects into four different groups, one of which was a control group (Ozekinci et al., 
2007).  This control group contained subjects having no history of contact with TB or 
TB-infected individuals.   
Experimental.  Very few experimental studies were located that were intended to 





(or noninitiation), or treatment adherence barriers.  One quasi-design detailed use of 
DOTs in TB patients along with long-term adherence outcome as measured by treatment 
completion (Hsieh et al., 2008).  LTBI preventive treatment adherence was studied in one 
example of a randomized drug trial by Menzies et al. (2005).  Both examples were 
somewhat similar in that adherence was related and measured as completion of long-term 
treatment therapy.  This type of experimental study protocol was also ruled out as a 
useful method in that no preventive treatment completion was estimated or measured as a 
function of adherence in this study. 
Qualitative.  A brief review of the literature to assess factors influencing 
adherence to LTBI and TB preventive treatment revealed several studies guided by 
behavioral models.  Focus groups were used to assess resistance to assess factors 
influencing HCW adherence to LTBI treatment (Joseph et al., 2004).  A combination of 
focus groups and ethnography qualitative methods assessed reasons for resistance to 
LTBI treatment among Mexican immigrant populations (McEwen & Boyle, 2007; 
Michaels et al., 2008).  One study combined mixed methods and a literature review to 
create a stigma assessment instrument aimed at assessing stigma experiences of those 
with active TB (Macq et al., 2006).  Only the Joseph et al. (2004) study dealt specifically 
with HCP and the perceived barriers in obtaining the TST, as well as the perception that 
LTBI treatment was harmful and may cause unwanted side effects.  The other three 
studies dealt with the cultural and behavioral issues outside the scope of this research. 
Reviews.  In all, 14 review papers were included in this review of the literature. 





useful citation references.  Seven of the 14 reviews were general and information, 
including summaries of laboratory-acquired infections (Pike et al., 1965; Sewell, 1995; 
Singh, 2009), summaries of TB and associated risk factors in laboratorians (Lonnroth et 
al., 2009; Sepkowitz, 1994), a general review of guidelines and recommendations for 
preventing TB in laboratories (Collins & Grange, 1999), and finally, a general review of 
LTBI risk estimates with the goal of creating a model for targeted LTBI treatment in the 
United States (Horsburgh, 2004).  Three papers presented as meta-analysis of 
occupationally-acquired LTBI or TB in health-care settings (Baussano et al., 2011; 
Menzie et al., 2007; Seidler et al., 2005).  The final four studies were classified as 
systematic reviews and dealt mainly with the topics of TB infection incidence and 
prevalence among HCP (Joshi et al., 2006), TB surveillance and control (Lonnroth et al., 
2010), effect of BCG on TST results (Farhat et al., 2006), and adherence to LTBI 
treatment measures, rates, and predictors (Hirsch-Moverman et al., 2008).  While these 
reviews covered LTBI and the TST, as well as some issues of treatment nonadherence 
(barriers, such as medication side effects), no one review dealt with preventive treatment 
initiation or associated risk factors. 
Size and duration of studies.  While descriptive data for healthcare personnel 
populations are numerous, data specific to laboratory personnel is limited.  Sample sizes 
in cross-sectional and cohort studies referring to TST positivity and/or conversion, as 
well as risk factors among HCP, varied from n = 101 (de Vries et al., 2006) to n = 10,795 
(Larsen et al., 2002).  In the study of New York City laboratorians by Garber et al. 





cross-sectional studies involving surveillance data (Hernandez-Garduno & Elwood, 
2008), where n = 59,791 individuals.  While most of the cross-sectional survey studies 
utilized questionnaires given at one point in time, an exception was the Garber et al. 
(2003) study involving measurement of TST conversion over 2 years.  The time of study 
duration of the prospective cohort studies involving the TST among HCP was limited 
from a minimum of 1.5 years (Panlilio et al, 2002; Roth et al., 2005) to a maximum of 8 
years (Cook et al., 2003).   Pertinent LTBI prevalence, incidence, and TB statistics were 
collected from studies performed in the United States (Cain et al., 2007; Cook et al., 
2003; Garber et al., 2003; Li et al., 2010; Panlilio et al., 2002; Shukla et al., 2002; Zuber 
et al., 1997), Canada (Gershon et al., 2004; Hernandez-Garduno & Elwood, 2008; 
Menzies et al., 2000; Menzies et al., 2003), Malaysia (Rafiza et al., 2011), and United 
Kingdom (Reid, 1957). The largest and most recent study of medical laboratory 
microbiologists was that performed by Garber et al. (2003), although a Russian study of 
LTBI in HCP established the laboratory as a significant entity (Drobniewski et al., 2007), 
as did the Malaysian research (Rafzia et al., 2011).    
One prominent systematic review described low- and middle-income countries 
with respect to LTBI and TB prevalence and incidence among HCP (Joshi et al., 2006).  
Seidler et al. (2005) described occupationally acquired active TB in low-incidence areas, 
and Menzies et al. (2007) performed a notable systematic review with meta-analysis on 





In general, the research methodologies chosen for TST positivity, treatment 
initiation, and treatment nonadherence (barriers) depended on study design, size of 
chosen study population, and length of study duration.   
Analysis Methods Used in Latent and Active Tuberculosis Research 
In the review of the literature, cross-sectional studies using self-administered 
surveys or interviews to obtain data pertaining to suspected risk factors often included 
calculations of outcome prevalence and survey response rates.  Four such studies have 
been compared in order to determine useful analysis methods.  LTBI (defined as TST 
positivity or TST conversion) and associated risk factors were compared using univariate 
and bivariate analysis by Garber et al. (2003), Hernandez-Garduno & Elwood (2008), 
Menzies et al. (2003), and Rafiza et al. (2011) against risk factors (such as age, foreign 
birth, BCG immunization, years and/or type of work).  Multivariate analysis of the 
significant risk factors was then performed and depicted by use of tables.  Preventive 
treatment initiation was also reported as a percentage by Garber et al. (2003), although no 
reasons were given in the Garber et al. research for individuals choosing not to initiate 
treatment.  In the only paper to analyze treatment initiation, Rafiza et al. (2011) reported 
initiation as a function of whether or not the individuals received any treatment for active 
TB, using univariate analysis of characteristics.  However, no study in this review 
demonstrated research performed using univariate, bivariate, or multivariate analysis of 
the preventive treatment initiation data. 
Similar analyses appeared throughout the cohort study design literature, with the 





suspected risk factors.  Again, in literature examples where comparison of group 
characteristics was made using univariate or bivariate analysis, predictors of outcome 
were determined by multivariate analysis (Bailey et al., 1995; Baussano et al., 2006; 
Kraut et al., 2004; Panlilio et al., 2002; Roth et al, 2005).  Cook et al. (2003) reported 
only on characteristics of employees, occupation, as well as prevalence of TST positivity 
at baseline and TST conversion rates.   
A flurry of research occurred during the mid-1990s and early 2000s because of an 
upsurge of U.S. TB cases, most especially associated with HIV comorbidity.  A long and 
notable history of research involving occupational TB in laboratorians has been 
published, most occurring during the mid-twentieth century.  An understanding of TB 
prevention and the advent of engineering controls have changed the face of LTBI and 
active TB in the United States.   
These points aside, of significance is the lack of notable literature representing 
HCP and preventive treatment initiation (or noninitiation), as well as treatment adherence 
barriers (as related to treatment nonadherence).  Only one pertinent study emerged 
demonstrating analysis of these variables.  A prospective cohort study by Shukla et al. 
(2002) reported on rate of treatment initiation as well as on rate of treatment completion.  
Analysis of adherence to LTBI treatment among HCP was performed using univariate, 
bivariate, and multivariate analysis against BCG vaccination and disease symptoms.  
However, this example was limited in that the grouping ‘laboratory workers’ appeared to 
be misclassified as nonclinical, and included in the same outcome groups as clerical and 





 Confounders.   Confounders were only briefly mentioned as such in the literature 
under review, although most of the reviewed studies did assess for them by using 
multivariate (logistic regression) analysis.  For outcomes involving tuberculin skin test 
positivity, three main confounders have been identified as (a) immunization with BCG 
(Diel et al., 2009; Wang, Turner, Elwood, Schulzer, & FitzGerald, 2002), (b) 
nonoccupational exposures to active TB cases (Garber et al., 2003), and (c) unmeasured 
indicators of occupational exposure such as numbers and days of occupational exposures 
(Joshi et al., 2006).  Age has been identified as a confounder because older individuals 
had a greater exposure prior to the advent of treatment in the 1940s and 1950s (CDC, 
2010b; Nobelprize.org, 2012).  One study by Farhat et al. (2006) dispelled previous 
issues of confounding among those infected with nontuberculosis TB in most 
populations, and also among those receiving BCG vaccine during infancy.  But in the 
latter cases, the TST was tested > 10 years after the initial immunization occurred, in 
agreement with Wang et al. (2002) findings suggesting that BCG no longer remains a 
confounder if the immunization was given years prior to the TST.  Work by Kunimoto et 
al. (2009) has also dispelled BCG as a confounder in TST research, backed by use of the 
newer IGRA blood test. 
Gap in the Literature 
In reviewing the prior sections on research and analysis methods used in 
determining LTBI or TST positivity, risk factors, preventive treatment initiation, and 
barriers to treatment adherence (medication side effects) among HCP,  a gap is noted in a 





the national level in the United States.  In addition, no one study demonstrated any type 
of deep inquiry into the association between risk factors and preventive treatment 
noninitiation or barriers to treatment adherence (medication side effects).  Treatment 
nonadherence (barriers) was noted principally in qualitative studies when compared with 
this review of quantitative studies.  Although research instruments have been used to 
gather quantitative treatment adherence data from the general population, no one study as 
represented by this literature review utilized any specific instrument in the HCP or 
medical laboratory microbiologist population. 
Conclusions Regarding Tuberculin Skin Test Positivity and Treatment Among U.S. 
Medical Laboratory Microbiologists 
The literature review provided background information on past and current TST 
use in the screening of individuals for latent or active TB.  In addition, this review 
showed that in most cases, U.S. medical laboratory workers (especially microbiologists 
and/or mycobacteriology laboratory workers) are at higher risk of LTBI and/or active TB 
infection than their HCP counterparts and the general public.  In the United States and 
Canada, risk factors for this population include age, foreign birth, BCG immunization, 
and work in the mycobacteriology laboratory (Garber et al., 2003), and years of work 
experience (Menzies et al., 2003; Rafiza et al., 2011).  As a subpopulation, little data are 
available regarding LTBI preventive treatment initiation, treatment nonadherence 
(barriers to adherence), or associated risk factors.  A very low preventive treatment 
initiation rate has been attributed to the laboratorian by Garber et al. (2003), but reasons 





Summary of the Literature Review 
This research was necessary in order to identify and target this meaningful 
subpopulation of HCP in the United States, the medical laboratory microbiologist, for 
determination of self-reported lifetime history of TST positivity prevalence and risk 
factors, preventive treatment initiation prevalence and risk factors, and risk factors of 
treatment nonadherence (barriers).  The elimination of TB infection in the United States 
is an overarching goal of the IOM (2000) and the U.S. Healthy People 2020 document 
(U.S. Department of Health & Human Services, n.d.).  This research will add to the 
existing knowledge of literature by adding data assembled from a nationally known U.S. 
registry group of medical laboratory microbiologists registered with the American 
Society for Clinical Pathology (ASCP).   
Research of U.S. HCP has been limited in that is has not been consistent in 
breaking out the subgroup having indirect contact with patients contaminated with TB 
microorganisms—the medical laboratorian working in the microbiology or 
mycobacteriology laboratory.  The HCP workforce in the United States is also changing 
with large numbers of foreign-born employees presently working in all disciplines.  The 
TST continues to be the primary tool for screening at-risk populations, such as the 
foreign-born immigrant population, and mycobacteriology laboratory personnel for 
LTBI.  TST positivity prevalence is high in some laboratory workers, gauged to be 57% 
according to one small but significant study (Garber et al., 2003), and risk factors 
associated with LTBI prevalence and incidence included BCG immunization, foreign 





(Garber et al., 2003; Menzies et al., 2003).  Preventive treatment initiation rates have 
been reported at only 20% in medical laboratorians (Garber et al., 2003), although this 
literature review has reported higher treatment initiation rates among other groups of 
HCP.  Treatment nonadherence (barriers to adherence) has not been reported among 
medical laboratorians; but among HCP, significant barriers have involved perceptions of 
adverse drug effects or drug toxicity.  The Brief Medication Questionnaire has been used 
to document these types of treatment adherence barriers in disease outcomes other than 
LTBI or TB. 
Methods for assessing TST positivity prevalence and risk factors have been 
limited to cross-sectional, or a combination of cross-sectional with cohort design when 
seeking incidence of TST conversion.  The most useful and well-designed study 
pertaining to this research was the Garber et al. (2003) study of microbiology laboratory 
workers in New York City.  From this literature review, TST positivity and risk factors 
were most frequently assessed using survey questionnaires or interview techniques.  
Because the current study did not intend to assess TST conversion or over time, the 
cohort design was not indicated. 
Validity of self-reported TST seems acceptable based on studies discussed earlier 
in this paper (Garber et al., 2003; Kunins et al., 2004; Martin et al., 2000; Wolfe et al., 
1995).   However, no true validation study was found specific to self-reported TST 






Although a few subgroups have been studied (physicians, nurses, non-clerical 
HCP, and limited data on laboratories as a whole), prevalence of LTBI among one large 
subgroup of HCP, U.S. medical laboratory microbiologists, is not known.  New advances 
in blood testing have come on the market during the past decade; however, LTBI is best 
measured at this time using the TST.  Risk factors associated with TST positivity in this 
study group are not well known.  Preventive treatment noninitiation rates and treatment 
nonadherence (barriers to adherence) are not yet described among this subpopulation.  In 
order to establish a baseline and to address the knowledge gap for this subpopulation of 
HCP, the data must be gathered.   In addition, new and shortened preventive treatment 
guidelines have been published (Jereb et al., 2011), further promoting the need to 
determine baseline data.  This data will benefit further research that may address the 
newly described treatment regimen.  
This research is theoretically justified using the epidemiologic triad model, where 
the tubercle bacilli is the agent of disease, and the infected human host (medical 
laboratory microbiologist), presenting as TST-positive (depending on susceptibility risk 
factors of the host, environment, and agent), is dependent on self and  environment to 
allow for preventive treatment initiation.  Treatment nonadherence is a function of 
barriers in this model, where barriers in the environment (such as medication side effects) 
may act to prevent completion of prescribed therapy.  This study will not attempt to 






This research is empirically justified for nonoccupational and occupational 
reasons.   In past decades, lack of engineering controls in the microbiology laboratory led 
to increased risk of acquiring TB infection (CDC, 2009; Reid, 1957).  Today, a different 
risk is at hand.  Today, a high number of HCP working in the United States has 
immigrated from outside the United States (thus, considered foreign-born).  The HCP 
subpopulation of medical laboratory microbiologists is at risk to contract and spread TB 
infection among patients, coworkers, and family members.  To summarize the findings of 
the literature review regarding methodology, the cross-sectional survey method remains 
the best choice for collecting and assessing lifetime TST positivity and risk factor data, as 
well as data on preventive treatment noninitiation and treatment nonadherence (barriers).  
Although some biases and limitations exist when using this technique (which will be 
described in more detail in Chapter 3), this method design is best utilized when study 
funding and time limits are present.  Subsequently, this research used the cross-sectional 
survey questionnaire method, reaching out to the largest cohort of medical laboratory 
microbiologist members registered with a national registry in the United States.  Details 





Chapter 3: Research Method 
Introduction 
This study was conducted in an attempt to explore the relationships of 
independent variables of self-reported history of BCG immunization, place of birth, and 
years of laboratory experience against three dependent variables of (a) self-reported 
lifetime of TST positivity (Research Question 1), (b) preventive treatment noninitiation 
(Research Question 2), and (c) barriers to treatment adherence (presence of medication 
side effects) as measured by one portion of the Brief Medication Questionnaire (Research 
Question 3) in U.S. medical laboratory microbiologist members registered with the 
American Society for Clinical Pathology (ASCP).  Methodological approaches employed 
in this study are now discussed in detail.  Major sections of this chapter include the study 
design, study population, data collection, and analysis approach.  An algorithm 
describing study population by self-reported history of TST positivity, treatment 
noninitiation, and barriers to treatment adherence is described, as is an explanation of 
how data were obtained through statistical analysis. 
Tuberculin skin test (TST) positivity among healthcare personnel (HCP) has 
become a surrogate method for measuring prevalence of latent tuberculosis infection 
(CDC, 2005b).  Detection of target populations for preventive treatment initiation is 
important in stopping the spread of tuberculosis (TB).  The U.S. HCP population has 
become more diverse, with an increase over the years in foreign-born workers (Clearfield 
& Batalova, 2007).  Foreign birth and associated BCG immunization may be greater risk 





population.  Medical laboratory microbiologists frequently work in a healthcare setting 
where although direct patient contact may not have occurred, exposure to patient 
specimens and sample containers may constitute an increased occupational exposure to 
TB organisms (CDC, 2005b). Years of work in the laboratory setting may therefore be a 
risk factor in this population (Menzies, Fanning, Yuan, Fitzgerald, & the Canadian 
Collaborative Group, 2003; Rafiza et al., 2011). Because no one study has focused solely 
on a large group of U.S. laboratorians, the ASCP national registry membership was 
chosen for access to this population.  
A review of the literature (see Chapter 2) has revealed that many researchers have 
used these independent variables in cross-sectional research methods to study HCP but 
only a few have focused on similar data from laboratorians (Garber et al., 2003; Menzies 
et al., 2003; Rafiza et al., 2011).  One of the most recent publications explored preventive 
treatment noninitiation and barriers to treatment adherence (medication side effects) in 
HCP (Shukla et al., 2002).  Garber et al. (2003) touched only briefly on items of 
treatment initiation and treatment barriers among public health laboratorians in New 
York City.  While the Chapter 2 review of the literature described U.S. HCP in terms of 
TST positivity prevalence and risk factors, not much is known about the U.S. medical 
laboratory microbiologist population as a whole.  Through this survey research, I sought 
to answer the study’s research questions, as well as describe the U.S. ASCP target 





Research Design and Approach 
This study was a cross-sectional quantitative study using data that were obtained 
from a self-administered mail survey questionnaire.  These mail surveys were used to 
collect demographic data and self-identified tuberculin skin test history.  (TST positivity 
was used as a surrogate for LTBI status in previous research [Garber et al., 2003]).  
Independent variables of self-reported history of BCG immunization, place of birth, and 
years of laboratory experience were compared against three dependent variables of (a) 
self-reported lifetime TST positivity (Research Question 1), (b) preventive treatment 
noninitiation (Research Question 2), and (c) barriers to treatment adherence (presence of 
medication side effects) as measured by one section of the BMQ (Research Question 3) 
using the self-administered survey questionnaire as found in Appendix A. 
Justification for the Design and Approach 
This cross-sectional research method was chosen because TST positivity in target 
populations is most often used to measure LTBI prevalence, as demonstrated throughout 
the Chapter 2 literature review.  The purpose of the survey questionnaire was to gather 
data used to describe a target study population.  The data collected through this survey 
questionnaire were categorical and descriptive in nature.  The type of survey instrument 
chosen for this dissertation was that of a self-administered mail questionnaire.  The 
questionnaire was built from demographic questions found on other questionnaires and 
reported on in other studies (Garber et al., 2003; Shukla et al., 2002; Svarsted et al., 
1999).  This questionnaire was used to collect demographic and medical history data 





tuberculin skin test and BCG history, and work history (type of work, as well as years of 
work experience).  The basic questions used in this portion of the questionnaire have 
been used in other cross-sectional survey research and, more recently, in the Garber et al. 
(2003) study.  Two closed-ended questions taken from the Brief Medication 
Questionnaire (BMQ) were included for the purposes of assessing medication side-effect 
barriers as a measure of nonadherence (Svarstad et al., 1999).  (Additional information 
regarding validation of the BMQ and pretesting and pilot testing of this questionnaire will 
be discussed in latter sections of this chapter.) 
Advantages of using self-administered questionnaire surveys include (a) low cost, 
(b) ease of obtaining data, (c) speed and relative ease of administration, (d) privacy and 
anonymity for the respondent, and (e) ability to cover a large geographic dispersion of 
respondents.  In addition, no interviewer was present to bias outcome.  Disadvantages of 
this type of research method include (a) low response rate, which can limit 
generalizability; (b) misunderstood or skipped questions; (c) inaccurate reporting by 
respondent; (d) and misinterpretation of the question(s).  The greatest bias in this method 
involves self-reporting of past events and is termed recall bias (Choi & Pak, 2005). 
Based on the literature review described in Chapter 2, a gap in knowledge exists 
regarding the relationship of self-reported lifetime history of TST positivity and treatment 
initiation as well as treatment nonadherence (barriers) among medical microbiology 





Settings and Sample 
Target Population 
The American Society for Clinical Pathology (ASCP) is the oldest and largest 
certification agency for laboratory professionals in the United States (ASCP, 2011).  The 
Board of Certification at ASCP has certified more than 450,000 individuals since its 
inception and has become the gold standard for the certification of clinical laboratory 
personnel (ASCP, 2011).  The ASCP Board of Registry, accredited by the American 
National Standards Institute (ANSI), currently offers 30 separate certification or 
qualification examinations (ASCP, 2009).  ANSI accreditation is considered a benchmark 
of excellence in standardization of certification bodies, both national and international 
(ASCP, 2009), making ASCP’s registrant membership a valid U.S. target population for 
studies regarding medical laboratorians.  The specific cohort with the area of 
responsibility known to ASCP as “Microbiology/Mycology/Parasitology/Virology” was 
chosen as the subpopulation for this study.  This cohort was chosen because (a) a 
literature review revealed that this group is at risk of infection with tuberculosis (latent or 
active) infection due to repeated exposure to contaminated patient specimens and (b) a 
lack of documented research on this subgroup was apparent.  This group was accessed 
through the only marketing firm approved by ASCP to provide registry mailing lists: 
INFOCUS Marketing.   
The "area of responsibility" category database at ASCP is composed of data from 
three sources (E. Corral, ASCP Customer Service Representative, personal 





 SM (specialist in microbiology) and M (microbiology) category registrants. 
 Updates to login information (by ASCP members, and referring to primary 
area of responsibility). 
 Updates to annual (mailed) membership renewal notices (asking for primary 
area of work responsibility). 
According to INFOCUS Marketing, Inc. (2011), ASCP has approximately 51,802 
active members, and 13,378 (12-month) lapsed members.  The number of registrants 
listed with area of responsibility “Microbiology/Mycology/Parasitology/Virology” was 
approximately 5,138 at the time of this study’s proposal stage (INFOCUS Marketing, 
Inc., 2012). 
Sampling Method 
 The entire ASCP registrant membership cohort known as working in the area of 
responsibility of “Microbiology/Mycology/Parasitology/Virology” with U.S. mailing 
addresses was included in the survey research.  No sampling of this group took place.  
Participation was entirely voluntary; this was stated in the cover letter of the 
questionnaire (Appendix A).  The sampling frame for this study was the entire cohort of 
registrant membership listed with ASCP area of responsibility 
“Microbiology/Mycology/Parasitology/Virology,” approximately 5,138 at the time of the 
study proposal stage (ASCP, 2011).  Therefore, randomization (selecting randomly from 
the sampling frame) was not necessary.  The entire cohort was selected in order to obtain 
the largest representative sample for the survey response rate.  Every registrant had an 





correct address appeared on the ASCP mailing list.  Because only ASCP registrant 
members were included, results may not be generalizable to registered nonmembers of 
ASCP, or to other U.S. medical microbiologists (unregistered microbiologists or 
microbiologists registered with other groups).  
Sample Size  
This quantitative single stage cross-sectional study questioned eligible U.S. 
medical laboratory microbiologists, a cohort first estimated at approximately 5,138 
registrant members of the national group known as the American Society for Clinical 
Pathology (ASCP).  To assess adequate sample size for this study, a standard power size 
of .80 (80%) and an alpha level of 0.05 were chosen (Burkholder, 2010).  A beginning 
estimate of N = 5,138 was used to calculate the needed sample size.  This number (5,138) 
changed to reflect the most up-to-date number of registrants on file with ASCP upon 
commencement of the actual research activity.  (The number of individuals was later 
determined to be 4,335; additional sample size calculations are presented in Chapter 4.) 
Estimated sample sizes were calculated using the OpenEpi calculators for Sample 
Size—Proportion and Unmatched C/C Calculation (OpenEpi, 2011).  The calculation was 
made using these two different OpenEpi methods, picking the largest required sample 
size estimate, and then extrapolating to the final expected sample cohort (Appendix B; 
Table 3).   
But first, the proportion of the original cohort to achieve the final outcome (self-
reported medication side effect barriers to treatment adherence) was estimated using 





hypothesized prevalence rate of 33% (Joshi et al., 2006) was used.  (TST positivity, also 
referred to as prevalence of LTBI, ranged from 57% among microbiology workers 
according to Garber et al. [2003] compared with rates of 36 % [Cook et al., 2003] and 
33%-79% [Joshi et al., 2006] among all HCP.)  Research Questions 2 and 3 were 
answered from the respondent reporting TST positive “yes.”  (It was assumed not 
possible for a respondent to self-report as TST-negative and be eligible to respond to 
treatment-initiation and treatment-barrier questions.)  The estimate of the ASCP cohort 
expected to self-report a history of TST positivity and eligible to answer survey questions 
related to Research Question 2 was determined using a 20% treatment initiation 
prevalence rate (the lowest reported by Garber et al. [2003] in this literature search).  The 
proportion of the entire cohort proposed eligible to answer the BMQ survey questions 
associated with Research Question 3 was determined using 33.3% (the prevalence rate of 
those reporting medication side effect barriers according to Camins et al., 1996).   Thus, 
the proportion of the entire original estimated cohort to achieve this final outcome 
(medication side effect barriers to treatment adherence) was proposed to be an estimated 
prevalence of 2.2%.   
Because 2.2% is considered a very low prevalence rate among the population 
under study, the highest sample size attainable was desired in this study.  Sample size for 
the purpose of obtaining prevalence for each of the three research question outcomes was 
calculated using the OpenEpi (2011) software calculator for frequency in a population 
(95% confidence limit).  Sample sizes for the treatment initiation and barriers to 





outcome and were calculated using denominators of the at-risk population, not the overall 
cohort (Table 3).  Sample size for the purpose of obtaining the associations between 
exposures and each of the three research outcomes was then calculated using the 
OpenEpi (2011) software calculator for proportions between two groups (exposed versus 
unexposed), Sample Size—Proportion and Unmatched C/C Calculation (95% confidence 
limit).  (Refer to Appendix B.)  To assess this proportion of exposure, the literature was 
again consulted.  For Research Question 1 (RQ1), frequency of outcomes for BCG 
immunization among cases and controls was found to be less than that of foreign birth 
(Garber et al., 2003).  (Corresponding years of work experience frequency data were 
lacking in the literature and not estimated in this assessment.)  BCG rates and odds ratios 
(ORs) were thus used in the OpenEpi calculations in order to err on the side of caution.  
For Research Questions 2 and 3 (RQ2 and RQ3), BCG frequency and ORs were again 
used for calculations, but surrogate data among HCP noncompliance with therapy for 
LTBI (Shukla et al., 2002) were used in the absence of treatment initiation or side-effect 





Table 3  
Table Sample Size Calculations for Research Questions 1, 2, 3 (RQ1, RQ2, RQ3) 
 RQ1 RQ2 RQ3 
Estimated frequency 
(Using Open Epi 
calculation) 
 
319/5,138 total cohort  
(6.2%) 
215/1,696, or 
13.0% (5,138) = 668 
171/ 339, or  
50.0% (5,138) = 2,569 
Estimated association 
(Open Epi, Fleiss w/CC 
calculation) 
   
     Cases  (outcome) 17 30 36 
     Controls 33 118 72 
     Total 50 148 108 
 
Summary: Minimum 
sample size  
Extrapolated 
requirement with an 
















171(339) is 50% of total 
estimated cohort; 
n = 2,569, 36 of which 
must be positive for 
RQ3 outcome 
(possible, because a 
2.2% frequency of 2,569 
= 57 possible 
candidates) 
 
To double-check sample size requirement using the Walden University tables for 
Cohen’s d, assuming alpha level .05, effect size = 0.20 (this is the most conservative, and 
would lead to worst-case largest sample size requirement), and power = .80, the 
corresponding sample size from the Cohen’s d table is n = 199 respondents (Burkholder, 
2010).  In addition, Katz (2009) has reported that in multivariate analysis, the sample 
requirement is based on having at least 10 outcomes for each independent variable in the 
model.  For this research having three main independent variables, n = 30 samples with 





In summary, using an estimated cohort of 5,138 individuals to calculate the 
needed sample size, different methods were used to determine adequate sample size for 
each research question: 
 OpenEpi:  A sample requirement based on eligibility of the cohort to 
respond “yes” to TST positivity, treatment initiation, and reported 
medication side-effect barriers of adherence (all three research questions) 
would require at least n = 2,569 (based on an original estimated cohort of 
5,138).  In summary, a return of 50% of all surveys mailed and deemed 
eligible to participate (originally estimated at n = 2,569) needed to be 
realized in order to adequately capture sample size needed to answer all 
three research questions. 
 Cohen’s d Table: n = 199, sample requirement (RQ1 frequency) is based 
on the smallest effect size. 
 Katz (2009): n = 30 samples with the final outcome of interest (RQ3). 
The entire cohort was surveyed, but from previous research by Clark (2008), an 
estimated 22.5% return rate for an ASCP population would yield 5,138 (.225) = 1,156 
survey respondents.  This number is lower than the anticipated 2,569 required. To 
increase this number of respondents over those in the Clark (2008) study, two items were 
added.  First, an incentive using a group charity donation approach (a donation to the 
ASCP Scholarship Fund based on number of completed and returned surveys) was used, 
in part because incentives have been known to increase participation in some studies to 





prospective respondents 1 week ahead of the survey packet mailing.  Neither method was 
used in the Clark (2008) study.  INFOCUS Marketing has reported that the rate of 
returned mail should be much lower (no more than 1%) when compared with previous 
mailings involving ASCP marketing lists (S. Blake, INFOCUS Marketing Consultant, 
personal communication, September 17, 2012), such as the study reported by Clark 
(2008).  It was hoped that a yield of at least 50% of the entire cohort (n = 2569) would be 
realized after implementing these tools, a number equal to the required number of 
returned surveys yet more conservative than the higher percentage of return as estimated 
by Mangione (1995). 
Eligibility Criteria for Study Participants 
As mentioned in Chapter 1, study participant inclusion criteria were as follows: 
 Adult registrants have been certified and registered through the ASCP Board 
of Registry (BOR), and were included on the current ASCP member mailing 
list, all having U.S. mailing addresses. 
 Registrant members were reported to work in the primary work responsibility 
of microbiology known as “Microbiology/Mycology/Parasitology/Virology” 
as reported by ASCP.  (To address the entire ASCP registry would have 
proved too costly and was not necessary.  As stated previously, these 






No study participant exclusion criteria pertain (other than to address any 
individuals under the age of 18 years); it was hoped that all included in the survey 
mailing would respond.   
Characteristics of Selected Sample 
Characteristics of the selected ASCP cohort were described through a 
combination of statistical methods used to assess the questionnaire responses.  Note: This 
study did not include any type of treatment stage. 
Instrumentation and Materials 
Data Collection Tool 
Data were collected using a self-administered survey questionnaire mailed 
through U.S. first-class mail.  The full questionnaire instrument was able to be completed 
by a literate (able to see, read, and write in English) educated respondent.  Because this 
target population is highly educated and all registrants have applied for registry and/or 
taken their ASCP board exams in the English language, they were deemed well-prepared 
to take this survey questionnaire.  The mail questionnaire was short, two to three pages 
total in length.  No concurrent email questionnaires were sent because current email lists 
represented approximately one-third to one-half of this cohort only (INFOCUS 
Marketing, 2011), and because older adult ASCP registrants may not have access to 
computer email.  Completion of questionnaire was strictly on a voluntary basis.  No exit 
or debriefing strategies were required.  (The individual completed and submitted the 
survey anonymously, or opted out completely.  An announcement postcard preceded the 





questionnaire structure was considered low- to moderately-complex, with most questions 
as demographic or asking the participant to recall health history.  No calculations or 
difficult questions were asked.  The reading level, instructions, and questionnaire items 
were considered appropriate for this college level target population; many of the same 
questions were asked in the Garber et al. (2003) study.  The time required to take the 
survey was estimated at approximately 10 minutes. 
The name of the survey questionnaire for this study is, “Tuberculin Skin Test 
Questionnaire for ASCP Medical Laboratory Microbiologists—2013.”  The type of 
instrument was a self-administered, mailed questionnaire using closed-ended questions; 
this one-time survey questionnaire was intended to measure outcome prevalence.  This 
may be considered a period prevalence study in which the outcome (dependent variables) 
that existed during lifetime history were reported at one point in time –  the time of the 
taking of this survey questionnaire.  Prevalence studies are valuable for investigating risk 
factors associated with progressive diseases having no clear point of onset as in latent 
tuberculosis infection (Checkoway, Pearce, & Kriebel, 2004).  The end product of this 
survey is lifetime prevalence involving any self-reported TST positivity outcome, risk 
factors of self-reported TST positivity, preventive TB treatment noninitiation, and any 
barriers to treatment adherence (medication side effects) from an individual’s past or 
present (lifetime) history.  Of note, the actual survey questions were asked at only one 





The self-administered questionnaire was administered to all ASCP registrant 
members listed on the ASCP mailing list for the target group.  This survey questionnaire 
(Appendix A) included items such as 
 gender; 
 current age; 
 type of laboratory work experience; 
 years of laboratory experience; 
 place of birth (U.S. or foreign); 
 tuberculin skin test history and status; 
 any history of interferon gamma-releasing assay (blood test); 
 BCG immunization history; 
 history of active TB; 
 history of nonoccupational exposure; 
 history of preventive treatment prescription, treatment initiation, treatment 
refusal, and treatment completion; and 
 BMQ medication side effects treatment adherence questions.  
The questionnaire contained a combination of “yes” or “no” response type 
questions and several multiple choice.  The category of “don’t know” or “don’t 
remember” was included in only the history of TST, history of IGRA testing, and BCG 
immunization history sections for several reasons.  First, the questions are not knowledge 
questions, but rather questions of self-reported history.  Mangione (1995) has 





questions are introduced.  Second, in this literature review other researcher survey and 
analysis methods did not contain the “don’t know” category.  Because this study was 
interested mainly in those responding as TST-positive, the “don’t know” category was 
used only to assist the respondent by offering a third response choice for several history 
questions.  
All demographic and self-reported history questions (except for age) were tallied 
and coded as dichotomous responses (see Appendix E for codebook).  The final group of 
questions referring to medication treatment completion and perceived side effects was 
derived from the Brief Medication Questionnaire (Belief screen; see below for BMQ 
instrument detail).  The sections of the actual survey document are represented in Table 





Table 4  
Sections of the Questionnaire 
Section Source of content 
I. Consent Form (informed and implied, not 
returned with survey)  
 
Walden University Research Center 
 
II. Member Demographics (gender, age, type of 
work, years of laboratory work, place of birth)  
 
Not validated, demographic in nature (Garber et al., 
2003; Rafiza et al., 2011) 
III. Medical History (lifetime history of tuberculin 
skin test, IGRA blood test, BCG immunization, 
active TB, contact, exposure) 
 
Not validated, medical history (Garber et al., 2003)  
(Regarding IGRA blood test history: this 
information is informational only, and is not known 
to exist on any medical history questionnaire to 
date) 
 
IV. Positive Skin Test—Medical History 
(prescribed INH, initiation of treatment, completion 
of medications) 
 
Not validated, medical history (Garber et al., 2003) 
V. BMQ Belief Screen (questions 14 and 
15 a, b) 
 
Validated section, medication side effects screen 
indicating adherence or nonadherence (Svarstad et 
al., 1999) 
 
Reliability.  The reliability of this survey instrument as a whole has been 
addressed through use of the following items, intended to decrease sources of 
measurement error: 
 Questionnaire design: Consistency within the questionnaire has been 
addressed through the flow and order of questions (arranged to make sense to 
respondent). 
 Questionnaire design: Consistency within the questionnaire has been 
addressed through comparison of specific question answers to be certain the 
answers make sense (one cannot answer “no” to having a history of a positive 





treatment barriers).  This aspect was addressed by this researcher as data were 
input to the analysis software. 
 Processing of the questionnaire occurred through several questionnaire 
handling stages.  Quality controls by the researcher (use of spell check when 
composing the questionnaire, printer proofs, and professional appearance of 
questionnaire) were added to enhance reliability of this survey instrument.  
Quality control in the stuffing of the envelopes was out of the control of this 
researcher; the approved marketing group was solely responsible for this duty 
and was held accountable.  Abstracting and coding of items was controlled by 
numbering each completed questionnaire upon receipt by the researcher and 
then double-checking each numbered questionnaire with the corresponding 
data number in the software base in order to verify correct data entry. 
 The BMQ questions were written and validated in the English language, as are 
other examples of demographic questions as used in routine occupational TST 
and TB medical history questionnaires (no translation needs to take place).  In 
addition, all ASCP registrants have taken ASCP board exams in English and 
are familiar with the processes of reading questionnaires and test-taking. 
 The instrument was administered to ASCP members under self-administered 
conditions during pretest and pilot testing processes. 
Test-retest reliability is not applicable to this study.  
Validity.  The validity of this survey instrument as a whole has been addressed 





 Pretesting the questions and questionnaire (Walden University, n.d.) with 
culturally diverse ASCP registrants to assure cultural competency (as 
suggested by Fink, 2009).  Pretesting was informal, designed as a participating 
pretest to take place among three to five participants (Converse& Presser, 
1986).   
 Pilot testing the questionnaire with educated, professional ASCP registrants 
working in a similar (medical or clinical laboratory) work environment; those 
included in the pilot testing were not invited to participate in the actual study 
in order to avoid confusion and pretest bias.  At least 10 to 30 participants 
were sought for inclusion in the pilot test (25 participants were recommended 
by Converse and Presser, 1986).  A more thorough discussion of pretesting 
and pilot testing will follow in the corresponding chapter section.   
 Expert review by the dissertation committee members to review construct and 
face validity structure (Walden University, n.d.); the dissertation committee 
performed reviews of this study’s proposal and dissertation findings. 
 Construct validity has been addressed through a thorough literature review as 
noted in Chapter 2, revealing the best method for this research as well as 
examples of specific measures of the constructs (Walden University, n.d.).  In 
this dissertation, the best method for assessing tuberculin skin test positivity 
(prevalence) was determined to be cross-sectional survey research.  Specific 
measures of constructs in this dissertation have been identified as the 





 Use of a previously validated survey questionnaire, the BMQ (Part A) for 
inclusion of several important survey questions in the treatment nonadherence 
(medication side effect barriers) component of this questionnaire; see the 
BMQ section below for information related to the criterion related validity of 
the BMQ instrument.  Each section of the BMQ was previously validated 
(independently, and as an entire instrument).  The section known as the 
“Belief Screen” was included as a part of this questionnaire. 
Survey response rate.  Efforts made by the researcher to enhance survey 
response rate included the following: 
 An incentive (contribution to the ASCP Scholarship Fund charity) in the form 
of a $250 donation made to the ASCP Scholarship Fund for every 1000 
completed surveys received by survey deadline (within the accepted time limit 
of 8 weeks).   
 Voluntary participation, confidential, and anonymous.  
 Mail survey (chosen because the method provided respondents privacy and 
choice in responding to questions with no interviewer bias). 
 Mail versus email for the survey, because the email list represented 
approximately one-third to one-half only of this cohort (INFOCUS Marketing, 






 Advance mailing of a survey announcement postcard (Appendix C) to the 
entire cohort about one week prior to mailing of survey packet, as 
recommended by Fink (2009). 
 Cover letter and questionnaire were composed of two to three pages (short in 
length) as recommended by Bourque and Fielder (2003) and Mangione 
(1995). 
 Questionnaire paper was prepared using a color other than white (easy on the 
eyes); light green colored paper was used as suggested (Mangione, 1995). 
 Researcher contact name and information were added to enhance authenticity 
as suggested by Mangione (1995). 
 Self-addressed stamped return envelope was included for return of the 
questionnaire to researcher as suggested by Mangione (1995). 
 All survey packets were mailed out at the same point in time. 
Recall bias.  Efforts made to decrease questionnaire recall bias (respondent error 
as a source of measurement error) included the following: 
 Respondents were college educated, literate, professional laboratory worker 
with knowledge of tuberculosis and preventive laboratory measures to protect 
against infection (including receipt of TSTs on a regular basis).  Respondents 
were considered able to accurately interpret meaning of these questions, and 
honestly report personal recollections. 
 Questionnaire questions were considered clear and concise; the order of the 





history question).  The questionnaire length was held to two to three pages in 
order to hold the attention of the respondent. 
Brief Medication Questionnaire instrument.  As mentioned earlier, one portion 
of the self-administered mail questionnaire consisted of two questions reproduced from 
the Brief Medication Questionnaire (BMQ).  The BMQ instrument was chosen over 
several other questionnaire tools for addition to the main survey instrument for several 
reasons.  The BMQ sections were short, previously validated as survey instrument tools 
and related directly to treatment medications.  Comparison of several other survey tools 
(Charles P. Felton National Tuberculosis Center, 2005; Holstad, 2001a, 2001b; New 
Jersey Medical School National Tuberculosis Center, n.d.) revealed that most tools were 
not useful for surveys such as this proposed survey.  Other tools referred to active, 
current administration of treatment medications or were geared toward specific patient 
populations (and not toward an educated HCP population).  These types of items were 
not considered as applicable when asking HCP respondents to self-report past TST 
treatment history.   
The Brief Medication Questionnaire (BMQ) was first described by Svarstad et al. 
in 1999; the complete questionnaire instrument and scoring instruction was published in 
Redman (2003).  The BMQ is a self-report tool intended for use in screening adherence 
to many types of treatment medications and in identification of barriers to treatment 
adherence.  The tool was initially validated in patients taking angiotensin-converting 
enzyme inhibitors, and has also been used in patients with diabetes, depression, and other 





several sections (a) Regimen, (b) Belief, and (c) Recall screens.  The Belief screen was 
utilized in this questionnaire and will be discussed below.  The BMQ’s sensitivity was 
measured and validated by comparing responses to actual data obtained using the 
Medication Events Monitoring System (MEMS), a medication measuring system which 
uses a microprocessor in the cap of a patient’s medication bottle.  The microprocessor 
records date and time of bottle opening and has been termed a “gold standard” for 
measuring treatment adherence, according to Svarstad et al. (1999).  The Regimen screen 
portion of the BMQ provides a place for recording the number and times pills are taken 
or missed in the past week.  The Recall screen portion of the BMQ assesses two items 
referring to ability to remember taking the prescribed pills.  Neither of these screens is 
applicable to this study.  However, the Belief Screen portion of the BMQ is applicable to 
this study and refers to the reporting of actual or perceived adverse medication effects.  
Because these adverse effects have been measured as past barriers to treatment adherence 
in HCP (Camins et al., 1996; Joseph et al., 2004), the BMQ Belief Screen questions were 
included in this survey research.   
Concepts and specific questions in the BMQ Belief Screen as measured by the 
instrument are listed in Appendix D.  Scores were calculated by converting the answers 
to scores of 1 = yes, and 0 = no (see Appendix D).  With a scoring range of 0–2 possible, 
a score of ≥ 1 indicates a positive screen for belief barriers (Svarstad et al., 1999).   
Each of the three screens in the BMQ was analyzed against MEMS results for 
sensitivity (ability to detect true nonadherence), sensitivity, specificity, positive 





and Pearson correlation for continues measures (Svarstad et al., 1999). The three screens 
performed well independent of one another.  Specifically, for patients with repeat 
nonadherence, the Belief Screen results indicated (a) 100% sensitivity, (b) 80% 
specificity, (c) 62% positive predictive value, and (d) overall accuracy rate of 85%.  
However, “the belief screen failed to identify sporadic nonadherence” (Svarstad et al., 
1999, p. 119) at a sensitivity of only 10%.  The instrument authors suggested portions of 
this instrument, including the Belief Screen, may be useful in resolving different types of 
medication adherence barriers.  For the purposes of this study, barriers to treatment 
adherence refers to barriers of medication side effects as measured using the above Belief 
Screen portion (Part A) of the Brief Medication Questionnaire (Svarstad et al., 1999). 
Permission to use portions of the BMQ survey instrument was given to this 
researcher via electronic email correspondence on October 25, 2011 by the first author, 
Dr. Svarstad.  In addition, permission (see Appendix F) was granted (Dr. Svarstad, 
personal communication, May 6, 2012) to publish the sample questions and scoring 
instructions in this dissertation (see Appendix D). 
Variables and Codebook 
Dependent and independent variables are listed and described in the Codebook 
(Appendix E) as a function of the questions from the survey questionnaire (Appendix A).  
Data as related to the variables have been listed and described under subheadings as 
noted in the Codebook (Appendix E).  One independent variable in particular, BCG 
immunization, may also act as a confounder in this study.  Data were collected on other 





research questions at hand.  Additional data collected from the survey questionnaires 
were analyzed and reported as part of the overarching summary contingency table.  The 
variables included in the additional data analysis (by order as asked in the survey 
questionnaire) are as follows: 
 gender; 
 age; 
 prevalence of respondents who have ever received the new IGRA blood test, 
and number reporting a positive IGRA result (the importance of which was 
addressed in Chapter 2); 
 prevalence of respondents prescribed and completing anti-TB medications; 
 prevalence of respondents prescribed but refusing the treatment; and 
 reports of specific adverse drug (medication) side effects (frequency if drugs 
are named). 
In addition, data regarding survey response rate, bad address return rate, rate of 
late returns, and number of incomplete surveys were compiled and reported. 
Pretesting and Pilot Test 
An informal pretest of this survey questionnaire took place using a “participating 
pretest” method whereby at least three (to five) ASCP registrants known by this 
researcher were told they would be participating in a practice run, reading the survey 
aloud and allowing for this researcher to record any issues that might aid revision.  The 
participating pretest method, suggested by Converse and Presser (1986), is important in 





were asked to explain their reactions and answers in a written debriefing.  The 
participants were asked if any questions made them feel uncomfortable, if they had 
difficulty understanding any of the questions, and if any sections seemed to drag or were 
confusing (recommended by Converse and Presser, 1986).  After appropriate adjustments 
were made to the questionnaire instrument, the questionnaire was pilot tested among at 
least 10 with a maximum of 30 (with a goal of 25, as suggested by Converse and Presser, 
1986) consenting adult individuals having similar collegiate education, ASCP registry 
certification, and work experience in the medical/clinical laboratory work environment.  
These individuals were accessed through the ASCP member mailing list of Generalist 
laboratorians (Medical Laboratory Scientists) with U.S. postal addresses in the State of 
Georgia (Appendix J).  Test laboratorians were also invited to participate based on 
diversity in place of birth, to assess wording of the questionnaire and ability to 
understand the flow of questions.  The questionnaires were not mailed, but rather, handed 
out in sealed envelopes for anonymous return by USPS mail to this researcher.  The pilot 
test was used in order to test the questionnaire for clarity of language, and for looking for 
(a) failure to answer questions, (b) giving several answers to the same question, and (c) 
the writing of comments in questionnaire margins (as suggested by Fink, 2009).  
The pilot test data were evaluated based on the number of unanswered or 
misinterpreted questions.  Error rates of 15% have been used in past research to flag 
questions that warrant further investigation (CDC, 2003b).  The pilot test errors were 
coded onto a table for evaluation (see Appendix G) in order to assess error rate.  If a 





among a new group was acknowledged as a possibility.  Once the final adjustments were 
made in the questionnaire and approved by the Walden University Institutional Review 
Board (IRB), the survey packet was ready for printing and mailing by INFOCUS 
Marketing, Inc. 
Survey Packet 
The survey packet included a (a) cover letter with reason for study, incentive 
information, and informed consent statement; (b) survey questionnaire with closing 
instructions; and a (c) a postage paid return reply envelope.  A postcard announcing the 
survey questionnaire (Appendix C) was mailed approximately 1 week prior to the mailing 
of the survey packet.    
Operationalization 
 Definitions for each variable in this study were addressed in Chapter 1.  In 
addition, the term lifetime prevalence (period prevalence) was used in this study to 
describe the proportion of the target population with self-reported outcomes as related to 
the dependent variables (given conditions) over a specified time period (past and present 
lifetime of the individual study participant).  Specific operationalization of definitions 
follows.  
Target population.  Medical laboratory microbiologists: For the purposes of this 
study, this terminology refers to the group registered with and designated by ASCP as 
primarily working in the area of the laboratory known as 





Independent variables.  Bacille Calmette-Guérin immunization (BCG): For the 
purposes of this study, BCG immunization refers to the self-reported lifetime history of 
ever receiving an immunization with the BCG vaccine.  
Place of birth: In TB surveillance, a U.S.-born person is defined as someone born 
in the United States or its associated jurisdictions (U.S. territories include: American 
Samoa, C.N.M.I. [Commonwealth of Northern Mariana Islands], Guam, Puerto Rico, 
U.S. Virgin Islands), or someone born in a foreign country but having at least one U.S.-
citizen parent (CDC, 2012).  For purposes of this study, foreign-born persons are not 
U.S.-born.  Place of birth was denoted as U.S. birth or foreign birth. 
Laboratory work: For the purposes of this study, years of laboratory work refers 
to clinical or medical laboratory experience and includes training, as well as paid and 
unpaid work in areas where testing was performed on clinical specimens, control 
organisms, or isolates.  Years were signified as strata of (a) 0-2, (b) 3-5, (c) 6-10, (d) 11-
15, (e) 16-20, and (f) over 21 years. 
Dependent variables.  Tuberculin skin test (TST) positivity: For the purposes of 
this study, TST status refers to a self-reported lifetime history of ever demonstrating a 
positive TST, as recalled by the survey participant.  The respondent was asked if he or 
she was ever told by a health department employee, occupational health department 
employee, or other provider (doctor) that his or her TST was positive.  The term status 
may refer to a history of either a positive TST or a negative TST.   
Preventive treatment noninitiation: For the purposes of this study, treatment 





treatment was not completed.  Noninitiation refers to the act of never beginning the 
prescribed treatment. 
Barriers to treatment adherence (medication side effects): For the purposes of this 
study, terminology of barriers to treatment adherence refers to barriers of medication side 
effects as measured using the Belief Screen portion of the Brief Medication 
Questionnaire (Svarstad et al., 1999). 
Each variable was measured by responses indicated on the self-administered mail 
questionnaire.  Each variable (except for age) was manipulated in order to create nominal 
level measurements.  Example items may be found in the codebook located in Appendix 
E. 
Data Collection and Analysis 
Research Questions 
Research questions explored in this study and their hypotheses are as follows: 
Research Question 1.   What is the relationship of history of BCG immunization, 
place of birth (U.S. or foreign), and years of laboratory experience with self-reported 
lifetime tuberculin skin test (TST) positivity? 
HO:  There is no statistical association between self-reported individual 
independent variables of history of BCG immunization, place of birth (U.S. or foreign), 
and years of laboratory experience, and the dependent variable of self-reported lifetime 
TST positivity. 
HA:  There is a statistical association between self-reported individual 





and years of laboratory experience, and the dependent variable of self-reported lifetime 
TST positivity. 
Research Question 2.  What is the relationship of history of BCG immunization, 
place of birth (U.S. or foreign), and years of laboratory experience with preventive 
treatment noninitiation among those individuals prescribed treatment for a positive TST? 
HO:  There is no statistical association between self-reported individual 
independent variables of history of BCG immunization, place of birth (U.S. or foreign), 
and years of laboratory experience, and the dependent variable of preventive treatment 
noninitiation. 
HA: There is a statistical association between self-reported individual 
independent variables of history of BCG immunization, place of birth (U.S. or foreign), 
and years of laboratory experience, and the dependent variable of preventive treatment 
noninitiation. 
Research Question 3.  What is the relationship of history of BCG immunization, 
place of birth (U.S. or foreign), and years of laboratory experience with barriers to 
treatment adherence (medication side effects) among those initiating preventive treatment 
for a positive TST? 
HO:  There is no statistical association between self-reported individual 
independent variables of history of BCG immunization, place of birth (U.S. or foreign), 
and years of laboratory experience, and the dependent variable of barriers to treatment 
adherence (medication side effects) as identified using the Brief Medication 





HA:  There is a statistical association between self-reported individual 
independent variables of history of BCG immunization, place of birth (U.S. or foreign), 
and years of laboratory experience, and the dependent variable of barriers to treatment 
adherence (medication side effects) as identified using the Brief Medication 
Questionnaire (BMQ) in those respondents ever having initiated preventive TB treatment.   
Explanation of Descriptive Analysis Used in This Study 
Each dependent and independent variable was described as nominal scale 
measurements (see Appendix E for Codebook details). 
Description of Data Analysis 
All statistical procedures were performed using Epi Info™ Version 3.5.3 (CDC, 
2011c).  Epi Info™ provides open-access, free, and flexible software obtainable online 
from the Centers for Disease Control and Prevention.  It has been used by healthcare and 
public health workers for rapid creation of data collection instruments and advanced 
statistical analysis of data.  Epi Info™ software, accessible worldwide, has provided a 
useful platform for epidemiology techniques (CDC, 2011c).   
Completed questionnaires were numbered with a record number upon receipt by 
the researcher.  Data obtained from the completed questionnaires were cleaned and 
compiled into data sets within the Epi Info™ software.  Verification of data in the data 
set was performed by double-checking each numbered questionnaire with the 
corresponding data number in the software base.  Raw data are available as a separate 
Microsoft Excel (Microsoft Corporation, 2012) file accessible to this dissertation 





conjunction with the approval of ASCP and the Walden University Institutional Review 
Board). 
All variables (independent and dependent) were transformed into categorical 
(nominal scale) measurements for statistical analysis.  Data were cleaned; of note, the 
initiation data were transformed at this point to noninitiation as an outcome.  The data, set 
into dichotomous variables, underwent analysis via contingency tables and logistic 
regression.  (Note that some of the data categories, such as age and years of laboratory 
experience were collapsed into appropriate dichotomous variables.)  A codebook was 
used to guide categorical placement of all data into dichotomous variables (see Appendix 
E).   
Statistical methodologies, including univariate, bivariate, and multivariate 
statistics were used in the data analysis.  Univariate statistics were used to describe some 
study population sample characteristics as related to Research Questions 1, 2 and 3, 
among those self-reporting as TST positive.  Univariate and bivariate statistics consist of 
frequency and percentage.  Bivariate analysis was used to examine the association 
between each of the independent (potential predictor) variables against each dependent 
(outcome) variable.  Non-parametric statistics such as chi-square were utilized because 
no assumption regarding distribution of the variables resides in the target population 
(Munro, 2005).  This use of the chi-square assumes that four assumptions will be met: (a) 
data has been categorized and frequencies can be obtained, (b) adequate sample size has 





research questions and theory have been established (Munro, 2005).  Chi-square analysis 
resulted in R statistics: X-squared, degrees of freedom (df-), and p-values. 
Multivariate statistics were used to build a model with all the important and 
statistically significant predictors.  Because this study utilized dichotomous dependent 
and independent variables, multiple logistic regression analysis statistics were selected 
for use.  Logistic regression analysis allowed for the investigation of one independent 
variable as a risk factor while controlling for the effect of the other independent variables 
and potential confounders (Pallant, 2007).   
Other covariates based on the survey data as collected were added to adequately 
assess for the presence of confounding among known variables.  In addition, a broader 
descriptive analysis was performed among these covariates. 
Variables were selected using preference (research questions were chosen from 
variables as they appeared throughout the literature review process).  Multicollinearity 
among the variables (highly correlated independent variables) was detected using chi-
square and bivariate analysis, as well as logistic regression analysis.  Collinearity was 
found, and it has been addressed in the post-hoc analyses section below.  Variables were 
not automatically discarded in initial models, as those variables that are theoretically 
important should be retained (Katz, 2009).  As recommended by Katz, if any pair of 
independent variables are “correlated at > 0.90...decide which one to keep and which one 
to exclude  If any pair of variables are correlated at 0.89 to 0.90 consider dropping one” 





The variable selection criteria chosen were the Yates corrected chi-square with 
two-tailed p (or Fisher exact p-values if cell sizes are < 5 [Gregg, 2008]); 0.15 was used 
as p-value cut-off for inclusion into models.  (Katz [2009] recommended including any 
variable that is associated with an outcome at P value of < 0.20 or .25 in order to avoid 
missing important confounders.)  Even if the variables do not meet criteria, those which 
are reported in literature as theoretically important should still be included in the initial 
model (Katz, 2009). 
For multiple logistic regression analysis in Epi Info™, outcomes were coded as 
“1” for “yes”, presence of the outcome (for example, TST—positive was coded as “1”, 
treatment initiation—no was coded as “1”, BMQ adherence barriers present—yes was 
coded as “1”), and “0” for the referent value or absence of the outcome (for example, 
TST—negative was coded as “0”, treatment initiation—yes was coded as “0”, BMQ 
adherence barriers present—no was coded as “0”, and so on for covariates).   
Independent variables were tested as potential confounders in a backward 
stepwise logistic regression approach.  Those not associated with an outcome at P value 
of ≤ 0.05 were excluded from the model, in association with and depending on the result 
of the odds ratio and Wald statistic (Munro, 2005).   
The odds ratio (maximum likelihood estimation or MLE, Mid-P exact) was 
assessed for each variable, along with confidence intervals (CI) to assess the probability 
of occurrence (Dean, Sullivan, & Soe, 2010). The level of significance for the nominal 
variables in 2x2 Epi Info™ tables was determined by chi-square.  The Wald statistic 





variable in order to compare each estimated coefficient with the univariate model in 
assessment of significance (Munro, 2005). 
The final, most parsimonious model includes main risk factors, as well as 
describes any potential confounders.  To test assumptions on the final model, this 
researcher checked data for outliers or unusual patterns.  Conclusions from the final 
model were assessed for answers to the three proposed research questions in this study. 
Missing Values 
Assuming missing value counts for a small portion of the total observations, 
analysis included the non-missing data for questions Q4, Q5, Q6, Q8, Q12, Q14, and 
Q15, as these questions are essential and applied directly to the research questions. If any 
of these essential questions were left unanswered, the respondent’s entire survey was 
coded as a non-response (NR) in the raw data table.  In other words, no partial answers 
for this specific group of questions were allowed.  No imputation of missing values was 
performed, meaning that no estimated values were coded in place of missing values.  All 
other survey questions should have been answered as part of the informational portion of 
this survey.  When any one of the unessential questions was left unanswered, each 
specific question was then coded as a non-response (NR) or left blank in the coded data 
file, but the remainder of the survey questions and responses were entered into the 
database for statistical analysis.  No large numbers of data were missing, and so no 
variables were dropped (rather than subjects), as suggested by Katz (2009). 
Because INFOCUS Marketing, Inc. printed and mailed the surveys on behalf of 





individual surveys for tracing of individual responses was not possible.  It was expected 
as highly unlikely that multiple entries would be made by the same person and so this 
concern was not addressed.  The surveys returned to this researcher will forever remain 
anonymous.  No follow-up of the target population was attempted after survey 
announcements and questionnaire packets were mailed.   
Study Algorithm 
This study followed the algorithm as presented in Appendix H.  The algorithm 
was used to demonstrate relationship of the dependent variables. 
Use of Tables 
Tables were used to represent data obtained and compiled in the course of this 
research (see Tables 5-27 in Chapter 4).  To search for any statistical interaction (and 
confounding) between the independent variables, stratified analyses were performed as 
appropriate.  Tables continued in the same manner for the remaining combinations of 
independent variables (covariables). 
Multivariate analysis: Multiple logistic regression was used to assess inter-
relationships of the covariates (as well as the variables analyzed in the bivariate analysis) 
in order to assess interrelationships and relative strengths and probabilities of variables.  
This process was used to identify individual contributions as related to the dependent 
variables.  Initially, all covariates (already known to have suspect or established 
associations) were entered along with the dependent variables.  At this point in the data 
analysis, type of laboratory work was collapsed into nominal bivariate groups based on 





experience groups were collapsed into nominal bivariate groups based on the mean of the 
respondent data.  Gradual elimination of the nonsignificant variables using a backwards 
step approach was used to lead to a final model.  These findings were compared with the 
bivariate analyses to check for possible interactions.  When suspected, additional 
stratified analyses followed, and logistic regression analysis was repeated (while 
eliminating the probable interaction covariate by creating interaction terms in Epi 
Info™). 
The same tables were repeated to assess initial full model logistic regression all 
variables, for treatment noninitiation and again for barriers to treatment adherence 
(medication side effects) as measured by the BMQ.  Tables were then repeated to assess 
stepwise model logistic regression for each covariate/independent variable (removing one 
at a time), for treatment noninitiation and again for barriers to treatment adherence 
(medication side effects as measured by the BMQ). 
The final, most parsimonious model for each dependent variable (research 
question variable) is composed of the statistically significant independent variables 
identified through multiple logistic regression.  Confounding (a presence of > 15% 
relative change of the odds ratio of the independent variable [exposure] with and without 
the confounder) has been addressed in Chapter 4.  Based on results of the Chapter 2 
literature review, BCG immunization and its relationship to foreign birth was confirmed 





Measures Taken for Protection of Participants’ Rights 
This study was based on self-administered questionnaires performed on a specific 
ASCP study population.  ASCP provided preliminary basis approval to this researcher for 
use of a questionnaire in survey research of this target population (S. Blake, personal 
communication, May 10, 2012).  Final ASCP approval for use of the IRB-approved 
questionnaire was provided on January 24, 2013.  The Letter of Cooperation—
Permission Letter (Appendix I) was addressed with ASCP through INFOCUS Marketing, 
Inc. (provided by INFOCUS Marketing, Inc. at time of contract assignment).  Final 
approval for conducting the pilot study was also granted by ASCP, and the Letter of 
Cooperation (Permission—Pilot Test) has been added to this dissertation (Appendix J).    
The pilot test was conducted on respondents’ off-duty work time, and anonymous pilot 
test questionnaires were handled in the same manner as the approved survey 
questionnaires (see below).  Final approval to include the previously selected BMQ 
questionnaire questions in the completed proposal and subsequent dissertation documents 
was given by BMQ first author, Dr. Bonnie Svarstad, on May 6, 2012 (and restated to 
this researcher via email correspondence on July 4, 2013).   (See Appendix K.) 
All data arrived via U.S. mail in a de-identified state, because no survey numbers, 
names, or respondent return address information were included on the questionnaire.  
Therefore, all returned questionnaires contained no personal identifiers making them 
anonymous.  Informed consent was addressed by using a cover letter that explained the 
study promised confidentiality, and that informed consent was implied by completing and 





the questionnaire signified an individual’s informed consent has been obtained) were 
stated as, “By returning a completed questionnaire, I consent.”  In addition, survey 
respondents were instructed not to use name or personal information on the return 
questionnaire. 
This research is valid to this population and to other health care professionals, and 
not socially harmful. No state or federal reporting requirements as they apply to 
reportable diseases apply in this study, because the respondent was asked only about 
recollection of past events.  A positive TST or active TB disease would have already been 
reported by the provider to the appropriate public health entity.  This researcher was the 
only researcher handling questionnaire data and so the training of other research 
assistants was not necessary. This research questionnaire did not pose any unnecessary 
risk, such as a physical or mental strain.  Because responses were anonymous, no 
respondent should have felt hesitant to answer questions in an honest manner, or felt at 
risk of losing employment because of their answers.  These survey recipients are highly 
educated college graduates and professional adults (18 years of age or older), accustomed 
to working in the medical laboratory field.  No special population was at risk.  
Issues of confidentiality were addressed by the following: 
 No names or addresses were used on any of the paper questionnaires. 
 No conflict of interest existed with respect to the choice of ASCP Scholarship 
Fund as the incentive for donation on behalf of the ASCP survey respondents.  





donation.  The ASCP Scholarship Fund provides scholarships to medical 
laboratory students in the U.S. 
 Completed paper questionnaires returned to the researcher have been secured 
in a locked file cabinet (and will continue to be locked in this state) for a 
period of at least five years.  Return envelopes were not retained, but rather 
shredded when any personal information (such as a return address) was 
present.  All de-identified data sets used for computer analysis were 
transferred to a separate hard drive (from the only computer used for this 
research) for locked storage.  This hard drive will remain in storage for a 
period of at least five years. 
 I have not, nor will I share or disclose any individual responses with any 
friends or family members. 
 I have not, nor will I publish any data that will allow readers to determine the 
identification of the survey respondents. 
No participants were contacted and no data were collected until I received 
approval from the Walden University Institutional Review Board (IRB).  Once Walden 
University granted IRB approval, the corresponding IRB approval number was listed on 
the survey cover letter.  The survey packet was not mailed until after this IRB approval 







To summarize, cross-sectional quantitative research was performed by accessing 
the U.S. mailing addresses of the ASCP registry membership target population, area of 
work responsibility known as Microbiology/Mycology/Parasitology/Virology.  A self-
administered mailed survey questionnaire using a combination of previously recognized 
TST history questions and a portion of the validated BMQ instrument (Svarstad et al., 
1999) was mailed at one point in time, following the mailing of an announcement 
postcard.  (A pretest and pilot test preceded these mailings.)  Data obtained were 
analyzed using Epi Info™ software provided free of charge by the CDC.  Bivariate and 
multivariate analysis methods were used to predict the most parsimonious models and 
answer the three research questions posed previously in this chapter. 
Chapter 4 describes the process that was followed and provides results from 
actual statistical analysis of data.   The research results have been presented in the form 






Chapter 4: Results 
Introduction and Purpose of the Study 
The purpose of this cross-sectional quantitative survey was to gather data to 
describe the American Society of Clinical Pathology (ASCP) medical laboratory 
microbiologist target study population in terms of three outcomes: (a) self-reported 
lifetime history of tuberculin skin test (TST) positivity (prevalence), (b) preventive TB 
treatment noninitiation, and (c) barriers to treatment adherence (presence of medication 
side effects as measured by the BMQ) using a written questionnaire.  In addition, 
independent variables of BCG immunization, place of birth, and years of laboratory work 
experience were assessed as potential risk factors in the occurrence of all three of the 
above outcomes.  An evaluation of how each outcome varied across demographic and 
work-related factors such as gender, age, type of work, history of TB disease, and 
exposure to TB was also performed.   
Data collected in this survey questionnaire are categorical and descriptive in 
nature.  The type of survey instrument chosen for this study was a self-administered mail 
questionnaire: Tuberculin Skin Test Questionnaire for ASCP Medical Laboratory 
Microbiologists—2013 (see Appendix A).  The questionnaire was composed of basic 
demographic and medical history questions commonly encountered in the public domain.  
Two closed-ended questions borrowed from the Brief Medication Questionnaire (BMQ) 
were approved for inclusion by the first author for the purposes of assessing medication 





information regarding validation of the BMQ and pretesting and pilot testing of this 
questionnaire will be discussed in latter sections of this chapter.)   
The three null hypotheses for this study predicted that self-reported lifetime 
history of BCG immunization, place of birth (U.S. or foreign), and years of laboratory 
experience would not contribute to (a) self-reported lifetime tuberculin skin test 
positivity, (b) preventive treatment noninitiation, or (c) barriers to treatment adherence 
(medication side effects) among those ever initiating preventive treatment for a positive 
TST.  Chapter 4 describes the results of this research study.  
Chapter 4 describes the process that was followed and provides actual results 
from the statistical analysis of data using Epi Info™ Version 3.5.3 (CDC, 2011c), an 
epidemiology software obtained through public domain.   As described in Chapter 3, a 
pretest and pilot test were performed.  As a result, minor adjustments were made to the 
questionnaire prior to commencement of the actual survey study.  The procedures for 
performing pretest, pilot test, and survey are described, and results of statistical analyses 
are presented in this chapter in the form of tables. 
Pretest and Pilot Study 
As described in Chapter 3, the validity of this study’s survey instrument as a 
whole was addressed through two phases of testing.  These two phases of testing were 
performed prior to actual mailing of the study announcement postcard and survey packet 
and are described as pretest and pilot test phases.  Both the pretest and pilot test were 
used to provide feedback on demographic and health history question flow only (CDC, 





clinical trial, this pretest and pilot test were not used for the purpose of instrument scale 
development, or to gauge prevalence or sample size.  (If they had been designated for 
these purposes, a larger sample size would have been required for each phase [Hertzog, 
2008; Johanson & Brooks, 2010; Julious, 2005; Lancaster, Dodd, & Williamson, 2004]).   
Pretesting was informal, designed to take place among several ASCP member 
participants who volunteered to participate.  After making two minor changes requiring 
correction of question numbers (typos), pilot testing the questionnaire was performed 
using educated, professional ASCP registrants working in a similar (medical laboratory) 
work environment.  Those included in the pilot testing were not invited to participate in 
the actual study in order to avoid confusion and pretest bias.   
Pretest Phase  
In the first phase, the informal pretest, four ASCP members who volunteered were 
questioned about the question order and flow after having an opportunity to read and 
answer the written survey questions.  This number of participants was chosen based on 
prior literature recommendations to obtain a few individuals for the purpose of obtaining 
feedback (Converse & Presser, 1986; Mangione, 1995; Suskie, 1996; Tools4dev.org, 
2013).  The informal pretest of this survey questionnaire took place in early March 2013 
using a “participating pretest” method (as suggested by Converse & Presser [1986]) 
whereby the four ASCP members were told they would be participating in a practice run.  
The participants were instructed to read the survey aloud and then answer the survey 
questions in writing.  I documented all suggestions and comments in an effort to record 





not make them feel uncomfortable in any way.  All reported not having any difficulty 
understanding questions or the order of the questions.  One respondent reported 
confusion on page 2 of the questionnaire due to two simple typographical errors 
involving numbering of questions.  The typos were corrected with permission of the 
Walden University IRB prior to the pilot test.  All questions were answered completely as 
anticipated, except in the case of Pretest Respondent 4, who left “AGE” as a blank field; 
it was assumed that this respondent did not respond to the prompt because the pretest was 
voluntary but not anonymous.  (Respondent 4 may not have desired for me to know 
his/her age.)  This nonresponse did not adversely affect the outcome of the pretest.  As a 
result, age was not removed from the questionnaire at this stage.  A decision was made to 
evaluate again after the pilot test. 
Pilot Test 
In the second phase, the formal pilot test, 30 ASCP members were invited to 
participate; 20 consented, but I received only 13 completed survey packets via USPS 
mail.  Again, for the purpose of obtaining feedback on the questionnaire itself, this 
number was accepted based on prior recommendations to include at least 10 to 12 
individuals similar to those in the study sample (Bourgue & Felder, 2003; Fink, 2009; 
Suskie, 1996).  Fewer individuals are required to pilot test a short mail questionnaire than 
would be required for a long questionnaire (Fink, 2009). 
After appropriate typographical corrections were made to the questionnaire 
instrument, the questionnaire was pilot tested among the 20 adult individuals having 





medical laboratory work environment.  These individuals were accessed through the 
ASCP member mailing list for Generalist laboratorians (Medical Laboratory Scientists) 
with U.S. addresses in the State of Georgia.  Atlanta metropolitan addresses were selected 
for use in the pilot test.   I chose the Atlanta subgroup in order to facilitate the dispersal of 
invitations by me in order that these ASCP members might participate in the pilot test.  
These individuals received all necessary instructions, a consent letter, and the full survey 
packet in person.  (Because these individuals might have been confused by a mailed 
survey referencing a professional affiliation as a U.S.-based microbiologist, they were 
invited to attend an informal gathering where the questionnaires were handed out in 
sealed envelopes for anonymous return to me via USPS mail.)   
The pilot test took place during mid-March 2013.  The pilot test data were 
evaluated based on the number of unanswered or misinterpreted questions.  (No analysis 
of actual responses was performed.)  Thirty individuals were invited to participate.  Of 20 
individuals who agreed to participate, 13 completed surveys were received via USPS 
mail, indicating a 65% response rate and surpassing the minimum number of 10 
individuals required for this pilot test (as set forth in the proposal stage).  The original 
goal of reaching 25 participants (CDC, 2003b; Converse & Presser 1986) was not met, 
suggesting that more individuals should have been invited to participate in the pilot test.   
Upon return receipt via USPS mail, questionnaires were marked with a “P” for 
pilot and numbered to designate order received.  Pilot test errors were coded onto a table 
for evaluation (see Appendix G) in order to assess question-error rate.  Error rates of 15% 





errors (0% error rate) were noted on question (Q)1-Q10, or Q13-15(b), although a 7.7% 
error rate was discovered on Q11 and on Q12.  In one case, the respondent ignored 
instructions to “stop here.”  No corrective action was warranted because respondent error 
rates were less than 15% per question.  A determination was made that in the future 
study, I would not record any responses found after the “stop here” instruction noted in 
the survey questionnaire, noting that these additional responses might lead to a spurious 
finding.  In addition, no problems were noted with the reporting of age in the pilot test 
responses, as was mentioned in the section on pretest findings.  Age remained on the final 
survey questionnaire. 
At this point, a discussion of Cronbach’s alpha in relationship to this 
questionnaire survey instrument is warranted.  Cronbach’s alpha is not a statistical test, 
but rather a measure of internal consistency where a scale measurement is analyzed.  The 
two questions in this survey questionnaire that are considered scale measurements are 
those borrowed from Part A (Belief Screen) of the BMQ.  The Belief Screen was 
previously validated by Svarstad et al. (1999) for patients with medication nonadherence.  
While Svarstad et al. (1999) did not report a Cronbach’s alpha, a recent comparison of 
several medication adherence scales performed by Lavsa et al. (2011) did note that the 
reliability in BMQ reflected 95% overall accuracy, and for the Belief Screen, a sensitivity 
of 1.0 and specificity of 0.8 for identifying nonadherence.  These values were compared 
against Cronbach’s alphas of other nonadherence screens, where reliability ranged from 





reliability.)  Thus, according to Svarstad et al. (1999) and Lavsa et al. (2011), the two 
BMQ Belief Screen questions are considered to reflect high internal consistency. 
Data Collection 
Recruitment 
The chosen target population consisted of adult medical laboratory 
microbiologists registered with and designated by ASCP as members primarily working 
in the area of the laboratory known as Microbiology/Mycology/Parasitology/Virology 
and having U.S. mailing addresses.  This group was accessed through the only marketing 
firm approved by ASCP to provide registry mailing lists: INFOCUS Marketing, Inc.  
After pretesting and pilot testing, the actual study was conducted over a period of 8 
weeks, taking place from March 25 through May 20, 2013.  Of note, no treatment or 
intervention took place among this study group.   
Time Frame 
The survey announcement postcard and packet were printed and mailed by 
INFOCUS Marketing, Inc.  Survey announcement postcards were mailed to the target 
population (N = 4,335) in mid-March.  It should be noted that the entire cohort was 
originally estimated to be N = 5,138 at time of the study proposal; however, the final 
ASCP membership number of the target cohort was not known to me until INFOCUS 
Marketing, Inc. actually printed and mailed the announcement postcards.  (The number 
was not released to me until initial payment for printing and mailing services was 
received by this marketing firm, and first postal delivery was sent out to the postal 





informed to expect large deliveries of mail over the course of the next 2 months.   Survey 
packet mailings to the same target population addresses (N = 4,335) occurred 1 week 
later.  As a result, the official cut-off for receipt of completed surveys for inclusion in 
statistical analysis was then determined as May 20, 2013.  Twice during May, I double-
checked each numbered survey questionnaire with the corresponding Excel file entry in 
order to confirm accuracy in coding.  The $250 incentive donation (for receipt of the first 
1,000 completed surveys) was paid during the first week of May 2013 to the ASCP 
Scholarship Fund.  (No additional incentive was paid because the final number of 
completed surveys received, n = 1,693, did not surpass the next payout tier of n = 2,000.) 
Response Rates 
INFOCUS Marketing mailed a total of N = 4,335 survey packets to individuals 
who encompassed the entire ASCP target cohort, the same group that received 
announcement postcards 1 week prior.  (As mentioned previously, the original estimated 
cohort of N = 5,138 dropped to N = 4,335 at the time of mailing.  Please refer to the 
sample size section below for more detail.)  Twelve surveys were returned to me by 
USPS as address unknown.  This equated to a bad address return rate of 0.3%, in line 
with the expected less than 1% previously predicted by INFOCUS Marketing.  The 
number of completed questionnaires returned by the 8-week deadline was n = 1,693, 
realizing a 39.1% overall response rate.  Incomplete surveys (previously designated 
“critical questions” related to independent and dependent study variables were left blank) 
that it was not possible to analyze numbered three in all.  (In reality, these three 





questionnaires returned to me by the deadline numbered n = 1,628, an eligible respondent 
return rate of 37.6%.  This response rate is much higher than the 22.5% realized by Clark 
(2008) in research involving a different ASCP questionnaire mailing.  Of note, 45 
completed questionnaires were received well after the predetermined cut-off date and 
thus were not analyzed. 
A review of the literature was previously performed in order to assess estimated 
sample size.  Calculation of sample size justified use of the entire ASCP target cohort in 
order to statistically satisfy all research questions as posed.  The target sample size 
required to reach enough individuals capable of answering Research Question (RQ) 1 
(referencing individuals with positive TSTs) was originally estimated as n = 638 (based 
on an estimated cohort of N = 5,138).  The total estimated target sample size required to 
obtain enough individuals capable of responding to questions about treatment 
initiation/noninitiation and therefore treatment side effects and possible adherence 
barriers (RQ2 and RQ3) was n = 2,569.  In this study, the n = 2,569 was not met.  A 
thorough discussion of sample size and generalizability of results follows in a subsequent 
Sample Size section of this chapter. 
Coding and Missing Data 
Responses were coded as nominal variables (see Codebook, Appendix E) in Excel 
format.  Missing value counts accounted for only a small portion of the total 
observations.  Analysis was not performed on any respondent questionnaire that was 
missing data for Q4, Q5, Q6, Q8, Q12, Q14, or Q15, as these questions were essential 





the Excel file, indicating nonresponse (NR).  (Out of all the essential questions, only Q8 
regarding BCG immunization was determined as missing three critical responses, a NR 
rate of 0.2%).   No partial answers for this specific group of questions were allowed.   I 
did not substitute imputed (calculated or estimated) values for any missing values based 
on other responses.  During the coding process, the following situations resulted in 
deletion from the n = 1,693 survey group prior to final statistical analysis (these surveys 
were excluded from analysis): 
 Nonresponse (NR) for critical survey questions (Q8: BCG, where n = 3). 
 Respondents who responded “no” or “don’t know” to Q6: Ever had a TST? (n 
= 58). 
 Respondents who responded “don’t know” to Q6a: Ever been told that the 
TST was positive? (n = 5). 
After removal of the above individual survey results from the coded Excel file, the final 
number of surveys eligible for processing was calculated as n = 1,628. (Note: One 
respondent’s survey results overlapped two of the above deletion situation groups.)  
Discrepancies in Data Collection 
Coding of the independent variable “years of laboratory experience” occurred by 
strata.  Prior to analysis, I noted that that the highest two strata categories (majority of 
responses) were “16 to 20 years” and “> 21 years,” where a response of exactly 21 years 
was not allowed.  For purposes of data analysis, the category of “> 21” years has been 





Coding of Q8 (self-reported lifetime history of BCG immunization) revealed a 
high number (n = 151) of “don’t know” responses. This presented a challenge in the way 
data were coded from the plan presented in Chapter 3.  Rather than remove all 151 
surveys from further analysis, the literature was consulted.  The 151 questionnaire 
responses were cleaned and recoded as “no” responses, per the precedent set forth by 
Passalent et al. (2007), where a self-reported BCG vaccination status of “unknown” or 
“uncertain” was recoded as “no” for designating a “nonrecipient” of BCG. 
Sample Size and Generalizability   
In 2012, the initial ASCP target population cohort of interest (reportedly working 
in area of responsibility referred to as “Microbiology/Mycology/Parasitology/Virology” 
and having U.S. mailing addresses) was estimated to be N = 5,138 (ASCP, 2011).  The 
actual ASCP target population cohort membership in spring 2013 was found to be 
composed of N = 4,335 individuals, rather than N = 5,138 individuals according to 
INFOCUS Marketing, Inc.  Survey packets were thus mailed to the entire cohort 
(individuals having current membership and addresses on file with ASCP) with the 
expectation of receiving the minimum sample size required in order to generalize 
findings to this population.  The entire cohort was selected in order to obtain the largest 
representative sample for survey response rate.  (Randomization was not necessary.)  
After coding and cleaning, eligible survey responses numbered n = 1,628 individuals, a 
number much lower than the original estimated target response of n = 2,569. 
This discrepancy is in part due to the change in ASCP cohort membership from N 





extrapolation of the initial estimated sample size calculations for N = 5,138 to reflect 
corresponding sample size calculations for the actual ASCP membership of N = 4,335 
individuals.  This was necessary because the original sample sizes were calculated using 
Open Epi software (available in the public domain); the original estimated population 
size of N = 5,138 was utilized in these software calculations.  The results of this 
extrapolation follow in the post-hoc analyses section. 
Analysis and Results 
All survey responses (serving as independent and dependent variables) were 
transformed by coding into nominal scale measurements for statistical analysis, with the 
exception of age.  (Data on age were collected, coded, and analyzed as a continuous 
variable.)  After coding data, basic univariate and bivariate statistics consisting of 
frequency and percentage were performed using Epi Info™ software, Version 3.5.3 
(CDC, 2011c).  I analyzed for frequencies (FREQ) to get an indication of the respondent 
data characteristics as a whole, and then to examine by TST status.   Frequency data from 
Epi Info™ were depicted in percentages with 95% confidence intervals (CI).  Data were 
then cleaned in an effort to determine which surveys were eligible for full analysis 
according to a priori decisions (no TST status, TST status unknown, or missing data).  In 
addition, at this point the treatment initiation data were transformed to reflect 
noninitiation as the final (dependent variable) outcome described in Research Question 2.   
Using Epi Info™, “TABLES” (or “Single Table Analysis”) provided information 
on 2x2 tables, such as odds ratios (OR) maximum likelihood ratio (MLE) with a 95% 





(with 2-tailed p value), and Fisher exact 1-tailed p value (if less than 5 observations were 
present in a cell).  These values were then double-checked against original frequency 
calculations to ensure accuracy and direction of data.  Bivariate analysis was used to 
examine the association between each of the dichotomous independent (potential 
predictor) variables against each dependent (outcome) variable.  Odds ratios (MLE) using 
mid-P were reported according to preferred prior public health Epi Info™ statistical 
models (Dean et al., 2010).  The Yates corrected chi square (χ2) with two-tailed p, or 
Fisher exact test p-values (if cell sizes were < 5), were selected as per recommendation of 
Gregg (2008); chi-square results were summarized and included in contingency tables.  
(Exception: Age study outcomes were examined using ANOVA and t test because age 
was the only continuous variable in the study.)  Of the several choices of chi-square 
available in the Epi Info™ printout, the Yates corrected chi-square was selected because 
it gives the largest P value.  According to Gregg (2008), Yates is preferred by 
epidemiologists because this large P minimizes the likelihood of making a type I error 
(although a limitation is that it increases the likelihood of making a type II error).    
The initial simple regression model for each outcome was composed of the three 
main independent variables (forced into the final model by a priori decision, literature 
based), and any independent variable or covariates (including suspected confounders) in 
the models that were bivariately associated with the outcomes at p ≤ .15.  Unconditional 
logistic regression was selected in order to assess interrelationships of the covariates in 
order to determine relative strengths and probabilities of variables.  Sequential 





leave first) using a backward selection step approach led to a final model.  This final 
model included only those variables statistically associated with the dependent variable 
(outcome) at a p < .05. 
Multicollinearity among the variables (highly correlated independent variables) 
was detected using chi-square and logistic regression analysis.  Assessment for 
confounders and statistical interaction for suspect confounders (a) place of birth, and (b) 
BCG immunization were tested individually against independent variables of BCG 
immunization, history of TB, and nonoccupational exposure to TB for dependent 
outcome variable of self-reported lifetime TST positivity.  The detail and findings of this 
analysis is presented later in the post-hoc analyses section of this dissertation. 
Descriptive Statistics 
Characteristics of All Survey Respondents 
Of the total number of survey packets mailed to individuals comprising the entire 
target cohort (N = 4,335), descriptive and demographic characteristics of all survey 
respondents (n = 1,693) were determined.  This determination took into account that 
some questions were left unanswered.  Females (n = 1,450, 85.6%) outnumbered males 
(n = 243, 14.4%).  Ages of respondents ranged from 24 to 82 years, with a mean age of 
55 years and mode of 58 years. The majority of respondents reported working in more 
than one type of microbiology laboratory setting.  Of the total, 1,237 (73.1%) individuals 
reported to have worked more than 21 years in the microbiology setting, outnumbering 
the other “years of laboratory experience” categories 3 to 1, and creating a cut-point for 





(n = 1,564, 92.4%) reported to have been born in the U.S., a U.S. territory, or of one U.S. 
citizen parent.  Of the n = 1,564 individuals reporting U.S.-birth, n = 39 individuals 
(2.49%) were not born in a U.S. territory, but were born of a U.S. citizen parent.  This 
was determined by hand count of those surveys indicating a “no” response to written 
survey questionnaire Q5, and “yes” response to Q5(a).  Table 5 represents univariate 







Univariate Analysis: Characteristics of ASCP Medical Laboratory Microbiologists (All 
Survey Respondents, n = 1,693)  
Characteristic      No. (% of total)                               CI95            Total Reponses 
Gender 
  Male 




















Type of Work* 
Mycobacteriology 
  Yes 
  No 
Virology 
  Yes 
  No 
Bacteriology 
  Yes 
  No 
Parasitology 
  Yes 
  No 
Mycology 
  Yes 
  No 
Serology 
  Yes 
  No 
Molecular 
  Yes 
  No 
Other 
  Yes 

























































Years worked in lab setting 
    0-2 
    3-5 
    6-10 
    11-15 
    16-20 











  0.2%, 1.0% 
  2.6%, 4.4% 
  6.7%, 9.3% 
  5.8%, 8.3% 
  6.9%, 9.6% 









Place of Birth 
   Foreign†  









TST Test (ever had one) 
  Yes 
  No 












  Yes 
  No 



















Characteristic  No. (% of total)    CI95 Total Reponses 
IFN-γ blood test 
  Yes 
  No 















  Yes 
  No 











History of active TB 
  Yes 











  Yes 











Note. No. refers to number of individuals; Frequency is reported in percent (%); Mean 
Age refers to age in years as a continuous variable, while SD refers to standard deviation; 
TST =  tuberculin skin test; IFN-γ blood test refers to interferon gamma blood test for 
latent tuberculosis infection; BCG = bacille Calmette-Guérin immunization. 
*For type of work: Respondents reportedly worked in more than one category. 
†Foreign birth refers to those born outside U.S. or one of the U.S. territories, unless one 
parent at time of birth was a U.S. citizen (CDC, 2012) 
 
From Table 5, it becomes apparent that n = 58 survey respondents self-reported 
“no” or “don’t know/don’t remember” to the question referring to ever having had a TST.  
In addition, n = 151 respondents reported “don’t know/don’t remember” to the question 
referring to ever having had a BCG immunization.  These two items were surprising 
results given the level of education and work experience of this target population.  In 
addition, given the very high mean age in this population as noted in Table 5, age 
distribution is discussed further and broken down by TST status (listed later in Table 9.)   
Increased age may have a possible effect on recall bias.  However, Coughlin reported no 
consistent relationship between accuracy of recall and demographic factors (such as age), 
stating that recall may be influenced by “differences in the study populations, the 





ASCP reseach, respondents have already been deemed highly educated health care 
personnel, many of whom are required to document an annual (or recent) TST history in 
the workplace.  Additional characteristics as related to age among the cleaned data set are 
presented later in Tables 7 and 9. 
Characteristics of Eligible Survey Respondents 
The cleaned data set was composed of n = 1,628 individual respondent records, 
representative of the entire ASCP target cohort, N = 4,335 individuals.  Descriptive 
characteristics of the individuals comprising the cleaned data set (n = 1,628) were similar 
to that of the original (raw) data set (n = 1,693).  The cleaned data set was then utilized 
for chi-square and logistic regression analyses.  Table 6 represents univariate summary 








Univariate Analysis: Characteristics of ASCP Medical Laboratory Microbiologists 
(Eligible Survey Respondents, Cleaned Data Set)  
Characteristic     No. (% of total)              CI95 Total Reponses 
Gender 
  Male 






















Type of Work * 
 Mycobacteriology  
   Yes 
   No 
 Virology 
   Yes 
   No 
Bacteriology 
  Yes 
  No 
Parasitology 
  Yes 
  No  
Mycology 
  Yes 
  No 
Serology 
   Yes 
   No 
Molecular 
  Yes  
  No 
Other 
  Yes 

























































Years worked in lab setting 
    0-2 
    3-5 
    6-10 
    11-15 
    16-20 











  0.2%, 0.9% 
  2.4%, 4.2% 
  6.7%, 9.4% 
  5.9%, 8.4% 







  ≥ 21 years 










Place of Birth 
  Foreign † 










  Yes 


















Characteristic  No. (% of total)    CI95 Total 
Reponses 
IFN-γ blood test 
(ever had one) 
  Yes 
  No  














  Yes 









History of active TB 
  Yes 











  Yes 












Note.  No. refers to number of individuals; Frequency is reported in percent (%); Mean 
Age refers to age in years as a continuous variable, while SD refers to standard deviation; 
TST = tuberculin skin test; IFN-γ blood test refers to interferon gamma blood test for 
latent tuberculosis infection; BCG = bacille Calmette-Guérin immunization. 
*For type of work: Respondents reportedly worked in more than one category. 
†Foreign birth refers to those born outside U.S. or one of the U.S. territories, unless one 
parent at time of birth was a U.S. citizen (CDC, 2012) 
 
As can be seen in Table 6, 17% of the eligible respondents self-reported a lifetime 
history for a positive TST.  Several other findings were of interest, and determined by 
hand count of the data: (a) only five respondents reported to have worked solely in the 
area of mycobacteriology; (b) 38 of 1,507 individuals reporting “no” to being born in the 
U.S. or a U.S. territory (Q5), reported “yes” to having at least one U.S. citizen birth 
parent (Q5a); and (c) 14 positive IGRAs were reported (of the n = 168 total respondents 
in the group reported ever having had an IGRA blood test for LTBI).   
To further describe age in this target population, the following Table 7 is used to 
explore an age cut-off of 35 years (as suggested by Shukla et al., 2002) to differentiate 









Characteristics of Young Versus Old in ASCP Medical Laboratory Microbiologists (n = 
1,620, Cleaned Data Set) 
Characteristics Young (≤ 35 yrs) 
n = 115 
No. (%) 
Old (≥ 36 yrs) 
n = 1,505 
No. (%) 
BCG immunization 7 (6.1%) 98 (6.5%) 
Foreign birth 12 (10.4%) 109 (7.2%) 
History of active TB 0 (0.0%) 11 (0.73%) 
TST positivity    8 (7.0%) 267 (17.7%) 
Note. TST = tuberculin skin test; BCG = bacille Calmette-Guérin immunization status, 
and No. refers to number of individuals. 
 
From Table 7, prevalence of self-reported BCG immunization was about the same 
in each age group while prevalence of foreign birth was higher in the ≤ 35 year age 
division.  History of active TB was present among the older (≥ 36 year) group, and not 
present at all among the younger group.  Self-reported TST positivity was more than 
double among the older population. 
The survey results respresenting the n = 276 individuals self-reporting “yes” to 
TST positivity status in Table 6  were segregated from the cleaned data set for additional 
analyses.  These results are listed in Table 8.  Eighteen individuals reported 
noncompletion of prescribed treatment.  From hand calculation of this cleaned data, 15 of 
the n = 18 individuals reported positive BMQ scores of “1” or “2” (83.33%), and 12  
cited specific medication side effects (detailed in responses to Q15a), a 66.67% rate of 





prescribed treatment.  Characteristics of those individuals self-reporting a lifetime history 
of TST positivity are depicted in Table 8. 
Table 8 
 
Univariate Analysis: ASCP Medical Laboratory Microbiologists With Self-Reported 
History of Lifetime TST-Positive Status (Cleaned Data Set) 
 
Note. No. refers to number of individuals; CI95 = 95% confidence interval 
* One nonresponse (NR) 
†Permission for use of these questions granted by primary owner of the Brief Medication 
Questionnaire (BMQ) survey instrument (Svarstad et al., 1999) on October 25, 2011, and 
permission to reprint selected questions for Appendix D received on May 6, 2012 via 
electronic correspondence.  (See Appendix F.) BMQ scores of 1 and 2 are graded as 
“positive” for barriers to treatment adherence. 
 
Of the n = 14 individuals who did not initiate treatment (see Table 8), 13 refused anti-TB 
medication treatment (9.1% of the n = 143 prescribed treatment), and one did not respond 
(0.7% of the n = 143 prescribed treatment).  Conversely, 129 of the n = 143 individuals 
prescribed treatment self-reported as initiating anti-TB medication treatment, a 90.2% 
treatment initiation rate, and a 9.8% noninitiation rate. 
Characteristic No. (% of Total)     CI95 (%) Total 
Prescribed anti-TB 
medication 
  Yes 















  Yes 
  No 
 
   
  129 (90.2%) 
    14 (9.8%) 
 
   
 84.1%, 94.5% 






  Yes 
  No 
 
   
111 (86.0) 









  0  
  1 
  2 
 
 85 (65.9%) 
 28 (21.7%) 













At this point in the data analysis, age was analyzed as a continuous variable 
(mean in years), not as a nominal dichotomous variable, which is consistent with TST 
status analyses in prior literature.  Years of laboratory experience was collapsed into two 
groups based on the mean of the respondent data.  Effect sizes were measured as OR.  
Summary results of the bivariate analysis involving an outcome of self-reported TST 
status among ASCP medical laboratory microbiologists (cleaned data set n = 1,628 of the 
original N = 4,335 cohort) may be viewed in the corresponding table (Table 9).  For all 
remaining bivariate and multivariate tables, decimals have been rounded to two places, 








Bivariate Analysis: Self-Reported TST Status Among ASCP Medical Laboratory 
Microbiologists (Cleaned Data Set) 
Characteristic TST Positive  
n = 276  
(17.0%)    
No. (%)      
TST Negative 
n = 1,352  
(83.0%)  
No. (%)       
Total OR CI95 χ2 ,p 
Gender 
  Male 





















 (±SD, years)  
Age groups 
(years): 
  Age (24-33) 
  Age (34-43) 
  Age (44-53) 
  Age (54-63) 
  Age (64-73) 


































ANOVA t-test p 
<.001 
 
Type of Work* 
Mycobacteriology 
  Yes 
  No 
Virology 
  Yes 
  No 
Bacteriology 
  Yes 
  No 
Parasitology 
  Yes 
  No 
Mycology 
  Yes 
  No 
Serology 
  Yes 
  No 
Molecular 
  Yes 
  No 
Other 
  Yes 























































  477 
 




    56 
 
1,214 
  414 
 
1,109 
  519 
 
  987 
  641 
 
  654 
  974 
 











































































Years worked in 
lab setting 
  0-2 
  3-5 
  6-10 
  11-15 
  16-20 



















      7 
    52 
  129 
  115 


















Characteristic TST  
Positive  
n = 276  
(17.0%)    
No. (%)      
TST Negative 
n = 1,352  
(83.0%)  
No. (%)       
    
Total 
       OR CI95 χ2 ,p 
Years worked in lab 
setting (collapsed) 
  ≥ 21 years 











    1,189 














Place of Birth     
  Foreign ‡ 











    121 











146.02, < .001 
 
BCG immunization 
  Yes 











  105 










200.81, < .001 
 
 
History of TB 
  Yes 
  No 
 






   12 













  Yes 




























19.58, < .001 
 
Note. TST = tuberculin skin test; No. refers to number of individuals; OR = MLE odds 
ratio; CI95 = 95% confidence interval; χ2 = Yates corrected with 2-tailed p chi-square 
test; Mean Age refers to age in years as a continuous variable (note that age was broken 
out by groups strictly for the purpose of obtaining distribution), while SD refers to 
standard deviation; BCG = bacille Calmette-Guérin; REF refers to referent group. 
*For type of work: Respondents reportedly worked in more than one category 
†Fisher Exact Test 
‡Foreign birth refers to those born outside U.S. or one of the U.S. territories, unless one 
parent at time of birth was a U.S. citizen (CDC, 2012) 
 
Bivariate analysis was performed to assess several factors on the likelihood that 
survey respondents would report ever having had a positive TST (Table 9).  Eight of the 
independent variables emerged as statistically significant predictors of a positive TST 
(male gender, age, work in mycobacteriology, work in parasitology, place of birth: 
foreign, history of BCG immunization, history of TB, and nonoccupational 





skin test was a history of TB, with an OR of 55.89, indicating that respondents who 
reported prior history of TB were almost 55 times more likely to report a positive TST 
than those who reported a negative TST. 
For the outcome of treatment noninitiation among respondents numbering n = 
143, n = 14 did not initiate preventive treatment.  Table 10 depicts the characteristics of 







Bivariate Analysis: Self-Reported Treatment Initiation Status Among TST-Positive ASCP 
Medical Laboratory Microbiologists (Cleaned Data Set) 
Characteristic Noninitiate   
No. (% of n = 
14)    
Initiate 
No. (% of n = 
129)    
Total OR CI95 χ2, p 
Gender 
  Male 
  Female 
 
 
  3 (21.4%) 
11 (78.6%) 
 
 28 (21.7%) 
101 (78.3%) 
 
    31 









   0.10, .623† 
  








 ANOVA t-test p=.610 
Type of Work‡ 
Mycobacteriology 
  Yes 
  No 
Virology 
  Yes 
  No 
Bacteriology 
  Yes 
  No 
Parasitology 
  Yes 
  No    
Mycology 
  Yes 
  No  
Serology 
  Yes 
  No 
Molecular 
  Yes 
  No 
Other 
  Yes 










   0 (0.0%) 
 
12 (85.7%) 
  2 (14.3%) 
 
12 (85.7%) 
  2 (14.3%) 
 
10 (71.4%) 
  4 (28.6%) 
 
  8 (57.1%) 
  6 (42.9%) 
 
  5 (35.7%) 




  22 (17.1%) 
 
  47 (36.4%) 
  82 (63.6%) 
 
123 (95.3%) 
     6 (4.7%) 
 
105 (81.4%) 
  24 (18.6%) 
 
  95 (73.6%) 
  34 (26.4%) 
 
  77 (59.7%) 
  52 (40.3%) 
 
  51 (39.5%) 
  78 (60.5%) 
 
  42 (32.6%) 




  25 
 
  55 
  88 
 
137 
    6 
 
117 
  26 
 
107 
  36 
 
  87 
  56 
 
  59 
  84 
 
  47 











































































Years worked in lab setting 
    0-2 
    3-5 
    6-10 
    11-15 
    16-20 




  0 
  0 
  0 
  0 




    0 
    3 (2.3%) 
    6 (4.7%) 
    7 (5.4%) 




    0 
    3 
    6 
    7 




(Collapsed. See below.) 
Years worked in lab setting 
(collapsed) 
≥ 21 years  
≤ 20 years 
     
 
 
  10 (71.4%) 





















Place of Birth         
  Foreign ∑ 









  18 (14.0%) 
111 (86.0%) 
 



















Characteristic Noninitiate   
No. (% of n = 
14)    
Initiate 
No. (% of n = 
129)    
Total OR CI95 χ2, p 
BCG immunization 
  Yes 






  15 (11.6%) 
114 (88.4%) 
 











History of TB 
  Yes 
  No 
 
 
   0 (0.0%) 
14 (100.0%) 
 
   11 (8.5%) 
118 (91.5%) 
 












  Yes 
























Note. No. refers to number of individuals; TST = tuberculin skin test; No. refers to 
number of individuals; OR = MLE odds ratio; CI95 = 95% confidence interval; χ2 = Yates 
corrected with 2-tailed p chi-square test; undef = undefined, zeroes in cells; Mean Age 
refers to age in years as a continuous variable, while SD refers to standard deviation; 
BCG = bacille Calmette-Guérin; REF refers to referent group. 
*n = 142 
†Fisher Exact Test 
‡For type of work, respondents reportedly worked in more than one category 
∑Foreign birth refers to those born outside United States or one of the U.S. territories, 
unless one parent at time of birth was a U.S. citizen (CDC, 2012). 
 
Bivariate analysis was performed to assess several factors on the likelihood that 
survey respondents would report never having initiated preventive treatment (Table 10).  
Two of the independent variables emerged as statistically significant predictors (place of 
birth: foreign, and history of BCG immunization) for treatment noninitiation.  Both of 
these predictors had similar ORs, indicating that respondents who did not initiate 
treatment were 4 times more likely to report treatment noninitiation than those who 
reported treatment initiation. 
Table 11 depicts characteristics of the subgroup initiating preventive TB treatment 













Bivariate Analysis: Barriers to Treatment Adherence (by BMQ Score) Among TST-
Positive ASCP Medical Laboratory Microbiologists Initiating Treatment (Cleaned Data 
Set) 
Characteristic BMQ 
positive score     
No. (% of n = 44)        
BMQ 
negative score  
No. (% of n = 85)     
Total OR CI95 χ2, p 
Gender 
  Male 
  Female 
 





















128  ANOVA t-test p= .781 
Type of Work† 
Mycobacteriology 
  Yes 
  No  
Virology 
  Yes 
  No 
Bacteriology 
  Yes 
  No    
Parasitology 
  Yes 
  No    
Mycology 
  Yes 
  No   
Serology 
  Yes 
  No    
Molecular 
  Yes 
  No    
Other 
  Yes 










   2 (4.5%) 
 
38 (86.4%) 









































  22 
 
  47 
  82 
 
123 
    6 
 
105 
  24 
 
  95 
  34 
 
  77 
  52 
 
  51 
  78 
 
  42 










































































Years worked in lab setting 
(collapsed) 
≥ 21 years  
≤ 20 years 


























Place of Birth 
  Foreign ∑ 
  U.S. 
 
 
  6 (13.6%) 
38 (86.4%) 






  18 
111 










  Yes 
  No 
 
 






  15 
114 
 
  0.67 
  REF 
 
 















positive score     
No. (% of n = 44)        
BMQ 
negative score 
No. (% of n =85)    
Total OR CI95 χ2, p 
History of TB 
  Yes 
  No 
 
 






  11 
118 
 
  0.18 








  Yes  
  No 
 
 












  0.80 








Note.  No. refers to number of individuals; OR = MLE odds ratio; CI95 = 95% confidence 
interval; χ2 = Yates corrected with 2-tailed p chi-square test; Mean Age refers to age in 
years as a continuous variable; BCG = bacille Calmette-Guérin; REF refers to referent 
group. BMQ = Brief Medication Questionnaire; permission for use of these questions 
granted by primary owner of the Brief Medication Questionnaire survey instrument 
(Svarstad et al., 1999) on October 25, 2011, and permission to reprint selected questions 
for Appendix D received on May 6, 2012 via electronic correspondence.  (See Appendix 
F.) BMQ scores of 1 and 2 are graded as “positive” for barriers to treatment adherence. 
*n = 128 
†For type of work, respondents reportedly worked in more than one category 
‡Fisher exact test 
∑Foreign birth refers to those born outside the United States or one of the U.S. territories, 
unless one parent at time of birth was a U.S. citizen (CDC, 2012) 
 
 
From Table 11, it is apparent that no one variable (as evident in the bivariate analysis) 
demonstrated a statistically significant association of p < .05 for outcome of a positive 
BMQ score. 
Statistical Assumptions 
For nominal data and use of chi-square, the following four assumptions were met: 
(a) data were categorized (with the exception of age) and frequencies obtained, (b) 
adequate sample size was met, (c) the measures were mutually exclusive, and (d) 
research questions and theory were previously established by a thorough review of the 





original assumptions.  In this study, the chi-square result and degrees of freedom (df = 1 
for 2x2 tables) were compared.  (If chi-square value = 1, then the model perfectly fit the 
data.)   The following assumptions for use of unconditional logistic regression were met: 
(a) the logarithm of the odds of the outcome (logit) is being modeled, (b) this logit of the 
outcome changes linearly with multiple independent variables, (c) outcome variables 
(with the exception of age) are distributed in binomial manner, and (d) the variance of the 
outcome variable depends only on the mean (Katz, 2006).  In addition, any outliers were 
removed during the data cleaning stage. 
Research Questions: Bivariate Analysis and Logistic Regression 
 Research Question 1: TST positivity. The first null hypothesis predicted that 
there would be no statistical association between self-reported individual independent 
variables of history of BCG immunization, place of birth (U.S. or foreign), and years of 
laboratory experience, and the dependent variable of self-reported lifetime TST 
positivity.  This hypothesis was tested using odds ratios (ORs) obtained using Epi Info™ 
TABLES analysis; resulting chi-square has been reported.  Tables 12, 13, and 14 provide 







2x2 Table BCG Immunization vs. Self-Reported History of Lifetime TST Positivity  
BCG Immunization TST positive TST negative           Total 
BCG yes 71 (25.7%) 34 (2.5%) 105 
BCG no 205 (74.3%) 1,318 (97.5%) 1,523 
Total 276 1,352 1,628 
Note. TST = tuberculin skin test; OR = MLE odds ratio; CI95 = 95% confidence interval; 
χ2 = Yates corrected with 2-tailed p chi-square test; BCG = bacille Calmette-Guérin. 
 
For BCG immunization “Yes”: 
 
Odds ratio (OR) = 13.39 (95% confidence interval [CI95], 8.71 -20.87) 
 
Chi-square (χ2) = 200.81 
 
p < .001 
 
Table 12 shows that a self-reported history of BCG immunization is a statistically 
significant predictor of a self-reported history of lifetime TST positivity.  In addition, the 
OR of 13.39 indicates that survey respondents who reported a history of BCG 
immunization were more than 13 times more likely to report a positive TST than those 






Table 13  
 
2x2 Table Place of Birth (U.S. or Foreign) vs. Self-reported History of Lifetime TST 
Positivity 
Place of birth TST positive TST negative Total 
Foreign  69 (25.0%) 52 (3.8%) 121 
U.S.  207 (75.0%) 1,300 (96.2%) 1,507 
Total 276 1,352 1,628 
Note. TST = tuberculin skin test; OR = MLE odds ratio; CI95 = 95% confidence interval; 
χ2 = Yates corrected with 2-tailed p chi-square test; Foreign birth refers to those born 
outside the United States or one of the U.S. territories, unless one parent at time of birth 
was a U.S. citizen (CDC, 2012) 
 
For foreign birth “Yes”: 
 
Odds ratio (OR) = 8.32 (95% confidence interval [CI95], 5.64 -12.31) 
 
Chi-square (χ2) = 146.02 
 
p  < .001 
 
Table 13 shows that a history of foreign birth is a statistically significant predictor 
of a self-reported history of lifetime TST positivity.  In addition, the OR of 8.32 indicates 
that survey respondents who reported a history of foreign birth were more than 8 times 








2x2 Table Years of Laboratory Experience vs. Self-reported History of Lifetime TST 
Positivity 
Years of Experience TST positive TST negative Total 
≥ 21 years  211 (76.4%) 978 (72.3%) 1,189 
≤ 20 years  65 (23.6%) 374 (27.7%) 439 
Total 276 1,352 1,628 
Note. TST = tuberculin skin test; OR = MLE odds ratio; CI95 = 95% confidence interval; 
χ2 = Yates corrected with 2-tailed p chi-square test; ≥ 21 years refers to years of 
laboratory experience. 
 
For ≥ 21 years of laboratory experience group: “Yes”: 
 
Odds ratio (OR) = 1.24 (95% confidence interval [CI95], 0.92 -1.69)  
 
Chi-square (χ2) = 1.76 
 
p = .184 
 
Table 14 shows that a history of ≥ 21 years of laboratory work experience is not a 
statistically significant predictor of a self-reported history of lifetime TST positivity.  In 
addition, the OR of 1.24 indicates that survey respondents who reported a history of ≥ 21 
years of laboratory work experience were no more than likely to report a positive TST 
than those who reported a negative TST. 
For all following multivariate analyses, attributes were designated as coding of 
“1” (for “yes”, the attribute is present) in the Epi Info™ software ANALYZE DATA 
view.  (Referent attributes remained the same as previously listed in bivariate Tables 9, 
10, and 11.)  As previously stated, the age variable was the only variable in this analysis 





 Gender:  Male 
 Age in years (continuous variable): Age 









 Other areas 
 Self-reported lifetime history of TST positivity: TST positivity  
 Treatment noninitiation 
 BMQ score of ≥ 1 indicating a positive screen for medication barriers, drug 
effects, bothersome features as related to treatment nonadherence: Positive 
BMQ score  
 Self-reported history of obtaining a BCG immunization: BCG immunization 
 Place of birth: Foreign 
 ≥ 21 Years of lab experience 
 History of TB 





For logistic regression (a) all pertinent variables were included in the model,  and 
(b) then, stepwise (backward) removal of statistically nonsignificant variables (removed 
one at a time based on highest P values) was performed.  Overall model significance for 
the logistic regression was determined by the effect of the independent variable(s) and 
was represented with the OR.  The individual predictors were assessed by the Z-statistic.  
The final logistic regression model included only those variable(s) that were statistically 
associated with the dependent (outcome) variable.  An evaluation for confounders and 
assessment for statistical interaction also took place and has been detailed later in the 
post-hoc analyses section. 
Table 15 represents the initial logistic regression model for respondents self-
reporting a lifetime history of positive TST among the cleaned data set of n = 1,628.  All 
variables previously identified in the bivariate analyses as individually associated with a 
















Initial Logistic Regression Analysis for Self-Reported History of Lifetime TST Positivity 




Note. TST = tuberculin skin test. Using Epi Info™ Version 3.5.3 (CDC, 2011c), CI refers 
to confidence interval; the Z-statistic has been calculated from the Wald statistic.  The 
initial regression model for each outcome was composed of the three main independent 
variables (≥ final model by a priori decision.  Age was input as a continuous variable.  
Foreign birth refers to those born outside the United States or one of the U.S. territories, 
unless one parent at time of birth was a U.S. citizen (CDC, 2012); BCG = receipt of a 
bacille Calmette-Guérin immunization.   
*Cases included n = 1,620 as restricted by AGE. 
 
In the initial model represented in Table 15, age, BCG immunization, foreign 
birth, exposure to nonoccupational TB, history of active TB, and work in areas other than 
microbiology are statistically associated with the outcome of self-reported history of 
lifetime TST positivity, significant at p < .05.  ORs are greater than 1.0, indicating a 
potential (and positive direction) association with TST positivity.  Table 16 represents the 
Characteristic Odds Ratio 95% C.I. Z-Statistic P-Value 
Age 1.06 1.04 1.08 5.7211 < .001 
BCG Immunization 9.10 5.18 15.99 7.6746 < .001 
Foreign Birth 3.28 1.92 5.62 4.3298 < .001 
Nonoccupational exposure 1.79 1.08 2.98 2.2474 .025 
History of TB 30.32 3.63 253.21 3.1505 .002 
Mycobacteriology Work 1.47 0.96 2.26 1.7796 .075 
Mycology Work 1.10 0.72 1.67 0.4337 .665 
Work in Other Areas of Laboratory 1.47 1.08 2.02 2.4152 .016 
Parasitology Work 1.08 0.71 1.65 0.3740 .708 
Gender: Male 1.14 0.77 1.71 0.6601 .509 
≥ 21 Years of Lab Experience 0.78 0.53 1.16 -1.21 .225 





final regression model after all backward stepwise eliminations occurred, based on 































Note. TST = tuberculin skin test. Using Epi Info™ Version 3.5.3 (CDC, 2011c), CI refers 
to confidence interval; the Z-statistic has been calculated from the Wald statistic.  The 
initial regression model for each outcome was composed of the three main independent 
variables (forced into the final model by a priori decision.  Age was input as a continuous 
variable.  Foreign birth refers to those born outside the United States or one of the U.S. 
territories, unless one parent at time of birth was a U.S. citizen (CDC, 2012); BCG = 
receipt of a bacille Calmette-Guérin immunization.   
*Cases included n=1620 as restricted by AGE. 
 
According to Table 16, as age increases by year, odds of TST positivity increase 
(OR=1.05).   The odds of TST positivity increase more than nine times for the BCG 
immunized, more than three times for the foreign-born (over U.S.-born individuals).  In 
the multivariate analysis, age, foreign birth, BCG immunization, nonoccupational 
exposure, history of TB, work in a mycobacteriology laboratory, and work in laboratory 
sections outside microbiology remained statistically significant and associated with a 
self-reported lifetime history of a positive TST (n = 1,620); thus, these variables remain 
predictors of self-reported TST positivity among the target population. 
Characteristic Odds Ratio 95% C.I. Z-Statistic P-Value 
AGE 1.05 1.03 1.07 5.80 < .001 
BCG Immunization 9.21 5.26 16.13 7.77 < .001 
Foreign Birth 3.35 1.97 5.72 4.45 < .001 
Nonoccupational Exposure 1.80 1.08 3.00 2.26 .024 
History of TB 31.21 3.75 259.67 3.44 .002 
Mycobacteriology Work 1.59 1.12 2.24 2.62 .009 
Work in Other Areas of the Laboratory 1.45 1.06 1.99 2.34 .019 





Conclusion: I am able to reject portions of the first null hypothesis which 
predicted there would be no statistical association between self-reported individual 
independent variables of history of BCG immunization (“yes”) and place of birth 
(“foreign”), and unable to reject years of laboratory experience, as these independent 
variables act on the dependent (outcome) variable of self-reported lifetime TST 
positivity.  Thus, the null hypothesis remains valid for independent variable of years of 
laboratory experience, while the alternate hypothesis is valid for independent variables of 
BCG immunization and foreign birth with respect to a self-report of lifetime TST 
positivity. 
 Research Question 2: Preventive treatment noninitiation. The second null 
hypothesis predicted that there would be no statistical association between self-reported 
individual independent variables of history of BCG immunization, place of birth (U.S. or 
foreign), and years of laboratory experience, and the dependent variable of preventive 
treatment noninitiation.  This hypothesis was tested using odds ratios (ORs) obtained 
using Epi Info™ TABLES analysis; resulting chi-square has been reported.  Tables 17, 
18, and 19 provide 2-by-2 table summaries as obtained from Epi Info™ TABLE analyses 






2x2 Table BCG Immunization vs. Treatment Noninitiation 
BCG immunization Treatment initiation NO Treatment initiation YES Total 
BCG yes 5 (35.7%) 15 (11.6%) 20 
BCG no 9 (64.3%) 114 (88.4%) 123 
Total 14  129 143 
Note. OR = MLE odds ratio; CI95 = 95% confidence interval; χ2 = Yates corrected with 
2-tailed p chi-square test; BCG = bacille Calmette-Guérin. 
* Refers to Fisher Exact Test 
 
For BCG immunization “Yes”: 
 
Odds ratio (OR) = 4.16 (95% confidence interval [CI95], 1.13- 14.23)   
 
Chi-square (χ2) = 4.25 
 
p = .028* 
 
Table 17 shows that a self-reported history of history of BCG immunization is a 
statistically significant predictor of a self-reported history of not initiating preventive 
treatment.  In addition, the OR of 4.16 indicates that survey respondents who reported a 
history of BCG immunization were over 4 times more likely to report treatment 






2x2 Table Place of Birth (U.S. or foreign) vs. Treatment Noninitiation 
Place of birth Treatment initiation NO Treatment initiation YES Total 
Foreign 6 (42.9%) 18 (14.0%) 24 
U.S. 8 (57.1%) 111 (86.0%) 119 
Total 14 129 143 
Note. OR = MLE odds ratio; CI95 = 95% confidence interval; χ2 = Yates corrected with 
2-tailed p chi-square test; foreign birth refers to those born outside the United States or 
one of the U.S. territories, unless one parent at time of birth was a U.S. citizen (CDC, 
2012) 
* Refers to Fisher Exact Test 
 
For foreign birth “Yes”: 
 
Odds ratio (OR) = 4.55 (95% confidence interval [CI95], 1.33 – 15.05) 
 
Chi-square (χ2) = 5.63 
 
p = .014* 
 
Table 18 shows that a history of foreign birth is a statistically significant predictor 
of a self-reported history of not initiating preventive treatment.  In addition, the OR of 
4.55 indicates that survey respondents who reported a history of treatment noninitiation 







2x2 Table Years of Laboratory Experience vs. Treatment Noninitiation 
Years of experience Treatment initiation NO Treatment initiation YES Total 
≥ 21 years  10 (71.4%) 100 (77.5%) 110 
≤ 20 years 4 (28.6%) 29 (22.5%) 33 
Total 14 129 143 
Note. OR = MLE odds ratio; CI95 = 95% confidence interval; χ2 = Yates corrected with 
2-tailed p chi-square test. 
* Fisher Exact Test 
 
For the ≥ 21 years of laboratory experience group “Yes”: 
 
Odds ratio (OR) = 0.73 (95% confidence interval [CI95], 0.22 – 2.85) 
 
Chi-square (χ2) = 0.03 
 
p = .410* 
 
Table 19 shows that a history of ≥ 21 years of laboratory work experience is not a 
statistically significant predictor of a self-reported history of preventive treatment 
noninitiation.  In addition, the OR of 0.73 indicates that survey respondents who reported 
a history of ≥ 21 years of laboratory work experience were no more likely to report 
treatment noninitiation than those who reported a treatment initiation. 
To summarize, BCG immunization and foreign birth are individually statistically 
significant predictors according to 2x2 Tables 17 and 18, while ≥ 21 years of laboratory 
experience is not significantly associated with the outcome of treatment noninitiation 
(Table 19).  The initial multiple regression analysis is represented in Table 20, and 





bivariate analysis (Table 10).  Independent variables associated with the research 
questions have been forced into the initial model based on a priori decision. 
Table 20 
 
Initial Logistic Regression Analysis for Preventive Treatment Noninitiation (n = 143) 
 
Note. Using Epi Info™ Version 3.5.3 (CDC, 2011c), CI refers to confidence interval; the 
Z-statistic has been calculated from the Wald statistic.  The initial regression model for 
each outcome was composed of the three main independent variables (forced into the 
final model by a priori decision.  Foreign birth refers to those born outside the United 
States. or one of the U.S. territories, unless one parent at time of birth was a U.S. citizen 
(CDC, 2012); BCG = receipt of a bacille Calmette-Guérin immunization.   
 
No P-values are statistically significant for preventive treatment noninitiation as 
represented in the initial logistic regression model (Table 20).  After stepwise (backward) 
deletion of each nonsignificant variable one at a time (where the highest P value is 




Characteristic Odds Ratio 95% C.I. Z-Statistic P-Value 
BCG Immunization 3.57 0.61 20.96 1.41 .159 
Foreign Birth 3.19 0.58 17.61 1.33 .183 
Nonoccupational Exposure 0.00 0.00 >1.00 -0.04 .970 
Virology Work 1.95 0.57 6.70 1.06 .291 
≥ 21 Years of Lab Work Experience 1.89 0.34 10.67 0.72 .470 










Note. Using Epi Info™ Version 3.5.3 (CDC, 2011c), CI refers to confidence interval; the 
Z-statistic has been calculated from the Wald statistic.  The initial regression model for 
each outcome was composed of the three main independent variables (forced into the 
final model by a priori decision.  Foreign birth refers to those born outside the United 
States. or one of the U.S. territories, unless one parent at time of birth was a U.S. citizen 
(CDC, 2012); BCG = receipt of a bacille Calmette-Guérin immunization.   
 
In the final multivariate analysis (Table 21), only the place of birth: foreign variable 
remained statistically significant when tested against an outcome of treatment 
noninitiation. 
 Therefore, I am unable to reject the second null hypothesis regarding independent 
variables of history of BCG immunization, and years of laboratory experience with 
respect to a self-report of lifetime preventive treatment noninitiation.  I am able to accept 
the alternate hypothesis regarding independent variable of place of birth (foreign) with 
respect to a self-report of lifetime preventive treatment noninitiation.   
 Research Question 3: Positive BMQ score. The third null hypothesis predicted 
that there would be no statistical association between self-reported individual 
independent variables of history of BCG immunization, place of birth (U.S. or foreign), 
and years of laboratory experience, and the dependent variable of barriers to treatment 
adherence (medication side effects) as identified using the Brief Medication 
Characteristic Odds Ratio 95% C.I. Z-Statistic P-Value 
Foreign Birth 4.63 1.44 14.90 2.57 .010 





Questionnaire (BMQ) in those respondents ever having initiated preventive TB treatment.   
This hypothesis was tested using odds ratios (ORs) obtained using Epi Info™ TABLES 
analysis; resulting chi-square has been reported.  Tables 22, 23, and 24 provide 2-by-2 
table summaries as obtained from Epi Info™ TABLE analyses for the independent 
variables. 
Table 22 
2x2 Table BCG Immunization vs. Treatment Nonadherence (by BMQ Score) 
BCG immunization BMQ score of ≥ 1  BMQ score of < 1  Total 
BCG yes 4 (9.1%) 11 (12.9%) 15 
BCG no 40 (90.9%) 74 (87.1%) 114 
Total 44 85 129 
Note. BMQ = Brief Medication Questionnaire (where a score ≥1 indicates barriers to 
treatment adherence may be present); OR = MLE odds ratio; CI95 = 95% confidence 
interval; χ2 = Yates corrected with 2-tailed p chi-square test; BCG = bacille Calmette-
Guérin. 
 
For BCG immunization “Yes”: 
 
Odds ratio (OR) = 0.67 (95% confidence interval [CI95], 0.18- 2.20)   
 
Chi-square (χ2) = 0.13 
 
p = .721 
 
Table 22 shows that a self-reported history of BCG immunization is not a 
statistically significant predictor of a self-reported history of treatment nonadherence as 
measured by a positive BMQ score.  In addition, the OR of 0.67 indicates that survey 
respondents who reported a history of BCG immunization were no more likely to report a 






2x2 Table Place of Birth (U.S. or Foreign) vs. Treatment Nonadherence (by BMQ Score)        
Place of birth BMQ score of ≥ 1 BMQ Score or < 1 Total 
Foreign   6 (13.6%) 12 (14.1%) 18 
U.S. 38 (86.4%) 73 (85.9%) 111 
Total 44 85 129 
Note. BMQ = Brief Medication Questionnaire (where a score ≥ 1 indicates barriers to 
treatment adherence may be present); OR = MLE odds ratio; CI95 = 95% confidence 
interval; χ2 = Yates corrected with 2-tailed p chi-square test; foreign birth refers to those 
born outside the United States or one of the U.S. territories, unless one parent at time of 
birth was a U.S. citizen (CDC, 2012) 
 
For foreign birth “Yes”: 
 
Odds ratio (OR) = 0.96 (95% confidence interval [CI95], 0.31 – 2.75) 
 
Chi-square (χ2) = 0.04 
 
p = .847 
 
Table 23 shows that a history of foreign birth is not a statistically significant 
predictor of a self-reported history of treatment nonadherence as measured by a positive 
BMQ score.  In addition, the OR of 0.96 indicates that survey respondents who reported 
foeign birth were no more likely to report a positive BMQ score than those who reported 







2x2 Table Years of Laboratory Experience vs. Treatment Nonadherence (by BMQ Score) 
Laboratory experience BMQ score of ≥ 1  BMQ score of < 1  Total 
≥ 21 years 34 (77.3%) 66 (77.6%)                     100 
≤ 20 years 10 (22.7%) 19 (22.4%) 29 
Total 44 85 129 
Note. BMQ = Brief Medication Questionnaire (where a score ≥ 1 indicates barriers to 
treatment adherence may be present); OR = MLE odds ratio; CI95 = 95% confidence 
interval; χ2 = Yates corrected with 2-tailed p chi-square test. 
 
For the ≥ 21 years of laboratory experience group “Yes”: 
 
Odds ratio (OR) = 0.98 (95% confidence interval [CI95], 0.41 – 2.42) 
 
Chi-square (χ2) = 0.03 
 
p = .862 
 
Table 24 shows that a history of ≥ 21 years of laboratory work experience is not a 
statistically significant predictor of a self-reported history of treatment nonadherence as 
measured by a positive BMQ score.  In addition, the OR of 0.98 indicates that survey 
respondents who reported a history of ≥ 21 years of laboratory work experience were no 
more likely to report a positive BMQ score than those who reported a negative BMQ 
score. 
To summarize, Tables 22, 23, and 24 demonstrate that no variables are 
statistically significant as predictor variables in the 2x2 tables involving the three 
independent variables addressed in Research Question 3.  The same three variables were 
included in assessment of stepwise model logistic regression (based on a priori decision) 





treatment adherence (medication side effects) as measured by BMQ scores.  Positive 
BMQ scores were coded as “1” in the regression analysis (Epi Info™) software; Table 25 
depicts the initial regression model which includes the independent variables represented 
in Research Question 3, as well as those variables found in the previous bivariate analysis 
(Table 11) where P value was found to be < .15. 
Table 25 
 
Initial Logistic Regression Analysis for Self-Reported Treatment Adherence Barriers as 




Note. BMQ = Brief Medication Questionnaire (where a score ≥ 1 indicates barriers to 
treatment adherence may be present); Using Epi Info™ Version 3.5.3 (CDC, 2011c), CI 
refers to confidence interval; the Z-statistic has been calculated from the Wald statistic.  
The initial regression model for each outcome was composed of the three main 
independent variables (forced into the final model by a priori decision.  Foreign birth 
refers to those born outside the United States or one of the U.S. territories, unless one 
parent at time of birth was a U.S. citizen (CDC, 2012); BCG = receipt of a bacille 
Calmette-Guérin immunization.   
 
Table 25 represents the initial logistic regression analysis for self-reported 
treatment adherence barriers as measured by a positive BMQ Score.  No independent 
variables are statistically significant for a positive BMQ score in this initial model.  Table 
26 represents the final regression model after stepwise (backward) removal of variables 
having the highest P values. 
Characteristic Odds Ratio 95% C.I. Z-Statistic P-Value 
BCG Immunization 0.39 0.07 2.30 -1.03 .301 
Foreign Birth 2.59 0.51 13.15 1.14 .252 
History of TB 0.14 0.01 1.24 -1.77 .077 
Gender: Male 0.43 0.15 1.19 -1.63 .103 
≥ 21 Years of Lab Experience 1.16 0.46 2.95 0.31 .757 







Final Logistic Regression Analysis for Self-Reported Treatment Adherence Barriers as 
Measured by a Positive BMQ Score (n = 129) 
 
Note. BMQ = Brief Medication Questionnaire (where a score ≥ 1 indicates barriers to 
treatment adherence may be present). Using Epi Info™ Version 3.5.3 (CDC, 2011c), CI 
refers to confidence interval; the Z-statistic has been calculated from the Wald statistic.   
 
In Table 26, no variables are retained in the final model.  After logistic regression, 
no P-values were found statistically significant or associated with the outcome of a 
positive BMQ score (representative of barriers to treatment adherence).   
Conclusion: The third null hypothesis predicted that there would be no statistical 
association between self-reported individual independent variables of history of BCG 
immunization, place of birth (U.S. or foreign), and years of laboratory experience, and 
the dependent variable of barriers to treatment adherence (medication side effects) as 
identified using the Brief Medication Questionnaire (BMQ) in those respondents ever 
having initiated preventive TB treatment.  I am unable to reject the null hypothesis for 
Research Question 3. 
Post-Hoc Analyses 
Several post-hoc analyses were performed and will be described in detail in this 
section.  First, sample size of entire ASCP cohort changed from N = 5,138 to N = 4,335 at 
exact time of survey (postcard announcement) mailing.  The ASCP membership number 
changed from the time of initial proposal sample size calculations.  Second, exploratory 
Characteristic Odds Ratio 95% C.I. Z-Statistic P-Value 
History of TB 0.17 0.01 1.41 -1.64 .101 





analyses included an evaluation of covariables for assessment of statistical interaction 
and confounding.  Third, exploratory analyses describing several additional findings have 
been discussed. 
The original estimated sample size requirement changed at the precise time of 
initial survey announcement postcard mailing.  This discrepancy is in part due to the 
change in ASCP cohort membership over the course of the year from 5,138 to 4,335 
members.  A recalculation of estimated, required sample size involved extrapolation of 
the initial estimated sample size calculations for N = 5,138 to reflect corresponding 
sample size calculations for the actual ASCP membership of N = 4,335.  This was 
necessary because the original sample sizes were calculated using Open Epi software 
(available in the public domain); the original estimated population size of N = 5,138 was 
actually utilized in these software calculations (Appendix B).    
Referring to Table 3 (Chapter 3), the required sample sizes corresponding to each 
of the three research question (RQ) response requirements were thus extrapolated to 
reflect the actual N = 4,335 cohort and associated minimum sample sizes. 
 RQ1: 638 of 5,138 = 12.42%; for N = 4,335, the new minimum sample size 
became 538 individual respondents. 
 RQ2: 1,336 of 5,138 = 26.00%; for N = 4,335, the new minimum sample size 
became 1,127 individual respondents. 
 RQ3: 2,569 of 5,138 = 50.00%; for N = 4,335, the new minimum sample size 
became 2,168 individual respondents.  Of these, 1.40% must be positive for 





of 2,168 individuals, the new sample size became n = 30 (individual 
respondents that had to be positive for the RQ3 outcome of medication side 
effects as measured by the BMQ).   
In conclusion, the updated (actual) sample size of n = 1,628 
 Surpassed the minimum sample size for RQ1 requirements (to reach enough 
individuals self-reporting TST positivity); 
 Surpassed the minimum sample size for RQ2 requirements (to reach enough 
individuals self-reporting treatment initiation for purposes of achieving 
sample size required for RQ3 treatment adherence barriers); and 
 Although minimum sample size of n = 2,168 was not achieved for RQ3, the 
total number of respondents reporting medication side effects, n = 44, was 
well above the required n = 30 individuals reporting the outcome as set forth 
in the original minimum sample size requirement. 
Although the original estimated 50% eligible survey response rate was not achieved in 
this study, minimum (adequate) sample size was achieved in order to generalize results to 
all three research questions, according to original sample size estimates based on 
estimates and prevalences of outcomes and case/control prevalences of independent 
variables as reported in the literature.  Therefore, these results may be generalized to this 
ASCP target population. 
Exploratory analyses were performed to assess confounding and statistical 
interaction of two variables, place of birth (foreign birth) and BCG immunization for 





using Epi Info ™ analysis recommended by Dean et al. (2010, pp. 133-136).  Foreign 
birth was analyzed by itself (and not controlling for any other variables) in order to obtain 
a crude OR.  P-values were deemed statistically significant for these variables, just as for 
the TABLES model obtained in the earlier bivariate analyses.  Foreign birth was then 
analyzed along with the BCG immunization variable, in order to control for BCG 
immunization.  This resulted in an adjusted OR.  An interaction term was then created in 
the Epi Info™ dialog box to assess whether the additional variable modified or 
confounded the relationship, and run in the logistic regression analysis in order to look at 
P-value only.   An assessment was made to determine if the P-value changed from 
statistically nonsignificant (p > .05) to statistically significant (p < .05).  If so, statistical 
interaction occurred.  To assess confounding, I analyzed the resulting crude and adjusted 
ORs using the equation provided by Dean et al. (2010): 
 
% Difference = (│CRUDE OR – ADJUSTED OR│) ⁄  (ADJUSTED OR) x 100 
 
Important confounding typically occurs when OR values differed by > 15% (Dean et al., 
2010; Gregg, 2008). 
For dependent (outcome) variable of TST positivity, Epi Info™ analysis of the 
independent variable, place of birth (foreign), was carried out to investigate whether any 
interaction occurred between it and each covariable of BCG immunization, 





repeated using independent variable BCG immunization.  The summary results obtained 




Summary Table: Epi Info™ Unconditional Logistic Regression Analysis, Confounding 
Assessment; Outcome TST Positivity (Final Analysis, n = 1,628*) 
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Note. TST = tuberculin skin test.  Foreign birth refers to those born outside the United 
States or one of the U.S. territories, unless one parent at time of birth was a U.S. citizen 
(CDC, 2012); BCG = receipt of a bacille Calmette-Guérin immunization.   
*Cleaned data set 
†OR = Odds Ratio as calculated by  Epi Info™ Version 3.5.3. 
From Table 27, it is reasonable to consider covariable BCG immunization as a 
confounder in the presence of foreign birth, considering the literature as a whole, where 
foreign-born are more likely to receive BCG immunization.  From the summary findings 





 No statistically significant interaction occurred among these variables, as 
assessed by the P values obtained from analysis of interaction terms using Epi 
Info™ unconditional logistic regression. 
 Foreign birth confounds the BCG immunization—TST positivity association 
in this population. 
 BCG immunization confounds the foreign birth—TST positivity association in 
this population. 
Several other post-hoc observations were made among data obtained during this 
study.  A large number of respondents indicated they never had (or did not know if they 
had ever had) a TST (n = 58).  This data set was not analyzed further in this dissertation.  
This outcome was unexpected, as it was thought that all medical microbiologists 
(previously or currently working) had experienced a TST.  
As mentioned earlier in this chapter, among 276 TST-positive individuals, 19 
U.S. citizens were born outside the United States, and reporting a history of BCG 
immunization. Among these 19, 10 individuals reported no BCG immunization (52.63%), 
and 9 reported a history of having had a BCG immunization (47.37%).  If those 19 
individuals born outside the United States (but defined by CDC as U.S.-born) were 
combined into the foreign birth category, the frequencies of BCG immunization among 
these groups would change to reflect prevalences more commonly seen in moderate- to 
high-risk endemic regions.  The number of BCG immunized in the United States would 
be assessed at n = 9, while those immunized outside the United States would become n = 





Thus, it is important to remember the definition currently in use by the CDC for the term 
foreign born. 
Summary of Findings 
The entire cohort (N = 4,335) of the microbiologists registered with and 
designated by ASCP as primarily working in the area of the laboratory known as 
Microbiology/Mycology/Parasitology/Virology and having U.S. mailing addresses was 
surveyed using a self-administered mail questionnaire: Tuberculin Skin Test 
Questionnaire for ASCP Medical Laboratory Microbiologists—2013 (see Appendix A).  
This final number of ASCP cohort members differed from the initial estimate of N = 
5,138 because of a drop in membership over the year (from time of study proposal to 
time of first survey announcement postcard mailing.) 
After a pretest and pilot test phases, this study was conducted over a period of 
eight weeks, from March 25 through May 20, 2013, resulting in n = 1,628 eligible 
responses.  (Responses initially numbered n = 1,693, but cleaning and coding of data led 
to a final number of eligible responses, n = 1,628.)  A summary of overall descriptive 
findings may be found in the study algorithm (Appendix H). 
The majority of eligible survey respondents in this study were female n = 1,393 
(85.6%).  The mean age of eligible respondents was reported at 58 years for those self-
reporting a history of TST positivity, 54 years for TST negativity.  Most reported to have 
worked in several areas of the laboratory, while only five reported to have worked solely 





more than 21 years in the laboratory setting.   The prevalence of self-reported lifetime 
TST positivity status among this cleaned data set was calculated at n = 276 (17.0%).  
Only 121 (7.4%) individuals of the eligible data set were foreign-born (less than 
that expected), and a small number, 168 (10.3%), reported ever having had the newer 
IGRA blood test replacement for the TST.  Twelve (0.7%) individuals reported having 
had a history of active TB during their lifetime, while n = 106 (6.5%) reported a history 
of nonoccupational contact. 
Among those self-reporting a history of TST positivity (n = 276), n = 143 (52%) 
reported to have been prescribed anti-TB medication; 129 (90.2%) reported initiation of 
this medication, while n = 13 (9.1%) refused treatment.  Of the 129 individuals who 
began (initiated) treatment, n = 111 (86%) completed the entire course.  Twenty-seven 
(20.9%) reported that these medications bothered them; 44 of the n = 129 (34.1%) 
reported a positive BMQ total score indicating presence of treatment adherence barriers 
(medication side effects).  The overall prevalence rate of a positive BMQ score among 
those reporting noncompletion of prescribed treatment among the cleaned data set (n = 
1,628) was 0.89% (less than 1%).  In addition to descriptive characteristics, risk factors 
were assessed by bivariate and multivariate analysis. 
Risk factors for the prevalence of self-reported TST positivity were assessed.  In 
the bivariate analysis, male gender, age, type of work setting (mycobacteriology, 
parasitology), foreign birth, BCG immunization, history of TB, and nonoccupational 
exposure to TB were associated with a positive TST.  Work in bacteriology, mycology, 





laboratory experience were not significant risk factors.  In the multivariate analysis, age, 
type of work setting (mycobacteriology and other areas of the laboratory), foreign birth, 
BCG immunization, history of TB, and nonoccupational exposure remained statistically 
associated with a self-reported lifetime positive TST status.  Years of work experience (≥ 
21 years) were not found to be significantly associated in any of the analyses. 
Risk factors for the prevalence of self-reported preventive treatment noninitiation 
were assessed.  In the bivariate analysis, foreign birth and BCG immunization were 
associated with preventive treatment noninitiation.  Male gender, age, type of work, 
history of TB, nonoccupational exposure, and ≥ 21 years of work experience were not 
significant risk factors.  In the multivariate analysis, only foreign birth remained 
statistically associated with self-reported lifetime preventive treatment noninitiation after 
stepwise backward deletion. 
Finally, risk factors for the prevalence of self-reported treatment adherence 
barriers (a positive BMQ score indicating perceived medication side effects) were 
assessed.  In the bivariate and multivariate analyses, no variables were associated with a 
positive BMQ score.   In the multivariate analysis, male gender, age in years, type of 
laboratory work, history of TB, nonoccupational exposure, foreign birth, BCG 
immunization, and  ≥ 21 years of laboratory work experience, were not statistically 
associated with a self-reported positive BMQ score (treatment adherence barrier of 
perceived medication side effects).  
To summarize, after adjustment, multivariate analysis identified age (odds ratio 





mycobacteriology (OR, 1.59; CI95, 1.12-2.24), and work outside of microbiology (OR, 
1.45; CI95, 1.06-1.99), foreign birth (OR, 3.35; CI95, 1.97-5.72), BCG immunization (OR, 
9.21; CI95, 5.26-16.13), history of TB (OR, 31.21; CI95, 3.75-259.67), and 
nonoccupational exposure (OR, 1.80; CI95, 1.08-3.00), as significant risk factors for a 
self-reported positive TST.  Foreign birth (OR, 4.63; CI95, 1.44-14.90) was associated as 
a significant risk factor for a self-reported history of treatment noninitiation.  No risk 
factors as tested in this study were significantly associated with treatment adherence 
barriers as measured by BMQ score.   
In post-hoc analyses involving TST positivity, no statistically significant 
interaction was found to have occurred for place of birth (foreign) and each covariable of 
BCG immunization, history of TB, and nonoccupational exposure to TB.  The same 
analysis of interaction terms was repeated using independent variable BCG 
immunization.  However, foreign birth was found to confound the BCG immunization—
TST positivity association in the target population.  In addition, BCG immunization 
confounded the foreign birth—TST positivity association in this population.   
Other post-hoc analyses findings involved unexpected prevalence results.  One 
finding was that a large number of respondents indicated they never had (or did not know 
if they had ever had) a TST (n = 58).  As previously mentioned, this outcome was 
unexpected as it was thought that all medical microbiologists (previously or currently 
working) had experienced a TST.  Also, among 276 TST-positive individuals, 19 U.S. 
citizens were born outside the United States, reporting a history of BCG immunization.  





BCG immunization (47.37%).  If those 19 individuals born outside the United States (but 
defined by CDC as US-born) had been considered as foreign-born rather than U.S.-born, 
frequencies of BCG immunization would change greatly to reflect prevalences more 
commonly found in moderate- to high-risk TB endemic regions. 
Chapter 5, Discussion, Conclusions, and Recommendations, discusses the 
research results within the context of a discussion comparing this study’s results with 
results obtained in other notable research.  Similarities and differences are debated, as 
well as a discussion of how the results are interpreted with regard to theory.  Study 






Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this cross-sectional quantitative survey was to gather data to 
describe the American Society of Clinical Pathology (ASCP) medical laboratory 
microbiologist target study population in terms of self-reported lifetime history of 
tuberculin skin test positivity prevalence, preventive treatment noninitiation, and barriers 
to treatment adherence (medication side effects as measured by the BMQ) using a written 
survey questionnaire.  In addition, independent variables of BCG immunization, years of 
laboratory work experience, and place of birth were assessed as potential risk factors in 
the occurrence of all three of the above outcomes.  An evaluation of how each outcome 
varied across demographic and work-related factors was also performed.  The purpose of 
this chapter is to interpret the data analysis.  Research findings are discussed in terms of 
similarities and differences, as well as in terms of theoretical constructs.  Study 
limitations, recommendations for future research, and conclusions are provided.   
Data collected in this survey questionnaire are categorical and descriptive in 
nature.  The type of survey instrument chosen for this study was a self-administered mail 
questionnaire: Tuberculin Skin Test Questionnaire for ASCP Medical Laboratory 
Microbiologists—2013 (see Appendix A).  This study represents lifetime prevalence (also 
termed period prevalence) to describe the proportion of the target population with self-
reported outcomes as related to the dependent variables (given conditions) over a 






Interpretation of Key Findings 
This quantitative cross-sectional self-administered mail questionnaire survey took 
place during Spring 2013; 1,693 individuals responded within the allotted time, a 39.1% 
overall response rate.  The total number of respondent surveys eligible for statistical 
analysis numbered 1,628 of the 4,335 survey packets originally mailed to the entire 
ASCP target cohort, an eligible respondent return rate of 37.6%.  This response rate is an 
improvement over the 22.5% realized by Clark (2008) in research involving a different 
ASCP questionnaire mailing.  The improvement in response rate may have been due to 
two items: (a) an announcement postcard that was mailed 1 week prior to the survey 
packet and (b) an incentive in the form of an ASCP scholarship donation that was offered 
on behalf of all survey respondents.  (A bad address return rate of 0.3% was realized, in 
line with the less than 1% previously predicted by INFOCUS Marketing.)  As discussed 
in Chapter 4, the respondent rate was high enough for all three required sample sizes to 
be achieved, allowing results to be generalizable to this ASCP target population of 
medical microbiologists. 
This study represents lifetime prevalence (also termed period prevalence).  A 
snapshot of the ASCP target population looks like this: The majority of eligible survey 
respondents were female, aged mid-50s, working more than 21 years in the laboratory 
setting, and most were born in the United States.  The ages of all survey respondents (n = 
1,693) ranged from 24 to 82 years, with a mean age of 55 years, higher than the ASCP 
reported average mean of 50 years for medical laboratorians (ASCP, 2008).  This target 





than previously expected.  Many survey respondents reported to have worked in several 
areas of the laboratory, while only a few individuals reported to have worked solely in the 
mycobacteriology section.   
Seventeen percent of the eligible study respondents (n = 1,628) surveyed in this 
study self-reported lifetime history of a positive TST.  There are few published studies 
describing TST positivity or preventive treatment initiation among medical laboratory 
microbiologists in the United States.   Although preventive treatment initiation rates were 
high among those prescribed anti-TB medications, almost half of those self-reporting a 
positive TST claimed not to have ever been prescribed medications in their past.  A high 
percentage (86%) of those prescribed treatment completed the entire course.  Those who 
did not complete treatment were most likely to claim medication side effects as the cause.  
(The use of Part A of the BMQ in this cross-sectional survey was found to be useful in 
ascertaining specifics regarding medication side effects in this target population.) 
The three null hypotheses for this study predicted that self-reported lifetime 
history of BCG immunization, place of birth (U.S. or foreign), and years of laboratory 
experience would not contribute to (a) self-reported lifetime tuberculin skin test 
positivity, (b) preventive treatment noninitiation, or (c) barriers to treatment adherence 
(medication side effects) among those ever initiating preventive treatment for a positive 
TST.  Risk factors were assessed by bivariate and multivariate analysis.   
Research Question 1: TST Positivity 
The self-reported prevalence rate of TST positivity was 17.0% among this eligible 





Bailey et al. (1995), yet much lower than the 57% among microbiologists in the Garber et 
al. (2003) research.  Findings of 17% TST positivity prevalence are low, confirming prior 
percent ranges determined by Joshi et al. (2006).  As expected, the 17% positivity rate is 
much less than the 49.2% to 88.9% positivity prevalence determined by Reid (1957) 
during a time long past when few or no engineering controls or treatment for TB were in 
place.  Unlike many of the cohort and case/control studies reported in Chapter 2, no 
incidence rates (TST conversion data) were collected in this study.   
The self-reported prevalence rate of active TB history in this eligible population 
was reported at 0.7% (n = 12), lower than the 3.8% estimated in U.S. HCP as reported by 
CDC (2010b).  The odds of reporting a history of TB among TST-positive individuals 
was calculated at an OR of 31.21 in the final multivariate analysis.  Nonoccupational 
exposure was reported at an OR of 1.80 in the final model.  These findings add to the 
existing knowledge of this U.S. subgroup of laboratorians. 
For gender, males were 1.48 times more likely (OR = 1.48) than females to self-
report a positive TST history.  Male gender was statistically significant in bivariate 
analysis but was not retained as a predictor in the final multivariate model for TST 
positivity.  This finding is consistent with the Garber et al. (2003) research where male 
gender was not retained in the final multivariate model as a predictor of a positive TST.  
In the current study, only four cases of TB disease were reported among males (n = 
1,628), but this equates to 246 per 100,000 individuals; this is extremely high when 
compared with the average male rate of 11.8 per 100,000 for cases of active TB in the 





The mean age of those eligible respondents (n = 1,620) self-reporting a lifetime 
history of TST-positive status was 58 years, and 54 years for those reporting TST-
negative status.  Increasing age was a statistically significant continuous variable in the 
bivariate and multivariate analysis, p < .001, suggesting a connection whereby prevalence 
of LTBI increases with age.  This finding is in agreement with the epidemiology of LTBI 
as reported by Heymann (2008).  Age appears to be connected with “years of experience” 
in the microbiology laboratory, as a majority (73%) of all eligible respondents reported 
working ≥ 21 years, with an OR of 1.24, although the years of experience variable was 
not retained as statistically significant in any of the prediction models.  This was an 
unexpected finding: ≥ 21 years of work experience was not a risk factor for a positive 
TST.   
Type of laboratory work areas mycobacteriology, parasitology, and other (work 
outside microbiology) were found to be statistically significant when bivariate analysis 
was performed.  After stepwise (backward logistic regression) multivariate analysis, the 
only work areas to remain statistically significant in the model used to predict TST 
positivity were mycobacteriology and other (work outside microbiology).  The finding of 
mycobacteriology type of work confirms research by Garber et al. (2003), as well as 
reinforces the need for microbiology laboratories to follow the CDC guidelines for 
biosafety in mycobacteriology laboratories (CDC, 2009) and prevention of TB among 
healthcare workers (CDC, 2005b).   
Among those self-reporting a history of TST positivity, a large number (74.6%) 





significantly associated for TST positivity, significantly associated at p < .001 in both 
bivariate and multivariate analyses.  The bivariate OR in this study was reported at 8.32 
in bivariate analysis of those self-reporting TST positivity, and adjusted OR of 3.35 
obtained in multivariate analysis (final model).  The number of medical microbiologists 
in this category reached n = 69 (25%) of those reporting TST positivity.  Although the 
raw prevalence percentage of 25% is less than that reported in the Cook et al. (2003) 
study, it is higher than that reported in the Clearfield and Batalova (2007) study.  The 
multivariate analysis adjusted OR of 3.35 realized in this study of ASCP medical 
microbiologists confirms the adjusted OR of 3.80 reported among New York City 
laboratorians in the Garber et al. (2003) research.   
With respect to BCG immunization, self-reported history of immunization as 
related to self-reported TST positivity yielded an OR of 13.39 in bivariate analysis, and a 
p < .001; the adjusted OR after multivariate analysis was reported at 9.21, p < .001.  This 
bivariate finding is at least 2.75 times (and multivariate finding more than double) the 
prior multivariate analysis reports (OR = 4.89) in HCP (Garber et al., 2003) and does not 
confirm the lack of association to TST positivity previously reported by Koppaka et al. 
(2003).   
With respect to Research Question 1 posed in Chapter 1, I am able to reject 
portions of the first null hypothesis, which predicted that there would be no statistical 
association between self-reported individual independent variables of history of BCG 
immunization (yes) and place of birth (foreign), and unable to reject years of laboratory 





TST positivity.  Thus, the null hypothesis remains valid for the independent variable of 
years of laboratory experience, while the alternate hypothesis is valid for the independent 
variables of BCG immunization and foreign birth with respect to a self-report of lifetime 
TST positivity.   
After adjustment, multivariate analysis identified age, work in mycobacteriology, 
and other work (outside microbiology), foreign birth, BCG immunization, history of TB, 
and nonoccupational exposure as significant risk factors for a self-reported positive TST.   
Research Question 2: Preventive Treatment Noninitiation 
For the dependent variable of preventive treatment noninitiation, initiation rates 
were first collected and analyzed prior to recoding to those of noninitiation.  In this 
research study, the noninitiation rate was only 9.8%, meaning that the treatment initiation 
rate was very high, 90.2% (among the n = 143 who were prescribed anti-TB treatment).  
This confirms the Camins et al. (1996) initiation rate of 84% among HCP but is at least 
1.5 times that of the initiation rate reported by Gershon et al. (2004) and 4.5 times the 
initiation rate noted in the Garber et al. (2003) study.  Of note, the Garber et al. (2003) 
study findings did not state whether their reported 20% treatment initiation rate was an 
overall rate (including all those who were prescribed treatment in the denominator).  The 
Garber et al. study did state that the 20% treatment with Isoniazid was calculated by 
dividing those treated by the total number of TST positive individuals, and that 
“eligibility for treatment ... was not assessed” (Garber et al., 2003, p. 806).  If I had 
attempted to recalculate the current study’s initiation rate based on the Garber et al. 





46.7%.  This new value is more than twice the Garber et al. rate.  These considerations 
point to the importance of fully understanding prevalence definitions as set forth in the 
literature. 
Treatment completion rates in the current study were based on the assumption that 
respondents were first prescribed treatment and then initiated treatment.  One hundred 
eleven completed an entire course of prescribed treatment (86.0%).  These findings are 
higher than the 27% to 82% ranges of completion rates among HCP as reported by Hirsh-
Moverman et al. (2008), higher than the 55% reported by Camins et al. (1996), and 
almost one and a half times higher than the general public’s completion rates, reported to 
be approximately 60% (CDC, 2000). 
For predictors, place of birth: foreign birth (with a bivariate OR of 4.55 and a 
multivariate adjusted OR of 4.63) was found to be significantly associated with treatment 
noninitiation and was retained as the lone variable in the multivariate analysis (final 
model).  BCG immunization and years of experience (≥ 21 years) were not retained in the 
final model as predictors.  These findings are new information in filling the gap of 
knowledge on HCP known as U.S. medical laboratory microbiologists.  To date, no other 
study has provided predictor information on this type of subpopulation of HCP. 
With respect to Research Question 2 posed in Chapter 1, I am able to reject the 
portion of the second null hypothesis as it refers to the independent variable of place of 
birth (foreign) with respect to a self-report of lifetime preventive treatment noninitiation.  
I am unable to reject the second null hypothesis regarding the independent variables of 





report of lifetime preventive treatment noninitiation.  Thus, the null hypothesis remains 
valid for the independent variables of BCG immunization and years of laboratory 
experience.  The alternate hypothesis is valid for the independent variable of place of 
birth (foreign) with respect to a self-report of lifetime preventive treatment noninitiation. 
After adjustment, multivariate analysis identified only foreign birth as a 
significant risk factor for a self-reported preventive treatment noninitiation.   
Research Question 3: Barriers to Treatment Adherence (Medication Side Effects) 
Real or perceived medication side effects were measured by a positive BMQ 
score (barriers to treatment adherence), numbering 44 individuals out of 129 individuals 
who initiated preventive treatment.  This equates to a 34.1% positive BMQ score rate, 
indicating perceived treatment adherence barriers (barriers of medication side effects).  
The actual number of respondents who named anti-TB medications and described 
specific medication side effects numbered 27 (20.9%).  Twenty-two of the 27 named INH 
as the medication and side effects, consistent with prior reports (nausea, liver toxicity, 
increased liver enzymes, exhaustion, appetite adversely affected).  Hepatotoxicity was 
reported in 11 of the 22 reporting specific side effects, a rate of 8.5%, or 85 per 1,000 
individuals, much higher than the 5.6 per 1,000 rate reported by Fountain et al. (2005). 
Of note, 15 of the 18 medical laboratory microbiologists in this study who did not 
complete treatment reported perceived medication side effects (as measured by a positive 
BMQ score), a rate of 11.6% of those initiating treatment.  This finding is only slightly 
higher than the 11.4% of HCP who did not complete treatment, stopping because of real 





entire respondent data set (n = 1,628), the prevalence rate of a positive BMQ score is 
0.89%, a very low prevalence rate.   The obtained noncompletion rate (among those 
initiating treatment) of 11.6% due to side effects in this study population is one-third of 
that reported by Camins et al. (1996) and almost one-fifth that reported by Joseph et al. 
(2004).  Current findings confirm these and the Shukla et al. (2002) studies in that 
treatment symptoms of anti-TB medications are severe enough to cause treatment 
nonadherence and noncompletion of regimen.  No risk factors were determined by 
bivariate or multivariate analysis of variables tested in this study. 
With respect to Research Question 3 posed in Chapter 1, the third null hypothesis 
predicted that there would be no statistical association between self-reported individual 
independent variables of history of BCG immunization, place of birth (U.S. or foreign), 
and years of laboratory experience and the dependent variable of barriers to treatment 
adherence (medication side effects) as identified using the Brief Medication 
Questionnaire (BMQ) in those respondents ever having initiated preventive TB treatment.  
I am unable to reject the null hypothesis for Research Question 3. 
After adjustment, multivariate analysis did not identify any of the tested 
independent variables as significant risk factors for self-reported barriers to treatment 
nonadherence (medication side effects).   
Findings in the Context of Theory 
In the context of the epidemiologic triad model as described in Chapter 1, it is 
reasonable to surmise that medical laboratory microbiologists in the United States may be 





reasonable to surmise that this subpopulation could also be at risk for experiencing these 
barriers.  In all three scenarios, the risk of acquiring TB infection (disease outcome 
reflected as TST positivity) was conjectured to be associated with (a) the exposure to 
tubercle bacilli (agent); (b) a lack of preventive treatment (host); and (c) place of birth, 
years of exposure, and barriers to treatment (environment).   
The findings of this study suggest an association to the tubercle bacilli (agent) 
through type of microbiology area of work “mycobacteriology” and “other” laboratory 
areas.  No assertions can be made from type of work area listed as “other”, because this is 
a general response, intended to assist those microbiologists who could not relate to the 
type of work areas as listed.  Work in mycobacteriology areas, however, is in line with 
previous research as having been associated with a possible occupational exposure hazard 
(CDC, 2000, 2005b).  History of TB and nonoccupational exposure to TB are also 
suggested as associated with the agent’s presence in the target population.  In general, 
these findings make it difficult to separate the actual source of agent in individuals: 
whether the agent’s presence is due to occupational or nonoccupational exposure. In 
addition, older age in years has been associated with increased exposure to TB agent 
because of occupational (lack of engineering controls) exposure, or nonoccupational 
exposure during a time when TB was quite prevalent in the United States (CDC, 2009, 
2010b; Heymann, 2008; Reid, 1957). 
Risk factors for preventive treatment noninitiation (in the host) were neither 
confirmed nor unconfirmed in this study.  Of the 276 individuals self-reporting a positive 





were not prescribed was beyond the scope of this study, but does leave almost half of the 
TST-positive population in this study untreated.)  Of the 143 individuals prescribed 
treatment, n = 129 (90.2%) did indeed report initiating treatment, and n = 111 (86%) 
completed the entire course of treatment.  Only n = 14 (9.8%) noninitiated preventive 
treatment; 13 of the 14 individuals refused treatment.  Only foreign birth was associated 
as a risk factor in treatment noninitiation in this study, perhaps because the foreign born 
assume a positive TST is due to BCG immunization and not due to the LTBI (agent 
infection).  
For the environmental leg of the triad, place of birth “foreign” remained a 
significant predictor for presence of the TB agent.  However, in this study, a lower 
number than expected, 121 (7.4%) of the total eligible respondents, were foreign born.  
Receipt of BCG immunization was strongly tied to foreign birth (as expected); 74.6% of 
those self-reporting TST positivity were foreign-born who received BCG.  Years of 
experience (≥ 21 years) was not found to act as a predictor, and no risk factors were 
found to be associated with barriers to treatment (medication side effects). 
This study’s findings are relevant to the epidemiologic triad model as it pertains 
to the overarching problem of identifying and halting the spread of tuberculosis among 
U.S. HCP, specifically, medical laboratory microbiologists.  A summary of survey 
responses indicate that several individuals reporting a positive TST and having received 
BCG immunization at some point in their lifetime did not report any treatment.  A closer 
look to uncover why this is so is needed in order to address the host (and BCG 





BCG vaccination be given the TST test (and/or the more sensitive IGRA blood test) and 
recommended prophylaxis.  Once a positive BCG immunization status has been reported, 
confusion in TST interpretation and subsequent prescribing of treatment persists among 
many that the positive TST is due to the BCG immunization (CDC, 2010a).  This 
misconception (and disconnect in these study results) may be the leg of the epidemiologic 
triad that requires intervention in order to prevent further spread of TB.  The older TST-
positive target population in this study should seek out additional testing to confirm or 
rule out any current infection with LTBI. 
Limitations of the Study 
Limitations which may have influenced the outcomes in this study were 
previously detailed in Chapter 1 as potential weaknesses.  Foremost among these is the 
use of a survey method incorporating a self-reported questionnaire tool, which may result 
in recall bias as well as concerns over coverage, sampling, nonresponse, and 
measurement types of errors (Dillman, Smyth, & Christian, 2009).  This survey was 
designed for the study population of U.S. ASCP professional health care personnel, and 
not necessarily generalizable to other groups.   
Recall bias in the self-reporting of history of BCG immunization might have been 
problematic.  BCG immunization responses of “don’t know” (n = 151 individuals) were 
troublesome.  Passalent et al. (2007) recommended recoding these responses to “no” 
(never had a BCG immunization) in order to lessen the chance of a Type I error.  
However, this might create an opportunity for a Type II error.  Conversely, recall bias in 





respondents reporting a positive TST (n = 276) drilled down through all the remaining 
questions without missing any responses.  The BMQ questions were completed in detail. 
This completeness in the latter portion of the survey provided validation in reports of 
prescribed treatment adherence and treatment completion. 
Sampling error was addressed by mailing surveys to the entire cohort; although, 
only a 39.1% overall response rate was realized (leaving a 60.9% nonresponse rate).  Of 
note, the ASCP mailing lists included only active members, not all ASCP registrants.  
 Selection bias may have been introduced when I found that the ASCP target 
group did not include everyone in the entire registry, but rather the members who opted-
in to outside receive mailings.  Results indicated older age among the target population, 
as well as a number of foreign-born that was much less than expected, possibly due to 
this bias.  Selection bias could be addressed in future research by surveying a state 
population of medical laboratorians who are required by law to have a license.  (The use 
of listings including all registrants, rather than a select membership, is preferable.) 
Even though minimal required sample size was achieved, the majority of this 
cohort was not represented in findings.  Study results were based only on those 
questionnaires returned within the allotted time frame.  At least 45 late responses 
postmarked more than one month past due date were not included, eliminating a portion 
of the survey sample results.   
Inaccuracy of responses was minimized through the use of pretest and pilot test 
phases.  However, both phases were limited in number of respondents.  The pilot test 





to participate.  To improve this response rate in future research, I suggest gaining 
approval to perform pilot testing at a formal conference for medical microbiologists, 
where large numbers of the target population might gather and the pilot might be easily 
explained to volunteer participants.  In addition, the pilot test group was composed of 
ASCP generalists, a group used in order to prevent test-retest bias.  This group was 
similar, but not the same as the cohort of medical microbiologists surveyed.   
Misclassification bias may have occurred.  Some respondents may not be 
currently engaged in the workforce; they may be retired.  Because of the structure of the 
questionnaire, there was no way to determine how many years or hours worked in each 
type of microbiology work area.  This may have caused misclassification bias with 
subsequent measurement error.  For example, it was thought that increased age might and 
should be related to years of laboratory experience.  However, this was not the case.  
Years of laboratory experience was not found to be a risk factor associated with any of 
the outcomes under study.  Although I worked from standardized demographic question 
syntax when presenting these questions in the questionnaire survey, I did not determine 
the extent to which years and type of experience related to actual contact with specimens 
harboring the TB agent.  Older aged individuals reported a greater history of active TB 
(Table 7), but perhaps not as great an exposure to TB in the workplace occurred as was 
previously thought. 
Limitations of the use of tuberculin skin test (TST) as a tool include  possible 
reporting of false results due to BCG immunization interference, and misreading of skin 





were outside the scope of this study.  However, one item of interest was the high number 
of individuals reporting that they had never had a TST.  Was this because they had a 
chest X-ray instead? Or, did these individuals refuse to have a TST performed?  These 
questions, although not mentioned in other literature outcomes, were missing from this 
study survey, and may have added more information in the context of those not reporting 
having had a TST. 
And finally, this survey was intended to collect general lifetime prevalence 
information.  Results are not to be assessed without remembering that a history of a 
positive TST in an individual may not be linked to a specific treatment response.  (The 
same individual may have had many negative TST results in the past, or even several 
positive outcomes.)  This may help explain why individuals reporting having had a 
positive TST, BCG immunization, and a positive IGRA blood test were never prescribed 
treatment. 
Recommendations for Future Research 
Recommendations do not exceed study boundaries.  Future research should seek 
to implement studies of other medical and nonmedical laboratorian groups (such as the 
ASCP generalist population) in order to seek out and target groups at high risk of 
developing a positive TST and subsequent LTBI.  It is not yet known whether these other 
groups contain large numbers of foreign born, especially those individuals arriving to the 
United States from regions of endemic TB.  In addition, future research should seek to 
incorporate new IGRA blood test findings in comparison with TST results.  This study 





IGRA test (with several reporting a positive result).  The current study analyses will 
make for solid baseline data, useful in future TST and IGRA research.   
The inclusion of all ASCP membership would further determine the need for 
appropriate TB interventions elsewhere in the laboratory.  In addition, expanding this 
research would allow for comparison of prevalence data among a diverse group of 
medical laboratorians, including an assessment of the foreign-born, as well as the 
younger population of laboratorians.   
For the survey tool itself, several enhancements are recommended in future use of 
this questionnaire.  First, for “years of laboratory experience”, a cut-point between years 
of work experience categories was chosen between 20 years and under, and > 21 years. 
This choice was based on the majority of respondents marking the highest category.  I 
would suggest adding several more levels of experience above the > 21 year subgroup, 
due to the mean age of the current target population.  I would also suggest clarifying the 
due date of the survey and placing it in a more conspicuous area of the questionnaire.  
(This action may increase response rate and decrease the amount of late responses.) 
In addition, additional research questions may be added to further investigate the 
TST-positive group reporting no treatment, and the “never had a TST” group.  These two 
groups will provide the information necessary to allow for understanding and 
development of an appropriate intervention.  Theoretical implications as pertaining to the 
epidemiologic triad relate to the agent (individual has not been tested for the TB 
bacteria), and host (in the questionnaire, respondents were not instructed to answer 





reasons may exist as to why these respondents reported never having had a TST or no 
treatment for a positive TST.  These implications should be investigated further.   After 
all, one goal of public health is to identify and treat LTBI in order to prevent it from 
becoming active TB. 
Implications 
These results make an important contribution to the existing literature, enhancing 
social change initiatives through identifying prevalence of self-reported lifetime 
tuberculin skin test positivity, risk factors, and preventive treatment noninitiation and 
barriers to treatment adherence (medication side effects) in the U.S. medical laboratory 
microbiologist subpopulation of healthcare personnel.  Strategies to promote improved 
understanding and TB prevention treatment of this high-risk subpopulation can be 
achieved by using knowledge obtained from this research.  Positive social change at this 
individual and target group level may result in the improvement of human and social 
conditions by contributing to decreases in TB disease mortality and morbidity, and proper 
stewardship of ever-decreasing resources.  Targeted strategies intended to reduce 
prevalence of positive TSTs among healthcare personnel and improve treatment initiation 
rates, as well as reduce barriers to treatment adherence, are important in preventing TB 
reactivation to active TB disease (CDC 2005a, 2005b; Charles P. Felton National 
Tuberculosis Center, 2005; Fitzpatrick et al., 2005).  
 Within the ASCP professional registry membership, educational strategies 
designed to target specific personnel when first certifying with ASCP or upon 





factors (such as foreign birth) are associated with barriers to treatment in this same group, 
educational interventions may be designed which will alleviate these barriers.  Additional 
research among other certification groups of ASCP could follow, adding to the initiative 
among laboratorians to halt the spread of TB. 
This study differs from previous HCP studies by addressing the U.S. medical 
laboratory scientist population identified by ASCP as working in the area of 
responsibility known as “Microbiology/Mycology/Parasitology/Virology.”  The 
collection of this data and subsequent analysis supports an epidemiologic model for 
describing this ASCP subpopulation.  The sharing of research findings with the ASCP 
and its membership, other healthcare professionals, and the public health community at 
the close of this study will assist in bringing the issue of TST positivity from an historic 
lifetime prevalence perspective and aspects of preventive treatment noninitiation and 
adherence barriers to light.  In addition, findings will be shared with the owners of the 
BMQ survey instrument (Svarstad et al., 1999).  
Although newer interferon-gamma blood tests promise more accurate 
identification of LTBI status, at present, the TST remains a recommended, inexpensive 
method for detecting LTBI among healthcare personnel (CDC, 2005a).  Gauging TST 
positivity among a national HCP group such as this ASCP subpopulation aids public 
health in further understanding LTBI among U.S. medical laboratorians.  New and 
shortened LTBI preventive treatment guidelines have been published (Jereb et al., 2011), 
promoting a need to determine baseline data.  This data will benefit further research that 





Implications for social change do not exceed this study’s boundaries.  Findings of 
this study suggest that while a low number of the target population (17.0%) is at risk for 
self-reported TST positivity, those prescribed treatment actually initiated the treatment 
(90.2%), and the majority initiating (86%) completed the entire course of treatment.  
However, a large percentage (48%) were never prescribed treatment (and if they were, 
refused treatment).  A recommendation of this study is that these individuals be targeted 
for the newer, more sensitive IGRA blood test to identify LTBI, and that appropriately 
prescribed treatment be implemented (CDC, 2010a). 
Although this study fulfills the first step of many in filling the knowledge gap 
regarding this target population of HCP, medical laboratory microbiologists, several 
recommendations for action may be made.  Study findings reflect the target population’s 
overall prevalence data, and several predictors (risk factors) of TST positivity were found 
to be statistically significant.  Results for treatment noninitiation and adherence barriers 
were not as noteworthy.  The results of this study remain important in the knowledge 
base as a whole, especially because this is one of the first studies to delve deeply into the 
treatment history of a large cohort of medical laboratorians.  Action should be taken to 
present study findings to local and state public health officials, as well as to occupational 
groups such as the Association for Professionals in Infection Control (APIC) and the 
American Society for Clinical Pathology (ASCP) through peer-reviewed journal articles 
and meeting abstracts. 
This study will further assist in helping understand LTBI (prevalence as measured 





subpopulation of healthcare personnel in the United States.  The CDC (2002) has 
reported that to maintain the current decline in TB incidence in the United States, timely 
treatment management of TB by “prevention of transmission through infection control” 
(CDC, 2002, p. 6) is of great importance.   
Conclusion 
To conclude, the “take home” message that captures the key essence of the study 
is that the target population has now been described, filling the gap previously not found 
in the literature.  This ASCP target population of U.S. medical laboratory microbiologists 
is at greatest risk for developing LTBI (and active TB) in those reporting positive TST 
histories, older in age, working (or having had previously worked) in mycobacteriology 
or areas outside the microbiology laboratory, and of foreign birth.  In addition, BCG 
immunization (although a confounder associated with foreign birth) is a predictor, 
although years of work experience does not appear to be a significant predictor of TST 
positivity.  As expected, history of TB and nonoccupational exposure were found to act 
as predictors of a positive TST.  Foreign birth is now known as a predictor of treatment 
noninitiation, but no predictors were identified in relation to barriers to treatment 
adherence through adjusted multivariate analyses (possibly due to the low prevalence rate 
of those noninitiating prescribed treatment.) 
This study represents pioneering research of the ASCP subpopulation of U.S. 
medical laboratory microbiologists, surveyed as an entire cohort.  This research describes 
this target population as well as investigates potential risk factors associated with TST 





(medication side effects).  These baseline results are generalizable to this target 
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Appendix A: Cover Letter and Survey Instrument 
TUBERCULIN SKIN TEST QUESTIONNAIRE FOR 




You are invited to take part in a research study about lifetime history of tuberculin skin 
test results, treatment, and associated risk factors. You were selected for participation in 
this study because of your professional affiliation with American Society for Clinical 
Pathology (ASCP) as a U.S.-based microbiologist. This study aims to provide a 
description of the self-reported lifetime history of tuberculin skin test positivity and other 
associated epidemiologic risk factors for microbiologists with work responsibilities in the 
areas of Microbiology / Mycology / Parasitology / Virology, and a U.S. mailing address 
on file with ASCP. You must be 18 years or older to participate in this study. 
 
This form is part of a process called “informed consent” to allow you to understand this 
study before deciding whether to participate in the study. This study is being conducted 
by a researcher named Julie Ann West, who is a doctoral student at Walden University. 
You may already know the researcher as a medical laboratory scientist, but this study is 
not affiliated with that role. 
 
Background Information: 
The purpose of this study is to describe medical laboratory scientists in terms of self-




If you agree to be in this study, you will be asked to: 
Complete a questionnaire. The questionnaire should take about 10 minutes of your 
time. (This is the only point in time you will be contacted for information.) 
Answer all applicable questions to the best of your recollection. 
Complete the front and back of the questionnaire form. 
Do not place your name or any identifying information on the questionnaire. 
Return the completed questionnaire in the self-addressed, postage prepaid envelope 
within 4 weeks of receipt. 
 
Voluntary Nature of the Study: 
Participation in this study is voluntary. Your decision to participate will in no way affect 
your relationship with ASCP or the researcher. 
 
Your responses are important and will remain confidential. Your data will only be shared 








Risks and Benefits of Being in the Study: 
Being in this study would not pose risk to your safety or wellbeing. Your answers will be 
combined with others to learn about tuberculin skin test results, treatment, and 
associated risk factors in the medical laboratory microbiologist population. Aggregate 
results will be shared with the public health community. 
 
Payment: 
On behalf of survey respondents, a donation of $250 will be made to the ASCP 
Scholarship Fund for every 1000 completed surveys received by survey deadline. 
 
Privacy: 
Any information you provide will be kept anonymous. The researcher will not use your 
personal information for any purposes outside of this research project. Also, the 
researcher will not include your name or anything else that could identify you in the study 
reports. Data will be kept secure (under lock and key) for a period of at least 5 years, as 
required by the university. 
 
Contacts and Questions: 
You may ask any questions you have now. Or if you have questions later, you may 
contact the researcher via phone (678-471-6708) or email (Julie.west@waldenu.edu). If 
you want to talk privately about your rights as a participant, you can call Dr. Leilani 
Endicott. She is the Walden University representative who can discuss this with you. Her 
phone number is 1-800-925-3368, extension 1210. Walden University’s approval 
number for this study is 01-16-13-0046714 and it expires on January 15, 2014. 
 
Please keep this consent form for your records. Statement 
of Consent: I have read the above information and I feel I understand the study well 
enough to make an informed decision about my involvement. By returning a completed 





















                                                                  
TUBERCULIN SKIN TEST QUESTIONNAIRE FOR  
ASCP MEDICAL LABORATORY MICROBIOLOGISTS—2013 
 
RETURN ONLY THIS QUESTIONNAIRE 
 
Instructions: Please respond to the following questions below by filling in direct answers 
and check marks (√) in the spaces provided. On completion, this questionnaire should be 
placed in the researcher’s stamped return envelope. Please do not place your name on 
any of the material.       
                     
Member Demographics:                                                                              
 
1. What is your Gender?   ________ Male     _________Female                                     
 
2. What is your current AGE? ___________years 
 
Type of Work: 
 
3. Laboratory Section(s) where you work or have worked in the past (check all that apply): 
    _____ Mycobacteriology        _____ Bacteriology                   _____Mycology          _____   Molecular 
    _____ Virology                           _____ Parasitology                   _____Serology             _____   Other areas    
 
4. How many years total have you worked in a laboratory setting? (Include training, as well as paid 
and unpaid work in work areas where testing was performed on clinical specimens, controls, or 
isolates.) Check ONE response to indicate an approximate total number of years: 
 _____0-2 yrs        _____3-5 yrs       ____  6-10 yrs      ____ 11-15 yrs     ____16-20 yrs      ____ over 21 yrs 
 
 
5. Were you born in the USA or a U.S. Territory?                            _____  Yes          _____  No 
 
(5a.) If “NO”, was at least one birth parent a U.S.-citizen?        _____  Yes          _____   No   
 
Lifetime History of Tuberculin Skin Test (PPD):  
 
6. In your lifetime, have you ever had a Tuberculin Skin Test (PPD)? 
  ______ Yes (Continue with question 6a., and complete reverse side of this questionnaire)                   
  ______  No (*Continue with questions 7, 8, 9, 10) 
  ______  Don’t know or Don’t remember (*Continue with questions 7, 8, 9, 10)       
 
(6a.) In your lifetime, have you ever been told that your Tuberculin Skin Test (PPD) was positive?  
  ______Yes (positive)            ______No (negative)       _______Don’t know or Don’t remember 
 
                                                                          Turn Page over for additional questions  





*If you answered “NO” or “Don’t know or don’t remember” to Question 6(a), STOP HERE. 
RETURN this questionnaire as instructed. 
 
The following questions refer to history of positive SKIN TEST (PPD) only: 
 
If you answered “YES” to question #6(a):  
11. Were you ever prescribed Isoniazid (INH) or other anti-TB medications by a health department, 
occupational health department, or by another provider (doctor)?     
      ____ Yes    (Go to question 12)       ____ No (End of survey. Stop here.)  
 
12. Did you begin taking these medications (begin your treatment, even if you did not complete it)?     
      ____ Yes    (Go to questions 13 - 15)       
      ____ No              Did you refuse treatment?  ___Yes     ___ No (End of survey. Stop here.) 
13. Did you complete these medications as prescribed (entire course of treatment)?    
      _____Yes                ______No 
 
Medications:  If you ever began taking Isoniazid (INH) or anti-TB medications for 
your positive Tuberculin Skin Test (PP(D):  
14. How well did the medication work for you? 
   ____well        _____okay       ____not well       ____don’t know 
15a. Did any of your medications bother you in any way?        ____ Yes          ____No 
15b. If YES, please name the anti-TB medication(s): 
___________________________________________________________________ 
In what way(s) did it bother you? _______________________________________ 
 
Thank you. Your participation is greatly appreciated. Please return your completed survey in the 
enclosed self-addressed postage-prepaid envelope within 4 weeks of receipt to: (Researcher Postal 
Address) 
Note:  Permission to use Part A of the BMQ survey instrument (see Questions 14, 15a, 15b) was given to 
this researcher via electronic email correspondence on October 25, 2011 by the first author, Dr. B. 
Svarstad. 
7.  In place of the PPD skin test: Have you ever received an interferon gamma-releasing assay (IGRA) 
blood test to detect latent tuberculosis?  
 ______  Yes                        _______No       ________Don’t know or Don’t remember 
If you answered “YES” to question #7:   
(7a.) Were you ever told that this blood test was positive? 
_____ Yes (positive)                        ______No (negative)  
Lifetime History of  bacille Calmette-Guérin (BCG) immunization: 
8.  Have you ever had a BCG immunization (vaccine)?  
   ______ Yes                _______No                      ________Don’t know or don’t remember 
 
History of active tuberculosis (T(B): 
9.  Have you ever been told that you had active TB?  
  ______ Yes                _______ No                                         
 
Contact or exposure: 
10.  Have you had nonoccupational contact with anyone that was diagnosed with active TB?  





Appendix B: Sample Size Calculations 
Research Question 1: 
Sample Size for Frequency in a Population 
Population size(for finite population correction factor or fpc)(N): 5138 
Hypothesized % frequency of outcome factor in the population (p): 33%+/-5 
Confidence limits as % of 100(absolute +/- %)(d): 5% 
Design effect (for cluster surveys-DEFF): 1  
Sample Size(n) for Various Confidence Levels 









Sample size n = [DEFF*Np(1-p)]/ [(d2/Z21-α/2*(N-1)+p*(1-p)]  
 
Research Question 2: 
Sample Size for Frequency in a Population 
Population size(for finite population correction factor or fpc)(N): 1696 
Hypothesized % frequency of outcome factor in the population (p): 20%+/-5 
Confidence limits as % of 100(absolute +/- %)(d): 5% 
Design effect (for cluster surveys-DEFF): 1  
Sample Size(n) for Various Confidence Levels 















Research Question 3: 
Sample Size for Frequency in a Population 
Population size(for finite population correction factor or fpc)(N): 339 
Hypothesized % frequency of outcome factor in the population (p): 33.3%+/-5 
Confidence limits as % of 100(absolute +/- %)(d): 5% 
Design effect (for cluster surveys-DEFF): 1  
Sample Size(n) for Various Confidence Levels 









Sample size n = [DEFF*Np(1-p)]/ [(d2/Z21-α/2*(N-1)+p*(1-p)]  
 
Research Question 1: 
Sample Size for Unmatched Case-Control Study 
For: 
Two-sided confidence level(1-alpha) 95 
Power(% chance of detecting) 80 
Ratio of Controls to Cases 2 
 
Hypothetical proportion of controls with 
exposure 27  
 
Hypothetical proportion of cases with 
exposure: 72.56  
Least extreme Odds Ratio to be detected: 7.15 
Kelsey Fleiss Fleiss with CC 
Sample Size – 
Cases 14 14 17  
Sample Size – 
Controls 28 27 33  






Kelsey et al., Methods in Observational Epidemiology 2nd Edition, Table 12-15 
Fleiss, Statistical Methods for Rates and Proportions, formulas 3.18 &3.19 
CC = continuity correction 
Results are rounded up to the nearest integer. 
Print from the browser menu or select, copy, and paste to other programs. 
 
Research Question 2: 
Sample Size for Unmatched Case-Control Study 
For: 
Two-sided confidence level(1-alpha) 95 
Power(% chance of detecting) 80 
Ratio of Controls to Cases 4 
 
Hypothetical proportion of controls with 
exposure 35  
 
Hypothetical proportion of cases with 
exposure: 65.33  
Least extreme Odds Ratio to be detected: 3.50 
Kelsey Fleiss Fleiss with CC 
Sample Size - 
Cases 26 26 30  
Sample Size - 
Controls 104 102 118  
Total sample size: 130 128 148 
References 
Kelsey et al., Methods in Observational Epidemiology 2nd Edition, Table 12-15 
Fleiss, Statistical Methods for Rates and Proportions, formulas 3.18 &3.19 
CC = continuity correction 
Results are rounded up to the nearest integer. 
Print from the browser menu or select, copy, and paste to other programs. 
 
Reseach Question 3: 
Sample Size for Unmatched Case-Control Study 
For: 
Two-sided confidence level(1-alpha) 95 
Power(% chance of detecting) 80 
Ratio of Controls to Cases 2 







Hypothetical proportion of cases with 
exposure: 65.33  
Least extreme Odds Ratio to be detected: 3.50 
Kelsey Fleiss Fleiss with CC 
Sample Size – 
Cases 32 31 36  
Sample Size – 
Controls 64 62 72  
Total sample size: 96 93 108 
References 
Kelsey et al., Methods in Observational Epidemiology 2nd Edition, Table 12-15 
Fleiss, Statistical Methods for Rates and Proportions, formulas 3.18 &3.19 
CC = continuity correction 
Results are rounded up to the nearest integer. 
Print from the browser menu or select, copy, and paste to other programs. 
 
Results from OpenEpi, Version 2, open source calculator--SSCC 
http://www.openepi.com/OE2.3/SampleSize/SSCC.htm 





















TUBERCULIN SKIN TEST HISTORY 
QUESTIONNAIRE FOR MEDICAL LABORATORY MICROBIOLOGISTS— 2013 
 
Attention Medical Laboratory Microbiologist: 
 
About one week from now, you will receive a questionnaire in the mail.  This study is 
important in describing the epidemiology of latent tuberculosis infection among our 
medical laboratory microbiologist population. The questionnaire is being administered by a 
Walden University doctoral student as dissertation research, and has been reviewed by the 
American Society for Clinical Pathology (ASCP) and the Institutional Review Board of 
Walden University. Aggregate results will be shared with the public health community. 
 
Your response will remain confidential. For every 1000 completed surveys received by 
the deadline, a donation of $250 will be made to the ASCP Scholarship Fund on behalf of 
study respondents. 
 
Thanking you in advance for your help, 
 






Appendix D: Items from the Brief Medication Questionnaire (BMQ) 
 
The following questions from the BMQ were approved for use on October 25, 2011, and 
approved for use in this dissertation on May 6, 2012 by: 
 
Bonnie L. Svarstad, Ph. D.  
Professor Emerita 
University of Wisconsin  




(Q1g) How well does the medicine work for you? 
1 = well  
2 = okay 
3 = not well 
 
(Q2) Do any of the medications bother you in any way? YES _____ NO_____ 
(Q2a) IF YES, please name the medication and check below how much it bothers you. 
                                                How much did it bother you? 
 Medication Name                  A lot Some A little Never In what way did it bother you? 
_______________                 _____ ____   ____   ____   _______________________ 
 
   
SCORING PROCEDURES for BMQ SCREENS 
Screen                                                                                             Scoring 
______________________________________________________________________ 
Belief Screen (Questions 1g and 2-2a) 
Did R report "not well" or "don't know" in response to Q 1g?     1 = yes 0 = no 
Did R name the prescribed drug as a drug that bothers him/her? 1 = yes 0 = no 
NOTE: Score of ≥1 indicates positive screen for belief barriers 
 






Appendix E: Study Codebook 
 
Tuberculin skin test questionnaire for medical laboratory microbiologists: Summary of 
questions (Q) and transformed data coded to be used for analysis (CODEBOOK) 
Question numbers to be 
analyzed for informational 
purposes to aid in describing 
the population 
Categorical levels           Codes 
(Q1) Gender Male/Female SEX 
Male = 0 
Female = 1 
 
(Q2) Current age in years Age in years AGE 









(Q6) Ever had a TST?  



























TSTT No = 0 
Yes = 1 
DK = 2 
 
(Q7) IGRA blood test? Yes/No/DK 
 
IGRA  
No = 0 
Yes = 1 
DK=2 
 
(Q7a) IGRA positive? Yes/No/DK IGRAPOS 





Yes = 1 
DK=2 
 
(Q11) Ever prescribed Isoniazid 
or other anti-TB medications? 
Yes/No 
(needed to establish flow of 
questions) 
PRESC 
No = 0 
Yes =  1 
 
(Q12, “no” response): Refused 
treatment 
Yes/No REF 
No = 0 
Yes = 1 
 
(Q13) Did you complete entire 




No = 0 
Yes = 1 
Questions analyzed in order to 
answer research questions #1, 
#2, #3: DEPENDENT VARIABLES 
Categorical Levels Codes 
1a. (Q6a) Dependent variable: 
Lifetime self-reported history 
of TST positivity 
Yes/No/DN TSTPOS 
No = 0 
Yes = 1 
DN = 2 
 
   
2. (Q12) Dependent variable: 





No = 0 
Yes = 1 
   
3. (Q14, Q15) Dependent 
variable: BMQ questions 
regarding medication and 
adherence: total range = score 
of 0-2 (Svarstad et al., 1999) 
 
  
Total score of ≥1 indicates 
positive screen for medication 
barriers (drug effects and 
bothersome features, related to 
treatment nonadherence) 
 
(Q14) Not well, don’t know  
Yes = 1 
 Well, okay 
No = 0 
 
(Q15) Yes = 1 
            No = 0 
 
Q14+Q15 = BMQ score; where: 
Nonadherence = Positive screen 
BMQ 
Adherence = Negative 





Nonadherence = Positive 
screen for medication 
barriers 
Positive = 1 





Adherence = Negative screen 
   
Questions analyzed in order to 
answer the research questions 
#1, #2, #3: INDEPENDENT 
VARIABLES  
Categorical Levels Codes 






No = 0 
Yes = 1 
DK = 2 
 
2. (Q5) Independent variable: 
Place of birth 
(a response of “yes” to either 
Q5 or Q5a = U.S.-born) 






U.S. = yes = 0 
Foreign = no = 1 
3. (Q4) Independent variable: 
Years of laboratory experience 
(1) 0-2 yrs          
(2) 3-5 yrs             
(3) 6-10 yrs           
(4) 11-15 yrs          
(5) 16-20 yrs        
(6) over 21 yrs 
 
 
Depending on responses: The 
mean will determine a split of 
categorical responses to be used 
in logistic regression  
 
< the selected cutoff  = No 




No = 0 
Yes = 1 
 
Possible Confounders Categorical Levels Codes 
(Q9) History of active TB? Yes/No HIST 
No = 0 
Yes = 1 
 
(Q10) Nonoccupational 
exposure to anyone diagnosed 
with active TB? 
Yes/No EXPOS 
No = 0 






Appendix F: Letter of Permission for Use of Selected BMQ Questions in Research 
Subject : Re: PhD student has question for you regarding Brief Medication 
Questionnaire instrument... 
Date : Tue, Oct 25, 2011 02:03 AM CDT 
From : Bonnie Svarstad 
To : Julie West 
  
You have permission.  
 
Bonnie L. Svarstad, Ph. D.  
Professor Emerita 
University of Wisconsin  
School of Pharmacy 
 
On Oct 24, 2011, at 4:07 PM, Julie West wrote: 
Hello Dr. Svarstad, 
Today, I received a copy of the Redman (2003) book, "Measurement Tools in Patient 
Education." I now have a published version of the BMQ. However, please see attached / 
forwarded email dated 10/17/2011. I have not heard from you since I mailed a response 
to your last email. I want very much to obtain permission to use the BMQ. As noted, I 
will require survey instrument validation data for the BMQ (if you agree to my response - 
seen below). 
Again, many thanks for your interest in my research. I appreciate any assistance you may 




Julie Ann West 
Walden University  
PhD Public Health student, specialization: Epidemiology 
 
--------------------------------------- 
Original E-mail  
From: "Julie West"   
Date: 10/17/2011 11:49 AM 
To: Bonnie Svarstad  
Subject: Re: PhD student has question for you regarding Brief Medication Questionnaire 
instrument... 
 





The HaPI database staff claimed not to have a copy of your BMQ survey instrument. I 
have since ordered the Redman (2003) book, "Measurement Tools in Patient Education", 
in order to obtain a published version of the BMQ.  
As per your instructions (noted in last email): 
1. I plan to use the BMQ (part A) in my PhD dissertation project for Walden University. 
My research involves performing a quantitative, descriptive survey of American Society 
for Clinical Pathology (ASCP)-registered medical laboratory scientists. A combination 
demographic questionnaire plus portions of the BMQ will be used in a mail survey 
format to evaluate self-reported tuberculin skin test status (TST), associated risk factors 
for positive TST, as well as latent tuberculosis infection (LTBI) treatment initiation and 
barriers to treatment adherence in status-positive individuals. The results will be 
analyzed, reported, and published in the Walden University dissertation database. 
2. I will acknowledge you and your co-authors, as well as the original 1999 article 
describing the BMQ. I plan to use acknowledgements in the text, in any tables or figures, 
and in the reference section of the dissertation. 
3. I agree not to charge anyone for the results I obtain using the BMQ, now or in the 
future. 
4. I agree not to publish the BMQ instrument itself in my dissertation, or in any future 
publication. 
I have already consulted my committee chair to determine if I must include the BMQ 
instrument in the appendix of the dissertation. He approved of your requirements, and has 
instructed me to agree to your terms. His contact information (should you require it) is as 
follows: 
 
Hadi Danawi, Ph.D. 
Public Health Faculty Mentor 
Walden University 
College of Health Sciences 
 
I appreciate your assistance in this matter. I look forward to sharing my results with you 
and your colleagues. 
If possible, please attach a copy of the entire BMQ and validation data to a reply email to 
me.  




Julie Ann West 
Walden University  
PhD Public Health student, specialization: Epidemiology 
 
--------------------------------------- 





From: Bonnie Svarstad  
Date: 10/14/2011 09:07 AM 
To: Julie West  
Subject: Re: PhD student has question for you regarding Brief Medication Questionnaire 
instrument... 
 
As first author/owner, I handle permissions. The database folks have no role in granting 
permissions. You simply need to tell me what you plan to do with it. I will grant 
permission if you agree to acknowledge the authors and original article in which the 
BMQ was described and evaluated, if you agree to NOT charge anyone for the results, 
and if you agree not to publish the instrument itself as we retain copyright. If you send a 














one expected (a) 
Errors: more than 








0 0 13 0 
2. 
 
0 0 13 0 
3. 0 0 
 
13 0 
4. 0 0 
 
13 0 
5. 0 0 
 
13 0 
5.a. 0 0 
 
13 0 
6. 0 0 
 
13 0 
6a. 0 0 
 
13 0 
7. 0 0 
 
13 0 
7.a 0 0 13 0 
 
8 0 0 
 
13 0 
9. 0 0 
 
13 0 
10. 0 0 
 
13 0 
11 0 1 
 
12 7.7% 
12 0 1 
 
12 7.7% 





0 0 13 0 
15.a 0 0 
 
13 0 







Barriers to Treatment Adherence as measured by the Brief Medication Questionnaire 
Part A score: (n = 44, positive score) 
 
How well did the medication work for you? Well/Okay     Not Well/Don’t Know 
                                                                              (n = 96)                 (n = 33) 
Did any of your medications bother you in any way?   Yes        No 
                                                                                          (n = 27)  (n = 102) 










































*Note: n = 58 self-reported never having had/not knowing if they had a TST 
Cleaned data set (n = 1,628); Ever been told your 
tuberculin skin test (TST) was positive? 
 
No (n = 1,352) 
Yes 




Yes (n = 143)                 
Preventive treatment 
initiated? 
No (n = 132) 
Yes  
(n = 129) 
No (n = 14, noninitiated); 13 of 
14 individuals refused treatment 
Non 
Respondents 
(n = 2,642) 
(Includes n = 12 
‘address unknown’ 
and n = 45 late 
returns, not 
processed) 
ASCP Medical Microbiologist Study Population 





Appendix I: Letter of Cooperation, ASCP 
American Society for Clinical Pathology (ASCP) American Society for Clinical Pathology 
(ASCP) 
ASCP Headquarters 
                                   33 West Monroe Street, Suite 1600, Chicago, IL 60603-5617 
                                   312-541-4999 (phone); 312-541-4998 (fax) 
January 24, 2013 
 
Dear Julie Ann West (Walden University Student),  
   
Based on my review of your research proposal, we give permission for you to mail the study survey 
questionnaire entitled “TUBERCULIN SKIN TEST QUESTIONNAIRE FOR MEDICAL 
LABORATORY MICROBIOLOGISTS—2013” As part of this study, we grant you to access ASCP’s 
mailing list of lab professionals through InFocus Marketing, Inc., and mail the survey questionnaires to 
those listed as having primary ‘area of work responsibility’ as designated by ASCP in 
“Microbiology/Mycology/Parasitology/Virology.” Individuals’ participation will be voluntary and at their 
own discretion.  
 
We understand that our organization’s responsibilities include: Approval of the announcement postcard, 
cover letter/consent, and self-administered mail questionnaire prior to reproduction and mailing by our 
partner, Infocus Marketing, Inc. We reserve the right to withdraw from the study at any time if our 
circumstances change.  
 
 
We understand that the data collected will remain entirely confidential and may not be provided to anyone 
outside of the research team without permission from the Walden University Institutional Review Board.. 
We understand that the Walden University Institutional Review Board has assigned approval number 01-
16-13-0046714 to this study.   
   
Sincerely, 
Senior Marketing Analytics Manager 
Contact Information: ASCP  
                                   33 West Monroe Street, Suite 1600 
         Chicago, IL 60603 









Appendix J: Letter of Cooperation (Pilot Test), ASCP  
Letter of Permission (Pilot Test) 
 
 
American Society for Clinical Pathology (ASCP) 
        ASCP Headquarters 
                                   33 West Monroe Street, Suite 1600, Chicago, IL 60603-5617 
                                   312-541-4999 (phone); 312-541-4998 (fax) 
February 18, 2013 
 
Dear Julie Ann West (Walden University Student),  
   
Based on my review of your research proposal, we give permission for you to pilot test the study survey 
questionnaire entitled “TUBERCULIN SKIN TEST QUESTIONNAIRE FOR MEDICAL 
LABORATORY MICROBIOLOGISTS—2013.”  As part of this study, we grant you access to ASCP’s 
mailing list of lab professionals through InFocus Marketing, Inc., and distribution of the survey 
questionnaires to those listed as having primary ‘area of work responsibility’ as designated by ASCP in 
“Generalist”- “MLS/MT” category, U.S., State of Georgia mailing addresses. Individuals’ participation will 
be voluntary and at their own discretion.  
 
We understand that our organization’s responsibilities include: Approval of the announcement postcard, 
cover letter/consent, and self-administered mail questionnaire prior to distribution of the pilot test survey 
packet.  We reserve the right to withdraw from the study at any time if our circumstances change.  
 
We understand that the data collected will remain entirely confidential and may not be provided to anyone 
outside of the research team without permission from the Walden University Institutional Review Board. 
We understand that the Walden University Institutional Review Board has assigned approval number 01-
16-13-0046714 to this study.   
   
Sincerely, 
Senior Marketing Analytics Manager 
 
 
Contact Information: ASCP  
                                   33 West Monroe Street, Suite 1600 
         Chicago, IL 60603 















Appendix K: Letter of Permission for Use of Select BMQ Questions in Dissertation 
Subject :   
Re: PhD student has question for you regarding Brief Medication Questionnaire 
instrument... 
Date :  Thu, Jul 04, 2013 08:14 PM CDT 
From :  Bonnie Svarstad  
To :  Julie West  
 
That's fine.  
 
Bonnie L. Svarstad, Ph. D. 
Professor Emerita 
University of Wisconsin  




On Jul 4, 2013, at 4:56 PM, Julie West wrote: 
 
> Hello Dr. Svarstad, 
>   
> I hope you have been well. Some time has passed since I last requested permission to 
use Part A of your Brief Medication Questionnaire as part of my Walden University 
public health dissertation project... almost 2 years (discussion thread attached to this 
email).  Well, I am happy to report that I am writing Chapter 5 of the dissertation. The 
research itself was a long process, but I acquired a great deal of data in the process.  To 
refresh your memory, my research involved use of a quantitative, descriptive survey of 
American Society for Clinical Pathology (ASCP)-registered medical laboratory 
microbiologists. A combination demographic questionnaire plus Part A of your BMQ 
was used in a mail survey format to evaluate self-reported tuberculin skin test status 
(TST), associated risk factors for positive TST, as well as latent tuberculosis infection 
(LTBI) treatment initiation and barriers to treatment adherence in self-reported TST-
positive individuals. The results will be reported and published in the ProQuest 
dissertation database before year's end, if all goes as planned. 
>   
> I would like your permission to include a copy of my survey instrument in my 
dissertation appendix. The questionnaire document is attached. I have included this 
phrase at the bottom of page 2 of this appendix document: "Note:  Permission to use Part 
A of the BMQ survey instrument (see Questions 14, 15a, 15b) was given to this 
researcher via electronic email correspondence on October 25, 2011, by the first author, 
Dr. Svarstadt." 






> Thank you for your help in this matter.  Once the dissertation has been completed, I 
will share the findings with you. (I have accrued a great deal of interesting data for this 
target group.) 
>   
> Thank you, 
> Julie West 
>   
>   
> Julie Ann West 
> Walden University 
> PhD Public Health student, specialization: Epidemiology 
 
 
Subject :   
Re: PhD student has question for you regarding Brief Medication Questionnaire 
instrument... 
Date :  Sun, May 06, 2012 04:15 PM CDT 
From :  Bonnie Svarstad  
To :  Julie West  
 
Yes.  Best wishes. Bonnie 
 
Bonnie L. Svarstad, Ph. D. 
Professor Emerita 
University of Wisconsin  
School of Pharmacy 
 
On May 6, 2012, at 7:44 AM, Julie West wrote: 
 
> May 6, 2012 
> Hello Dr. Svarstad, 
>   
> In October, you granted permission allowing me to use portions of the Brief 
Medication Questionnaire (BMQ) in my PhD dissertation.  When giving permisson to 
me, I agreed not to publish the BMQ instrument.  I am about to submit my entire 
proposal to the Walden University IRB, and I would like to make one last request of you: 
>   
> In the Appendix of my dissertation: May I cite the two specific BMQ items that I plan 
to use in my research survey questionnaire? The dissertation will be published in the 






May I reproduce the following in the APPENDIX section of the dissertation? Something 
like: 
>   
> APPENDIX C: SAMPLE ITEMS FROM THE BRIEF MEDICATION 
QUESTIONNAIRE 
>   
> The following sample questions from the BMQ were approved to reprint in the 
dissertation by: 
>   
> Bonnie L. Svarstad, Ph. D. 
> Professor Emerita 
> University of Wisconsin 
> School of Pharmacy 
> 
> SAMPLE BMQ ITEMS: 
> (Q1g) How well does the medication work for you? 
> 1 = well   
> 2 = okay 
> 3 = not well 
>   
> (Q2, 2a) 
> Do any of the medications bother you in any way?   YES _____ NO_____ 
>   
> a. IF YES, please name the medication and check below how much it bothers you. 
> How much did it bother you? 
> Medication Name           A lot             Some              A little         Never     In what way 
did it bother you? 
> ______________            ______           ______               _____          ____          ____ 
> SCORING PROCEDURES for BMQ Part A 
>   
> Screen                                                                                            Scoring 
> ______________________________________________________________________ 
> Belief Screen (Questions 1g and 2-2a) 
> Did R report "not well" or "don't know" in response to Q 1g?          1 = yes   0 = no 
> Did R name the prescribed drug as a drug that bothers him/her?   1 = yes   0 = no 
> NOTE: Socre of >=1 indicates positive screen for belief barriers 
> (Svarstad, Chewning, Sleath, & Claesson, 1999) 
 
> Many thanks - I appreciate your time in considering this request. 
 
> Julie Ann West 
> Walden University 













Lakeland Community College, Mentor, Ohio                                   AAS           1981          
Medical Laboratory Technology, Certificate in Medical Laboratory Technology                             
 
Edison Community College, Ft. Myers, Florida                                  AA          1986                           
         
The University of the State of New York (Excelsior College), Albany, New York                                      
            BS          1989 
(Included combined coursework from The Ohio State University, University of South 
Florida, and The University of Florida) 
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PROFESSIONAL AFFILIATIONS AND OFFICES HELD 
 
Certifications:  
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American Society for Clinical Pathology (ASCP)                                        since 2005 
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Licensures:  
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